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Niemann-Pick Type C (NP-C) is a lysosomal storage disorder with neurological and 
visceral pathology, for which there is currently no major disease modifying 
treatment. Loss of NPC1 function, a late endosomal transmembrane protein, leads to 
systemic intracellular lipid accumulation. The subsequent premature death is usually 
associated with neurological manifestations, such as neurodegeneration and 
neuroinflammation. This project focuses on the development and preclinical 
evaluation of gene therapy for NP-C in a mouse model using an adeno-associated 
viral (AAV) vector. The vector would be capable of delivering and expressing 
human NPC1 in the mouse brain and providing therapeutic benefit. 
 
AAV vectors exhibit efficient and widespread gene delivery throughout the brain, 
however their limited packaging capacity can be a constraint for larger genes. In this 
project extensive construct modifications were carried out to incorporate the 
relatively large NPC1 cDNA into a functional AAV serotype 9 vector, where NPC1 
is controlled by a constitutively active neuronal promoter. Initial in vivo testing 
demonstrated successful NPC1 over-expression in administered mouse brains, 
compared to endogenous NPC1 levels in unadministered controls. No indications of 
toxicity were observed as a result of exogenous NPC1 overexpression in vivo. A 
series of preclinical proof of concept survival studies were subsequently carried out 
on the Npc1-/- model, where newborn Npc1-/- mice were administered with 4.6 x 109 
vector genomes of AAV9-NPC1 via intracerebroventricular injections. Treated 
Npc1-/- mice exhibited an increased lifespan (median survival - 116.5 days) 
compared to untreated Npc1-/- mice (median survival - 75.5 days). Low dose treated 
mice exhibited permanent normalisation of locomotor function and significant 
neuronal rescue in all brain regions analysed. A subsequent study with a 65-fold dose 
increase resulted in an additional significant extension of lifespan, along with 
improved weight maintenance. Combined, these results demonstrate the potential 
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Niemann-Pick Type C disease is one of over 70 genetically distinct lysosomal 
storage disorders. In 95% of cases the disease is caused by a loss of function 
mutation in the NPC1 gene, which results in the abnormal accumulation of lipids in 
cellular late endosomal and lysosomal compartments (Vanier, 2010). Although there 
are a small number of treatment options that have shown therapeutic efficacy in 
Niemann-Pick Type C animal models, there is currently no major disease modifying 
or curative treatment available for patients. Due to their monogenic nature and the 
potential benefit of cross-correction in the majority of cases, lysosomal storage 
disorders have been identified as attractive candidates for gene therapy. Combined 
with advances in viral vector technology, significant progress in the development of 
gene therapy for a number of lysosomal storage disorders has resulted in a series of 
currently ongoing clinical trials (Biffi, 2016). However, the development of these 
promising trials was thought to not be easily applicable to Niemann-Pick Type C 
disease, due to notable additional challenges relating to the defective gene and 
protein. 
 
The aim of this introductory chapter is to provide a background on lysosomal storage 
disorders and Niemann-Pick Type C disease, investigating pathology, clinical 
presentations, currently available treatment options and available animal models. 
Gene therapy, viral vectors and gene delivery to the central nervous system are also 
introduced. Finally, the rationale behind the approach taken and the aims of this 
project are presented. 
1.1 Lysosomal Storage Disorders 21 
1.1 Lysosomal Storage Disorders 
Lysosomal storage disorders are a heterogeneous group of inherited diseases, usually 
characterised by the accumulation of macromolecules, resulting in cellular 
dysfunction, cell degeneration and ultimately premature death (Table 1). Although 
these disorders are individually classified as rare diseases, their combined frequency 
is estimated at 1 in 7,500 live-born infants (Meikle et al., 1999). The accumulative 
frequency may be higher, if mis- or un-diagnosed patient numbers are also taken into 
account (Platt et al., 2012). Due to the critical importance and near-ubiquitous nature 
of lysosomes throughout the body, dysfunction of lysosomal proteins leads to multi-
system cellular dysfunction, oxidative stress, abnormal autophagy and impaired 
organ function (Bellettato and Scarpa, 2010). Visceral pathology is normally 
characterised by enlargement of the liver and spleen, but cardiac disease, 
haematological, pulmonary and skeletal dysfunction are also common (Parenti et al., 
2015). Classical lysosomal storage disorder pathology is usually associated with 
degeneration of the central nervous system. The critical importance of normal 
lysosomal function is further highlighted by the presentation of severe 
neurodegeneration in approximately 60% of all lysosomal storage disorders (Cox and 
Cachon-Gonzalez, 2012). In combination, neurodegenerative lysosomal storage 
disorders account for the most common cause of childhood neurodegeneration 
(Lloyd-Evans and Haslett, 2016), resulting in a substantial strain to both families and 
health care systems (Pastores, 2010). 
  





Defective enzyme or protein 
Sphingolipidoses 
Fabry disease Y α-Galactosidase A 
Farber lipogranulomatosis N Ceramidase 
Gaucher disease type I 









juvenile and adult variants 
Y β-Galactosidase 
GM2-gangliosidosis (Sandhoff): 
infantile and juvenile 
GM2-gangliosidosis (Tay–Sachs): 












GM3-gangliosidosis Y GM3 synthase 
Metachromatic leukodystrophy 
(late infantile, juvenile and adult) 
Y Arylsulphatase A 
Sphingolipid-activator deficiency Y Sphingolipid activator 
Mucopolysaccharidoses 
MPS I (Scheie, Hurler–Scheie and 
Hurler disease) 
Y α-Iduronidase 
MPS II (Hunter) Y Iduronidase-2-sulphatase 
MPS IIIA (Sanfilippo A) 
MPS IIIB (Sanfilippo B) 
MPS IIIC (Sanfilippo C) 










MPS IVA (Morquio syndrome A) 





MPS VI (Maroteaux–Lamy) Y 
N-acetylgalactosamine-4-sulphatase 
(arylsulphatase B) 
MPS VII (Sly disease) Y β-Glucuronidase 
MPS IX Y Hyaluronidase 
Glycogen storage disease 




α-Mannosidosis Y α-Mannosidase 
β-Mannosidosis Y β-Mannosidase 
Fucosidosis Y α-Fucosidase 
Aspartylglucosaminuria Y Aspartylglucosaminidase 
Schindler disease Y α-N-acetylgalactosaminidase 
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Sialidosis Y α-Neuraminidase 
Galactosialidosis Y Lysosomal protective protein 






Integral membrane protein disorders 
Cystinosis N Cystinosin 
Danon disease Y Lysosome-associated membrane protein 2 
Action myoclonus–renal failure 
syndrome 
N Lysosome membrane protein 2 
Salla disease Y Sialin 
Niemann–Pick disease type C1 Y NPC1 , NPC2 
Mucolipidosis IV Y Mucolipin 
Neuronal ceroid lipofuscinoses 
CLN1 Y Palmitoyl-protein thioesterase-1 
CLN2 Y Serine protease 
CLN3 Y CLN3 protein 
CLN4 Y DnaJ homologue subfamily C member 5 
CLN5 Y Protein CLN5 
CLN6 Y Protein CLN6 
CLN7 Y 
Major facilitator superfamily domain-containing 
protein 8 
CLN8 Y Protein CLN8 
CLN10 Y Cathepsin D 
CLN11 Y Progranulin 
CLN12 Y Unknown 
CLN13 Y Cathepsin F 
CLN14 Y 
Potassium channel tetramerization domain-
containing protein 7 
Additional disease types 
Multiple sulphatase deficiency Y Sulphatase-modifying factor 2 
Niemann–Pick disease type C2 Y NPC2 
Wolman disease (infantile); 
cholesteryl ester storage disease 
N Lysosomal acid lipase 
Galactosialidosis Y Cathepsin A 
 
Table 1: Summary of major lysosomal storage disorders, their defective proteins 
and neurological disease involvement. 
Abbreviations: MPS, mucopolysaccharidosis; NPC1, Niemann–Pick disease type C1 
protein; NPC2, Niemann–Pick disease type C2 protein. Adapted from (Boustany, 
2013). 
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Although pathology and symptoms are often shared between different lysosomal 
storage disorders, they are individually genetically distinct (Table 1 and Figure 3A). 
The majority of disorders are caused by mutations to genes encoding soluble 
lysosomal enzymes localised to within the lumen of late endosomal/lysosomal 
compartments (Cox and Cachon-Gonzalez, 2012), with their loss of function mostly 
resulting in the accumulation of a specific enzyme substrate. However, other proteins 
necessary for lysosomal function can also be the source of lysosomal storage 
disorders, such as integral membrane proteins, transporter proteins and activator 
proteins (Parenti et al., 2015). In comparison, these disorders generally result in the 
accumulation of various primary and secondary macromolecules. The complex 
nature of non-enzymatic disorders is associated with the lack of knowledge on the 
exact function of these proteins (Lloyd-Evans and Platt, 2010). Primary 
accumulation of the specific substrate or target macromolecule can also lead to 
secondary lipid accumulation or impairment of lysosomal pathways, further 
contributing to the pathology and complexity of lysosomal storage disorders 
(Walkley and Vanier, 2009, Prinetti et al., 2011). A wide range of lipid 
macromolecules accumulate within lysosomes in lysosomal storage disorders, 
depending on the specific disorder and dysfunctional lysosomal protein. However, 
these lipids can be broadly classified into major lysosomal storage disease categories 
of: glycosaminoglycan (Coutinho et al., 2012), sphingolipid (Platt, 2014), lipofuscin 
(Jolly et al., 1993) and cholesterol accumulation (Lloyd-Evans and Platt, 2010). 
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Figure 1: Mechanisms of neuropathology in lysosomal storage disorders. 
Summary of the range of potential intra- and inter-cellular mechanisms affected in 
lysosomal storage disorders, ultimately leading to cell damage and death. 
The complex nature of lysosomal storage diseases is reflected by their complex 
pathophysiology, as a number of diverse lysosomal and cellular mechanisms have 
been identified to potentially contribute towards disease pathology (Figure 1). One 
example is the lysosomal pH imbalance, observed in a range of lysosomal storage 
disorders, such as Gaucher disease (Sillence, 2013), mucopolysaccharidoses (Pereira 
et al., 2010) and most neuronal ceroid lipofuscinoses (Holopainen et al., 2001). The 
maintenance of lysosomal pH within the range of 4-5 is critical for normal lysosomal 
function, including lysosomal hydrolase maturation, phago-lysosome fusion, vesicle 
maturation, neurotransmitter loading into synaptic vesicles and autophagy (Schultz et 
al., 2011, Lloyd-Evans and Haslett, 2016).  
 
Autophagy is a highly conserved self-degradative process regulated by over 30 
proteins (Nakatogawa et al., 2009), crucial for development, energy conservation and 
clearance of both damaged organelles and intracellular pathogens (Glick et al., 
2010). Induced by cellular stress or starvation stimuli, macroautophagy results in the 




















Late / Early 
Endosome 
Neuronal inf ammation 
Glial activation 
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subsequently undergo fusion with lysosomes, thereby releasing lysosomal hydrolases 
for autolysosomal degradation (Xie and Klionsky, 2007). Impaired autophagy has 
previously been linked to cellular damage and neurodegeneration (Komatsu et al., 
2006, Hara et al., 2006), which are also observed in lysosomal storage disorders. 
Studies in various neurodegenerative and lysosomal storage disorder animal models, 
including neuronal ceroid lipofuscinoses (Cao et al., 2006), Pompe disease (Fukuda 
et al., 2006) and Niemann-Pick Type C disease (Pacheco et al., 2007), have 
confirmed impairment of macroautophagy and autophagic flux. These lysosomal 
storage disorder associated autophagy impairments have also been reported to result 
in significant mitochondrial dysfunction (Settembre et al., 2008), and lack of 
mitophagy mediated mitochondrial quality control (Kim et al., 2007). Cellular 
damage, apoptosis and inflammation may therefore be enhanced by the accumulation 
of reactive oxygen species and free radicals produced by dysfunctional mitochondria 
(Platt et al., 2012). 
 
Dysregulation of intracellular Ca2+ homeostasis has been observed in a range of 
lysosomal storage disorders (Lloyd-Evans et al., 2010). Ca2+ is utilised as an 
intracellular signalling molecule, by creating a Ca2+ concentration gradient from high 
concentration in organelles to low concentrations in the cytosol. Release of Ca2+ 
from intracellular stores such as lysosomes, mitochondria and the endoplasmic 
reticulum can activate various inducible mechanisms from transcription to vesicular 
fusion and exocytosis (Lloyd-Evans and Haslett, 2016). However, in many 
lysosomal storage disorders, intracellular Ca2+ stores fail to buffer these higher 
concentrations of cytosolic Ca2+, resulting in sustained Ca2+ elevation (Lloyd-Evans 
and Platt, 2011). Prolonged cytosolic Ca2+ elevation can result in mitochondria-
mediated apoptosis (Sano et al., 2009) and neuronal excitotoxicity, whereby nitric 
oxide synthesis results in the generation of free radicals and ultimately apoptosis 
(Lewen et al., 2000). 
 
Other potential sources of lysosomal storage disorder pathology include the 
activation of cell-death signalling, such as the over activation of Toll-like receptor 4 
via high glycosaminoglycan levels in mucopolysaccharidoses (Simonaro et al., 
2010), alteration of intracellular lipid content and lipid raft stoichiometry (Persaud-
Sawin and Boustany, 2005), prolonged inflammation (DiRosario et al., 2009) or 
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over-activation of the unfolded protein response, which results in stress to the 
endoplasmic reticulum and apoptosis (Tessitore et al., 2004). 
 
Although neurological pathology is common in most lysosomal storage disorders, 
the extent, severity and specific brain regions presenting neurodegeneration can 
differ. In the classical presentation of neuropathology in lysosomal storage disorders, 
neurodegeneration and inflammation will initially develop in specific brain regions, 
such as the cerebellum, thalamus or hippocampus, which will then ultimately 
advance to the rest of the brain (Platt et al., 2012). The initial susceptibility of certain 
brain regions during neurodegeneration progression is due to the combination of 
several factors. Certain neuronal populations appear more vulnerable to the 
accumulation of storage material, demonstrated by the commonly observed early 
degeneration of Purkinje neurons in the cerebellum of brains with lysosomal storage 
disorders (Walkley et al., 2010). The rates at which certain macromolecules are 
synthesised and utilised is dependent on the neuronal subtype, and as a result the 
detrimental effects of primary or secondary accumulation of individual storage 
materials can also differ between neuronal populations. Most lysosomal storage 
disorders also result in neuroinflammation through activation of the innate immunity 
in the central nervous system, which can further contribute towards neuropathology, 
exemplified by the neurotoxic affects of astrogliosis (Vitner et al., 2010). 
 
Although lysosomal storage disorders may share a range of fundamental 
characteristics, their age of clinical onset and resulting symptoms can vary greatly 
between individual disorders, or even within the same disorder depending on the 
relative mutation severity. Combined with the specific biochemistry and types of cell 
populations accumulating the stored material, the spectrum of neurological and 
visceral symptoms can be broad (Platt et al., 2012). Although in certain severe cases 
newborns can exhibit symptoms, the majority of lysosomal storage disorders develop 
deficiencies commencing from early to late infancy (Wraith, 2002). Adult-onset 
disease variants have also been observed, however associated disease progression is 
often less acute (Nixon et al., 2008). As a result of the wide clinical symptom 
spectrum comparable to many other metabolic disorders and the relative rarity of the 
individual disorders, correct and rapid diagnosis can be challenging. Definitive 
lysosomal storage disorder diagnosis in most cases has to be confirmed through 
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specialised biochemical testing, such as lysosomal enzymatic assays or through 
genetic testing (Filocamo and Morrone, 2011). 
 
The development of therapies for lysosomal storage disorders has progressed 
significantly in the last 25 years, as before treatment was mainly limited to palliative 
therapy, although this approach is still required for certain disorder groups (Parenti et 
al., 2015). Most current approaches focus on improving or stabilising the activity of 
the defective enzyme or regulating its upstream substrates. Enzyme replacement 
therapy, whereby a functional recombinant version of the defective protein is 
administered to patients, is now a standard form of care for many lysosomal storage 
disorders (Desnick and Schuchman, 2012). However, its use is restricted to soluble 
lysosomal proteins and has a limited bioavailability in the central nervous system, 
due to the inability of the majority of recombinant protein to cross the blood-brain 
barrier. Additionally, manufacturing costs of the specific recombinant proteins and 
the need for continual repeated administration results in a substantial burden for 
national health systems and individual families (Wyatt et al., 2012). 
 
Lysosomal storage disorders are often caused by missense mutations, resulting in a 
disruption to the three-dimensional structure and folding of the encoded protein, 
ultimately leading to protein degradation, endoplasmic reticulum (ER) retention, 
mistrafficking or protein dysfunction (Parenti et al., 2014). Pharmacological 
chaperones bind to these proteins, with the aim of improving protein folding and 
stability, leading to enhanced trafficking and protein activity (Valenzano et al., 
2011). A combination therapy of the α-galactosidase A stabilising pharmacological 
chaperone 1-deoxygalactonojirimycin (migalastat hydrochloride) and recombinant α-
galactosidase A enzyme replacement therapy has been demonstrated to be 
particularly effective in Fabry disease (Benjamin et al., 2012).  
 
Other potential therapies include bone marrow transplantation, substrate reduction 
therapy and gene therapy, which will be discussed later in more detail. Although 
remarkable advancements in lysosomal storage disorder treatment have been made, 
many disorders lack any effective and specialised treatment options. Where 
treatment may be possible, the delivery to critical yet isolated tissues, immunological 
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resistance, timing of diagnosis and access to the costly therapy still remain 
significant challenges (Boustany, 2013).  
1.2 Niemann-Pick Diseases 
Niemann-Pick diseases are a subgroup of lysosomal storage disorders first described 
by Albert Niemann and Ludwig Pick in the early 20th century (Pentchev, 2004). 
These can be further categorised by their respective lysosomal protein deficiency. 
Niemann-Pick Type A (NP-A) and B (NP-B) are caused by the loss of acid 
sphingomyelinase (ASM) function, whereas Type C1 and C2 result from the loss of 
either NPC1 or NPC2 function (Vanier, 2013). 
 
The autosomal recessive lipid storage diseases Niemann-Pick Type A and B result 
from loss of function mutations to the SMPD1 gene, which encodes the lysosomal 
hydrolase acid sphingomyelinase (ASM). The form and severity of the disease 
depends on the type of SMPD1 mutation and to date more than 120 disease causing 
mutations have been identified (Schuchman and Wasserstein, 2015). ASM 
deficiency is classified as a rare genetic disorder, with a prevalence of approximately 
1 in 100,000 (Poupetova et al., 2010), however this may be an underrepresentation 
due to the difficulties associated with a correct clinical diagnosis of the milder NP-B 
disease. The extent of ASM deficiency differs between the two types, with Type A 
patients producing little to no functional ASM activity (<1%), whereas Type B 
patients retain a certain level of ASM activity (~10%) (Schultz et al., 2016). ASM 
catalyses the breakdown of sphingomyelin to phosphocholine and ceramide, and as a 
result ASM deficiency leads to the primary accumulation of sphingomyelin in 
patients with NP-A and NP-B disease (Wasserstein and Schuchman, 1993). 
Sphingomyelin is a sphingolipid that forms a major component of the cellular plasma 
membrane and axon insulating myelin sheath (Quinn, 2014). A potential additional 
source of pathology along with storage material accumulation may result from 
abnormalities in the plasma membrane and myelin sheath, which in turn can cause 
secondary affects to receptor function, transport mechanisms and cell signalling 
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pathways (Schuchman and Wasserstein, 2015). Moderate secondary storage of 
cholesterol, gangliosides, glucocerebroside and lactosylceramide has also been 
observed, similar to the multi-lipid accumulation in Niemann-Pick Type C disease, 
suggesting an overlap of disease mechanisms. Foam cells, characterised as large 
lipid-laden cells, have been observed in the visceral organs of patients with ASM 
deficiency, particularly within the liver, spleen, lung and bone marrow (Wasserstein 
and Schuchman, 2015). The clinical disease presentation differs between Types A 
and B, where patients with NP-A exhibit severe hepatosplenomegaly from the first 
months of life. Progressive neurological pathology commences from 6 months of 
age, characterised by hypotonia, ataxia and spasticity, with premature death 
occurring before 3 years of age (Vanier, 2013). In comparison, NP-B does not show 
any neurological involvement, however patients do exhibit variable degrees of 
chronic hepatosplenomegaly from late infancy and most survive until late adulthood 
(McGovern et al., 2008). 
 
Symptomatic management currently remains the standard care for patients with 
Niemann-Pick Types A and B. Bone marrow transplantation in Type A patients 
showed moderate visceral efficacy, however no neurological therapeutic effects were 
observed and secondary complications associated to the procedure were severe 
(Victor et al., 2003). Patients with the non-neuropathic Type B disease should be 
ideal targets for enzyme replacement therapy and a recently completed phase I 
clinical trial demonstrated the safety of this treatment (Wasserstein et al., 2015). 
1.3 Niemann-Pick Type C Disease 
Niemann-Pick Type C disease (NP-C) is an atypical autosomal recessive lysosomal 
storage disorder, which can be further subcategorised into Niemann-Pick Type C1 
(NP-C1) or C2 (NP-C2) disease, depending on either NPC1 or NPC2 lysosomal 
protein deficiency. NP-C disease is characterised by the accumulation of multiple 
storage materials, resulting in neurovisceral symptoms. The following sections aim 
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to give a detailed overview of NP-C epidemiology, pathology, clinical presentation, 
diagnosis, available therapies and animal models. 
1.3.1 NP-C Epidemiology 
As with other lysosomal storage disorders, NP-C is classified as a rare disease. The 
actual prevalence of NP-C has been difficult to determine, due to the previously 
discussed challenges demonstrated by most lysosomal storage disorders, such as 
relative disease rareness, broad clinical spectrum and difficulty of diagnosis. The 
current clinical incidence is estimated at approximately 1 in every 100,000 live births 
(Vanier, 2010), however this is likely an underestimation. A recent study evaluating 
data from massive parallel exome sequencing data sets for damaging mutations to 
NP-C causing genes predicted a combined frequency of 1 in every 89,000 births, 
with a rate of 1:92,000 for NP-C1 and 1:2,860,000 for NP-C2 (Wassif et al., 2016). 
The authors also reported that when damaging mutations expected to cause protein 
dysfunction but not classical NP-C disease were taken into account, the frequency 
may be as high as 1:19,000 – 1:36,000. These cases may represent milder or atypical 
versions of the disease often described in older-onset patients, which are most likely 
misdiagnosed. NP-C occurrence is pan-ethnic, with two genetic isolates described in 
Spanish Americans in South Colorado and French Arcadians in Nova Scotia, which 
were previously misclassified as Niemann-Pick Type D patients (Wenger et al., 
1977). 
1.3.2 NP-C Proteins 
NP-C is caused by mutations to either of two genes, NPC1 or NPC2, resulting in NP-
C1 and NP-C2 disease respectively. Approximately 95% of NP-C cases are 
attributed to mutations in the NPC1 gene, whereas until 2010 only 30 cases of NP-C 
have been officially recorded due to mutations in the NPC2 gene (Vanier, 2010). The 
two proteins encoded by these genes are involved in late endosomal/lysosomal lipid 
trafficking, as opposed to metabolite catabolism observed in the majority of 
lysosomal storage disorders. NPC1 encodes a large 1,278 amino acid transmembrane 
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glycoprotein, shown to predominantly localise within late endosomal compartments, 
with only transient lysosomal interactions (Higgins et al., 1999, Neufeld et al., 1999). 
Analysis of NPC1 transmembrane domains revealed the presence of a sterol-sensing 
domain, a highly conserved region of five transmembrane segments proposed to be 
involved in the response to sterols in the lipid bilayer (Kuwabara and Labouesse, 
2002) (Figure 2A). Although the exact function and mechanism of this domain has 
remained unclear, its activity is crucial for NPC1 function (Watari et al., 1999, 
Ohgami et al., 2004, Millard et al., 2005). The recent publication of a detailed NPC1 
crystal structure led to the proposal that NPC1’s sterol sensing domain acts as a 
cavity for docking of individual cholesterol molecules, where the cavity is accessible 
from both the lipid bilayer and lysosome lumen (Li et al., 2016). This would allow 
the movement of cholesterol from the endosomal/lysosomal lumen to within the 
luminal leaflet of the lipid bilayer. The luminal N-terminal domain of NPC1 has also 
crucially been shown to bind cholesterol (Kwon et al., 2009) and is attached to the 
rest of the NPC1 protein via a long flexible proline-rich bridge (Infante et al., 2008a). 
 
In comparison, the NPC2 gene encodes the smaller 132 amino acid soluble NPC2 
protein, found within the lumen of late endosomes and lysosomes (Storch and Xu, 
2009). NPC2 is also thought to be involved in the trafficking of cholesterol 
(Naureckiene et al., 2000), as 1:1 stoichiometric binding of cholesterol with a 
cholesterol-binding site within the NPC2 protein has been observed (Friedland et al., 
2003). Previous studies have shown that the correct function of both NPC1 and 
NPC2 is necessary for the escape of cholesterol from within late 
endosomal/lysosomal compartments, with the affinity of cholesterol binding and 
dissociation to NPC1 greatly enhanced by the presence of NPC2 (Infante et al., 
2008b).  
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Figure 2: NPC1 structure and proposed pathway of cholesterol binding 
(A) Secondary structure schematic of NPC1 in relation to the late 
endosomal/lysosomal membrane, showing 13 transmembrane domains (1-13). 
NTD, N-terminal domain; MLD, middle luminal domain; SSD, sterol-sensing 
domain; CRL, Cysteine-rich loop (Lloyd-Evans and Platt, 2010, Li et al., 2016). 
(B) Suggested model of NPC2 and NPC1 mediated cholesterol transport in late 
endosomes/lysosomes. Cholesterol esters released from endocytosed low-density 
lipoprotein complexes are hydrolysed by acid lipase to produce unesterified 
cholesterol, which is subsequently bound by the soluble luminal protein NPC2. 
NPC2 transfers unesterified cholesterol to NPC1 at the N-terminal domain, 
resulting in a conformational change in NPC1 structure, giving unesterified 
cholesterol access to the transmembrane sterol-sensing domain. Unesterified 
cholesterol subsequently escapes the late endosomal/lysosomal by an unknown 
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Although the exact and complete mechanism for late endosomal/lysosomal 
cholesterol egress via NPC1 and NPC2 is still currently unknown, the combination 
of structural and biochemical studies have led to the proposal of a cholesterol 
transport chain (Figure 2B). Due to its poor solubility in water, cholesterol is 
distributed throughout the body in the form of cholesterol esters that are packaged 
into lipoproteins (Brown and Goldstein, 1986). These lipoproteins are absorbed by 
cells for downstream use via the cholesterol uptake pathway, to which both NPC1 
and NPC2 are crucial (Carstea et al., 1997). Endocytosis of these lipoproteins results 
in their transportation to late endosomes and lysosomes, where cholesterol is 
liberated via lipolysis by the lysosomal acid lipase enzyme (Goldstein et al., 1975). 
Luminal free unesterified cholesterol subsequently binds to the cholesterol-binding 
site of NPC2, with its hydroxyl group exposed (Xu et al., 2007). NPC2 bound 
cholesterol is then docked and transferred to a pocket in the N-terminal domain of 
NPC1, that has been shown to bind cholesterol in the opposite orientation to NPC2, 
with its hydrophobic side chain exposed (Kwon et al., 2009). Reorientation of the 
flexible proline-rich bridge connecting the N-terminal domain and the rest of NPC1 
may then allow the movement of cholesterol to within the sterol-sensing domain 
cavity, which gives access to the late endosomal/lysosomal bilayer. As the 
hydrophobic side chain remains exposed, the deposited cholesterol could escape via 
the membrane pocket’s lateral opening, releasing cholesterol into the luminal leaflet 
of the endosomal/lysosomal bilayer (Li et al., 2016). The embedded cholesterol must 
subsequently be flipped to the cytoplasmic leaflet of the late endosomal/lysosomal 
leaflet by an unknown mechanism, for subsequent downstream delivery to other 
intracellular membranes, such as the endoplasmic reticulum, recycling endosomes 
and mitochondria (Ikonen, 2008). 
1.3.3 NP-C Lipid storage 
Although NP-C is often characterised as a cholesterol storage disorder, NPC1 or 
NPC2 deficiency results in the storage of multiple lipid species within late 
endosomal/lysosomal compartments of cells throughout almost all tissues. Early 
studies revealed moderate levels of sphingomyelin storage, compared to the levels 
seen in ASM deficient NP-A and NP-B patients, leading to the denomination 
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Niemann-Pick Type C (Spence and Callahan, 1989). However, an extensive 
accumulation of unesterified cholesterol, multiple glycosphingolipids and 
sphingosine has also been shown (Lloyd-Evans et al., 2008), with the ratio of 
cholesterol to sphingomyelin significantly higher in NP-C than in NP-A or NP-B 
patients (Fan et al., 2013, Vanier, 2015). This indicated towards a different 
developmental pattern between the disease groups, where sphingomyelin 
accumulation was a secondary result of primary storage (Walkley and Vanier, 2009).  
 
Interestingly, differences in the ratio of individual lipid species accumulation within 
this multi-lipid storage disease has also been demonstrated between visceral organs 
and the central nervous system, in both patients and an NP-C mouse model (Vanier, 
2015) (Figure 3B). In the peripheral tissues such as the liver and spleen of patients, 
NP-C leads to the major accumulation of unesterified cholesterol, sphingomyelin and 
sphingosine, with significant elevations of several glycosphingolipids also observed, 
including glucosylceramide, lactosylceramide, globotriaosylceramide and 
gangliosides GM2 and GM3 (Rodriguez-Lafrasse et al., 1994, Walkley and Vanier, 
2009). The NP-C mouse model demonstrates similar visceral storage profiles, 
however in contrast to human patients, higher levels of lipid accumulation occur in 
the liver than in the spleen (Goldin et al., 1992, Sleat et al., 2004, Fan et al., 2013). In 
comparison, brains exhibit extreme levels of glycosphingolipid accumulation, 
including gangliosides GM3 and GM2, and to a lesser extent glucosylceramide, 
lactosylceramide and gangliotriaosylceramide in both patients (Tjiong et al., 1973, 
Vanier, 1999) and the NP-C mouse model (Sleat et al., 2004, Fan et al., 2013) 
(Figure 3B). Interestingly, no changes in overall brain cholesterol or sphingomyelin 
levels have been observed (Vanier, 1999), however histochemical analysis has 
revealed positive cholesterol accumulation in neurones of the NP-C mouse (Zervas et 
al., 2001a), suggesting a redistribution of intracellular cholesterol. The brain is the 
most cholesterol-rich organ, with the majority of cholesterol being contained in the 
myelin sheaths formed by oligodendrocytes. Most brain cholesterol is synthesised 
locally via de novo synthesis in the ER, independent of NPC1/2 function (Zhang and 
Liu, 2015). However, relatively small amounts of cholesterol uptake have been 
reported in neurons via glial delivery, which would require NPC1/2 functionality and 
may explain the low level neuronal cholesterol accumulation (Vance, 2012). 
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Figure 3: Sphingolipid structure and degradation pathway in the late 
endosomes/lysosomes of cells. 
(A) Graphical representation of the catabolic pathway of selected sphingolipids within 
the late endosomes/lysosomes of cells. The individual proteins and activator 
proteins required for each degradation step and their respective diseases are also 
presented. 
(B) Graphical representation of the structure of lipids that accumulate in the brain and 
liver of Npc1-/- mice (Lloyd-Evans and Platt, 2010). 
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The identification of the primary offending metabolite in NP-C still remains 
unanswered (Lloyd-Evans and Platt, 2010). While NPC1 and NPC2 have been 
demonstrated to bind cholesterol, NPC1 has still not been shown to function as a 
direct cholesterol transporter. NPC1 may also act as a cholesterol-regulated protein, 
where NPC1 transports other cargo in response to, or in combination, with 
cholesterol. This function would be consistent with other proteins containing a sterol-
sensing domain (Infante et al., 2008a), while NPC1’s sterol sensing domain would 
allow cholesterol sensing in both the late endosomal/lysosomal lumen and inner 
luminal leaflet. Other factors suggesting that cholesterol is not the primary offending 
metabolite in NP-C include: (1) lysosomal accumulation of cholesterol has been 
observed in other disorders despite the normal function of NPC1, (2) no clinical 
benefit of cholesterol lowering therapies to NP-C patients and (3) the only currently 
licenced drug in the European Union (EU) for NP-C disease is miglustat, which does 
not affect cholesterol levels (Lloyd-Evans and Platt, 2010). Lloyd-Evans and Platt 
have extensively covered cases for and against several other individual lipid species 
being the primary offending metabolite, however its identification and role in 
pathology remains unclear (Lloyd-Evans and Platt, 2010). 
1.3.4 NP-C Pathology 
Common to the majority of lysosomal storage disorders, the exact or combination of 
processes resulting in cellular damage and ultimately degeneration are not known in 
NP-C, however a range of potential NP-C specific pathology mechanisms have been 
identified and proposed. 
 
The previously discussed link between abnormal intracellular calcium homeostasis 
and lysosomal storage disorders has also been made in Niemann-Pick Type C 
disease. In contrast to other disorders, NPC1-mutant cells demonstrated normal Ca2+ 
concentrations within the endoplasmic reticulum and mitochondria, however 
significantly lower levels of Ca2+ were observed in late endosomal/lysosomal 
compartments (Lloyd-Evans et al., 2008). The release of calcium from these acidic 
compartments is crucial for endocytic fusion and transport events (Piper and Luzio, 
2004, Morgan et al., 2011), with this dysfunction thought to lead to the additional 
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multi-lipid accumulation observed in NPC1-mutant cells. Although NP-C is often 
considered primarily a cholesterol storage disease, the accumulation of sphingosine 
was identified as the initiating storage metabolite during altered calcium 
homeostasis, resulting in secondary cholesterol and sphingolipid storage via 
endocytic dysfunction (Lloyd-Evans et al., 2008). 
 
The block in late endosome and lysosome fusion and secondary lipid storage 
observed in NP-C mutant cells (Goldman and Krise, 2010) may also have a profound 
effect on cellular metabolic stress and autophagy. As endocytic and autophagic 
pathways are crucial for the maintenance of intracellular metabolic homeostasis 
(Platt et al., 2012), the loss in the release of lipid species from endolysosomes and 
autolysosomes necessary for downstream metabolic pathways may result in cellular 
metabolic stress (Walkley, 2007). This effect may be particularly significant in 
NPC1 or NPC2 deficient cells, due to the wide range of lipids that accumulate and 
become trapped in late endosomal/lysosomal compartments (Platt et al., 2012). 
Cholesterol and sphingomyelin demonstrate a particularly strong interaction, as these 
two lipids will normally co-localise in cells (Quinn, 2013). Together they stabilize 
bilayers and form lipid rafts, which are major sites of cell signalling activity (Skocaj 
et al., 2014). Interestingly, the loss of NPC2 function has been reported to result in 
the specific impairment of lysosome reformation, which should result in a similar 
pathological consequence as endocytic dysfunction (Goldman and Krise, 2010). 
Metabolic stress and starvation are stimuli for enhanced autophagy, where the fusion 
of late endosomes and lysosomes with autophagosomes are crucial steps resulting in 
cargo degradation within autophagy. However, NPC1-mutant cells demonstrated 
impairment of autophagy-specific traffic needed for amphisome and autolysosome 
formation (Sarkar et al., 2013). Additionally, the degradation of autolysosomal 
cargoes has also shown to be impaired in NPC1-mutant cells, with the reduction in 
autophagic flux due to the presence of accumulated storage material (Cologna et al., 
2014). Interestingly, the autophagic pathway was also shown to further exacerbate 
lipid storage by representing an additional source of stored cholesterol in lysosomes, 
thereby creating a positive feedback loop. 
 
The central nervous system is particularly sensitive to oxidative stress damage, due 
to the high concentration of polyunsaturated fatty acids available for peroxisomal 
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oxidation, high amounts of oxygen consumed during energy production and low 
concentrations of antioxidants (Vazquez et al., 2012). The extent of oxidative stress 
damage in NP-C pathology is unknown, however oxidative stress has been observed 
in the brain and livers of NP-C mice (Smith et al., 2009). Additionally, cholesterol 
oxidation products known as oxysterols have been detected in the plasma of NP-C 
patients (Porter et al., 2010) and NP-C patients exhibit decreased antioxidant defence 
capability (Fu et al., 2010). The likely driving force behind oxidative damage in NP-
C cells could be the dysfunction of mitochondria, as their dysfunction is a central 
part of many neurodegenerative disorders (Vazquez et al., 2012). Various studies 
have reported high levels of cholesterol within mitochondria of NP-C cells, which 
resulted in changes to the mitochondrial organisational network, abnormal 
mitochondrial morphology and impaired mitochondrial function, characterised by 
altered composition of the respiratory chain complex, reduction in cellular ATP 
concentrations and increased respiration (Yu et al., 2005, Charman et al., 2010, Wos 
et al., 2016). A further source of reactive oxygen species is the dysfunctional 
peroxisome (Bonekamp et al., 2009) and the impairment of fatty acid oxidation 
within peroxisomes has also been reported as an early indication of disease 
progression in the NPC1 mouse model (Schedin et al., 1997). Interestingly, 
peroxisomal disorders result in the storage of gangliosides within cells and may form 
a link with other lysosomal storage disorders including NP-C, where these 
gangliosides are observed as secondary storage metabolites (Platt et al., 2012). Other 
additional sources of oxidative stress include high concentrations of copper 
(Barnham and Bush, 2008), which was been reported to accumulate in the liver, bile 
and plasma of NP-C mice (Vazquez et al., 2011), and decreased bioavailability of the 
antioxidant vitamin E, which also accumulates in the lysosomes of NP-C mutant 
cells and is normally particularly abundant in the cerebellum (Vazquez et al., 2012). 
 
As with other lysosomal storage disorders, the prolonged activation of the innate 
immune system and resulting inflammation may represent an additional possible 
source of pathology (Platt et al., 2016). However, studies have pointed towards cell 
autonomous neurodegeneration, resulting in the proposal of neuroinflammation as a 
secondary result of neurodegeneration, rather than a primary cause (Lopez and Scott, 
2013). Additionally, complement has been shown to not be involved in NP-C 
neuropathology (Lopez et al., 2012). While innate immune activation may not be a 
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major source of pathogenesis, anti-inflammatory therapies demonstrated therapeutic 
efficacy and significant extension in the lifespan of NP-C mice (Smith et al., 2009), 
indicating that neuroinflammation may play a role in disease enhancement (Platt et 
al., 2016). 
 
Further reported sources of possible pathology include up-regulation of genes 
associated with death receptor signalling, resulting in the induction of apoptosis in 
the brains of the NP-C mouse model (Wu et al., 2005), necroptosis (Cougnoux et al., 
2016), altered transition metal homeostasis (Hung et al., 2014) and impaired 
neurosteroid synthesis (Griffin et al., 2004). 
1.3.5 Clinical Presentation of NP-C 
The clinical presentation of Niemann-Pick Type C is extremely heterogenous and 
complex, as the age of disease onset, average lifespan and symptoms can vary 
greatly (Vanier, 2010). As with the majority of other lysosomal storage disorders, 
NP-C is generally classified as a neurovisceral condition, however the extent of 
either visceral or neurological pathology development and timing of the respective 
disease manifestations can also differ. Visceral pathology has been reported to be 
absent in approximately 15% of all diagnosed patients, with an absence of 50% in 
adult-onset patients (Vanier, 2013). Visceral pathology severity increases with earlier 
disease onset, however there is no apparent link between timing of visceral disease 
onset and subsequent neurological pathology development. The strongest indicator of 
NP-C visceral pathology is isolated splenomegaly or in combination with 
hepatomegaly (Wijburg et al., 2012), which is observed in the majority of NP-C 
patients (Patterson et al., 2012). However, the degree of splenomegaly has no 
correlation with neurological disease severity or stage of overall disease progression 
(Mengel et al., 2013). Hepatomegaly is usually isolated to younger patients, 
developing simultaneously to splenomegaly (Sevin et al., 2007), while in extreme 
early-onset cases choleostatic jaundice and hepatopathy leading to liver failure have 
been observed (Kelly et al., 1993). Other visceral NP-C symptoms include lung 
disease and thrombocytopenia, however their occurrence is limited (Mengel et al., 
2013). 
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In comparison, the neurological manifestations of NP-C are even more diverse and 
occur in all patients, apart from severe perinatal cases where patients die before 
neurological disease progression. The development of ataxia is typical in NP-C 
patients and is linked to the degeneration of Purkinje cells in the cerebellum (Sarna et 
al., 2003, Walterfang et al., 2013). Ataxia in NP-C patients is classified as a ‘slow 
ataxia’ when compared to other non-NP-C ataxia patients, resulting in slow 
movements, impaired gait and general clumsiness (Mengel et al., 2013). Progressive 
ataxia will usually develop after dystonia, with the delay between manifestations 
correlating to disease progression. Dystonia, a neurological movement disorder 
observed in the majority of NP-C patients, is due to neuropathology in the basal 
ganglia and cerebellum, which results in excessive involuntary muscle contraction 
(Walterfang et al., 2013). The specific combination of ataxia and dystonia is a clear 
sign of NP-C (Wraith et al., 2014), however they can present individually, often 
resulting in misdiagnosis. A result of this combination is the development of 
dysarthria, where impaired coordination of the motor-speech system leads to 
irregular slurring of speech (Ogawa et al., 2010). Dysphagia is a common symptom 
in NP-C patients (Patterson et al., 2012), with impaired brainstem and cortical 
function ultimately causing swallowing difficulties (Ertekin and Aydogdu, 2003). A 
major implication of dysphagia is the correlation with aspiration pneumonia, which 
is a common cause of death in NP-C patients (Walterfang et al., 2012). One of the 
earliest neurological manifestations can be the development of hypotonia, 
characterised by weakness, low muscle tone and abnormal reflexes (Mengel et al., 
2013). Additionally, the early onset of hypotonia correlates to a more progressive 
infantile version of NP-C (Wijburg et al., 2012). The early development of vertical 
supranuclear gaze palsy (VSGP) in patients is a strong indicator for neurological NP-
C pathology and is present in approximately 65% of cases (Salsano et al., 2012). 
VSGP is characterised by a deficit in voluntary and reflexive vertical saccadic 
movements of the eyes, due to a lesion above the cranial motor nerve nuclei. 
Subsequent impairment of horizontal saccades correlates to progressive 
neurodegeneration and disease progression (Solomon et al., 2005). Other common 
neurological manifestations include partial or general seizures, cataplexy, high 
frequency hearing loss and delayed developmental milestones (Mengel et al., 2013). 
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Neurological manifestations are accompanied by progressive psychiatric symptoms 
in NP-C patients. Gradual cognitive decline has been observed in most NP-C patients 
and is characterised by the delay in cognitive development in younger-onset patients 
and impaired executive functioning, memory loss and cognitive slowing in older-
onset patients, which may be misinterpreted as other more common 
neurodegenerative disorders, such as Alzheimer’s disease (Mengel et al., 2013). 
Psychosis with a visual hallucinatory phenotype has also been reported to present in 
older-onset patients (Nia, 2014). 
 
 
Figure 4: Presentations of Niemann-Pick Type C disease 
Graphical representation of the common types of NP-C with their associated 
neurovisceral symptoms, depending on age of neurological pathology onset (Vanier, 
2015). 
Due to the extremely heterogeneous clinical presentations of NP-C disease, patients 
are categorised by NP-C types based on the age of neurological symptoms onset 
(Figure 4), regardless of prior visceral symptoms, apart from severe perinatal cases 
where death is caused by visceral pathology presumably before neurological disease 
progression (Vanier, 2010). 
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Perinatal presentation of NP-C is characterised by severe visceral pathology in the 
form of cholestatic liver disease and progressive hepatosplenomegaly. The majority 
of patients with this severe acute neonatal cholestatic form will die by 6 months of 
age (Vanier et al., 1988). Unlike all other forms, no neurological manifestations are 
observed during the neonatal period. 
 
The early infantile period (2 months – 2 years) is usually characterised by delayed 
motor development and central hypotonia from the age of 1 year and patients will 
often fail to learn to walk. Disease progression results in impaired motor skills, 
mental regression, spasticity and intention tremor, with death usually occurring 
before 5 years of age (Vanier, 2010). Visceral NP-C disease is mainly limited to 
splenomegaly or hepatosplenomegaly and occurs before neurological manifestations 
in the first months of life. 
 
NP-C patients with the late infantile type NP-C (2 – 6 years) present with early 
splenomegaly or hepatosplenomegaly, which may go undiagnosed. Subsequent 
neuropathology is associated with ataxic gait and clumsiness at the age of 3 to 5 
years. Disease progression can result in cataplexy, impaired mental development, 
seizures, dysphagia, dysarthria and increased spasticity, with death usually occurring 
before 12 years of age. 
 
The juvenile form of NP-C is the most common form of the disease and onset occurs 
from 6 to 15 years of age. Late infantile and juvenile forms are often combined under 
the heading childhood onset NP-C (Patterson, 1993). Moderate splenomegaly is 
frequent and may have commenced from the neonatal period, yet remained 
undetected. Neurological onset is characterised by writing difficulties, impaired 
attention and VSGP. As the disease progresses, patients exhibit learning disabilities, 
cataplexy, dysarthria, seizures, dysphagia and ataxia. The lifespan of patients with 
the juvenile form of NP-C is extremely varied, with patients often surviving until 25-
30 years of age (Group et al., 2009). 
 
The final form of NP-C is adult onset, occurring after 15 years of age. Visceral 
pathology in the form of splenomegaly appears rare at the time of diagnosis (Fensom 
et al., 1999), however previous visceral pathology cannot be ruled out. The diagnosis 
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of this form of NP-C is likely to be underestimated, due to a characteristically slow 
disease progression and large spectrum of neurological symptoms similar to the 
juvenile form (Vanier, 2010). VSGP is common along with cerebellar ataxia, 
dysarthria, cognitive decline and psychiatric disorders including psychosis, paranoia 
and visual hallucinations. 
1.3.6 NP-C Diagnosis 
As previously discussed, the correct and timely diagnosis of NP-C can be 
challenging and as a result the incidence of this disease is most likely underrated 
(Section 1.3.1). Although significant advancements in the understanding of NP-C 
genetics and biochemistry, laboratory testing has remained complex, expensive and 
localised to specialist centres (Vanier et al., 2016). Combined with a broad disease 
manifestation spectrum and limited disease awareness, the time between disease 
onset, diagnosis and subsequent treatment can be substantial (Group et al., 2009). 
Early diagnosis is particularly important, as treatments will be more effective the 
earlier in disease progression they are given. Initial steps towards diagnosis are the 
gathering and analysis of clinical history, where certain combinations of visceral, 
neurological and psychiatric symptoms can point specifically towards NP-C. To aid 
in this effort the screening tool ‘NP-C Suspicion Index’ was developed (Wijburg et 
al., 2012), however overlapping symptoms and heterogeneity of disease 
manifestations and onset can complicate this process.  
 
Current laboratory techniques utilised for NP-C fall into 3 major categories: lipid 
accumulation testing, biochemical markers and genetic testing. Until recently the 
filipin test was regarded as the standard assay for NP-C diagnosis, where the 
fluorescent polyene macrolide filipin is applied to patient fibroblasts, causing the 
fluorescent staining of accumulated unesterified cholesterol (Pentchev et al., 1985). 
Strong perinuclear staining is visible in 80% - 85% of NP-C patients, with the 
remaining patients exhibiting either an intermediate staining profile or no filipin 
staining, which will normally be followed by complementary NPC1 and NPC2 gene 
sequencing for further clarification (Vanier and Latour, 2015). Additionally, certain 
heterozygotes, compound heterozygotes, ASM deficient patients and patients with 
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other disorders associated with secondary impaired cholesterol egress such as Smith-
Lemli-Opitz syndrome (Platt et al., 2014) and Tangier disease (Sechi et al., 2014) 
have been shown to demonstrate abnormal filipin patterns (Vanier et al., 2016).  
 
The timing, cost and specialist knowledge required for filipin testing demonstrates 
the need for a high-throughput, cost-effective and specific biomarker analysis screen 
for NP-C. A further beneficial use of NP-C specific biomarkers would be their 
potential use in the tracking of treatment efficacy during preclinical animal studies 
and clinical trials. Two of the currently most promising biomarkers for NP-C are 
plasma oxysterols and bile acid metabolites. As previously discussed (Section 
1.3.4), the increase in oxidative stress in NP-C affected cells leads to elevated 
reactive oxygen species levels and a subsequent accumulation in abnormal oxysterol 
concentration, which has also been demonstrated by mass spectrometry in NP-C 
patients (Porter et al., 2010, Jiang et al., 2011). However, a certain number of 
confirmed NP-C patients have also shown non-significant levels of oxysterol 
elevation, and patients with other disorders including NP-A and NP-B have also 
exhibited elevated plasma oxysterol levels (Klinke et al., 2015). Bile acid metabolites 
represent another possible biomarker for NP-C patients, as they were identified at 
high concentrations in patient urine (Alvelius et al., 2001), thought to be due to the 
utilisation of different bile acid synthesis pathways in NP-C patients. While this 
assay is less prone to artefacts compared to oxysterol analysis and can be applied to 
dry blood spots as well as plasma, it may not be able differentiate between ASM-
deficient and NP-C patients (Vanier et al., 2016).  
 
Finally genetic testing of the NPC1 and NPC2 genes via Sanger sequencing is 
usually carried out for confirmation of NP-C diagnosis, in combination with 
biomarker or filipin testing (Patterson et al., 2012). However, advancements in 
availability, cost and throughput capacity of next-generation sequencing and whole 
exome sequencing techniques will result in increased routine genetic screening 
potential and is currently recommended for all patients (McKay Bounford and 
Gissen, 2014). 
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1.3.7 Therapeutic Options for NP-C 
As with many lysosomal storage disorders, there is currently no cure for NP-C, but a 
range of therapies have shown therapeutic efficacy in stabilising or slowing disease 
progression, in either preclinical NP-C animal model studies or in clinical trials. 
 
The rationale behind substrate reduction therapy is the inhibition of the biosynthesis 
of compounds that accumulate in specific lysosomal storage disorders, which will 
subsequently result in a decrease in storage material (Radin, 1996). N-
butyldeoxynojirimycin (miglustat, Zavesca®) is a small water-soluble imino-sugar 
that reversibly inhibits glucosylceramide synthase, the primary enzyme in 
glycosphingolipid synthesis (Platt et al., 1994). Miglustat can be administered orally, 
has a half-life of 7 hours and can readily cross the blood-brain barrier, allowing 
treatment of neurological pathology (European Medicines Agency, 2016). Although 
miglustat was initially approved for the treatment of Type I Gaucher disease (Cox et 
al., 2000), it has also shown beneficial effects in NP-C animal models by reducing 
storage material and significantly slowing neurodegeneration and disease progression 
(Zervas et al., 2001b, Lachmann et al., 2004, te Vruchte et al., 2004, Stein et al., 
2012). Several clinical trials involving NP-C patients have subsequently been carried 
out (Patterson et al., 2007, Patterson et al., 2010, Wraith et al., 2010), as well as 
multicentre observational retrospective cohort studies (Pineda et al., 2009). 
Generally, miglustat treatment resulted in the deceleration or stabilisation of key 
individual neurological manifestations after 6 - 12 months of treatment, including 
improvements in ambulation, manipulation, language and swallowing (Walterfang et 
al., 2012, Lyseng-Williamson, 2014). Benefits of miglustat were also generally better 
in patients with older onset of neurological manifestations, especially when 
administration was started in the early stages of disease progression (Santos-Lozano 
et al., 2015, Papandreou and Gissen, 2016). The use of miglustat has subsequently 
been approved for the treatment of neurological manifestations in both paediatric and 
adult NP-C patients in a number of countries including the EU, Australia, Brazil, 
Canada, Japan, Russia, Switzerland and South Korea, however the Food and Drug 
Administration have not approved its use in the USA. The main side effects of 
miglustat treatment are primarily tolerability issues relating to gastrointestinal 
affects, such as diarrhoea, flatulence, abdominal pain, nausea and vomiting. 80% of 
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patients present these side effects accompanied by mild to moderate weight loss in 
the first 6 months of treatment, which then decreased to 50 - 60% (Remenova et al., 
2015). These gastrointestinal effects are attributed to suboptimal hydrolysis of 
carbohydrates and osmotic diarrhoea, due to the inhibition of intestinal 
disaccharidase enzymes (Belmatoug et al., 2011, Papandreou and Gissen, 2016). The 
most common cause of miglustat treatment discontinuation is due to these 
gastrointestinal side effects (Belmatoug et al., 2011, Lyseng-Williamson, 2014). 
 
A recent promising candidate for NP-C treatment is the starch derivative 2-
hydroxypropyl-β-cyclodextrin (HP-β-CD). Cyclodextrins are a group of 
oligosaccharides that form a cone-like structure with a hydrophobic core and 
hydrophilic exterior, allowing the formation of water-soluble complexes with 
otherwise hydrophobic compounds (Pitha et al., 1988). It was initially given as an 
excipient with allopregnanolone to Npc1-/- mice (Griffin et al., 2004), however it was 
later identified that the beneficial effects of decelerated neurodegeneration and 
reduced lipid storage were mainly due to HP-β-CD (Davidson et al., 2009, Liu et al., 
2009). HP-β-CD is thought to bind unesterified cholesterol that accumulates in late 
endosomes/lysosomes of NP-C cells and facilitate in its egress (Rosenbaum et al., 
2010), however the exact mechanism by which HP-β-CD affects cholesterol 
trafficking and neurodegenration is unknown. It has been proven that HP-β-CD does 
not cross the blood-brain barrier efficiently (Pontikis et al., 2013) and as a result is 
most effective in decelerating neurological disease progression when administered 
directly into the cerebrospinal fluid (Vance and Karten, 2014, Vite et al., 2015). 
Systemic delivery via subcutaneous or intravenous administration of HP-β-CD 
resulted in amelioration of visceral liver pathology in the feline model of NP-C, 
however the higher doses necessary to affect neurological pathology resulted in 
pulmonary toxicity (Vite et al., 2015). Although HP-β-CD demonstrates a moderate 
half-life, the lack of movement across the blood-brain barrier results in the need for 
delivery to the cerebrospinal fluid via lumbar puncture or ommaya reservoir every 
one to two weeks. Continual invasive administration is accompanied by a side effect 
of high frequency hearing loss due to ototoxicity (Ward et al., 2010, Matsuo et al., 
2013, Maarup et al., 2015). Analysis of HP-β-CD treatment efficacy and safety in 
NP-C patients until now has been limited to individual cases (Matsuo et al., 2013, 
Maarup et al., 2015), however clinical trials with intrathecal delivery (Phase I 
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ClinicalTrials.gov Identifier: NCT01747135, Phase II/III ClinicalTrials.gov 
Identifier: NCT02534844) and intravenous delivery (Phase I ClinicalTrials.gov 
Identifier: NCT02939547, Phase I/II ClinicalTrials.gov Identifier: NCT02912793) 
are currently underway. 
 
As a high amount of NP-C cases are caused by mutations causing NPC1 misfolding 
and subsequent degradation, the use of chaperone protein based therapy may be 
beneficial to NP-C patients. The small molecular drug arimoclomol induces 
expression of molecular chaperones from the heat shock protein 70 family, thought 
to be involved in cellular protein repair pathways, thereby protecting pathologically 
challenged cells (Muchowski and Wacker, 2005). These molecular chaperones have 
also been linked to the folding and activity of NPC1 (Nakasone et al., 2014), and 
their upregulation via arimoclomol has subsequently shown efficacy in reducing lipid 
accumulation in NPC1 deficient cells (Kirkegaard et al., 2010) and moderate 
amelioration in both visceral and neurological pathology in the Npc1-/- mouse model 
(Kirkegaard et al., 2016). An observational study in NP-C patients is currently 
underway, which is being followed by a phase II/III clinical trial (ClinicalTrials.gov 
Identifier: NCT02612129). 
 
Histone deacetylase inhibitors represent another potential proteostatic therapy for 
NP-C. Histone deacetylase enzymes are involved in a number of cellular processes 
by influencing transcription regulation and have previously been used for various 
brain and neurodegenerative disorders (Kazantsev and Thompson, 2008, Haberland 
et al., 2009). The orally available histone deacetylase inhibitor, vorinostat, has shown 
to ameliorate cholesterol homeostasis in NP-C patient cells and a phase I/II clinical 
trial is currently in progress (ClinicalTrials.gov Identifier: NCT02124083). 
 
Other treatment options that have shown promise for NP-C include: acetyl-DL-
leucine, a natural amino acid derivative, previously shown to have a beneficial effect 
in patients with cerebellar ataxia (Strupp et al., 2013) and recently several NP-C 
patients (Bremova et al., 2015), and curcumin, the active ingredient of turmeric, 
which has been shown to normalise Ca2+ homeostasis and lipid storage in Npc1-/- 
mice, leading to a significant increase in the survival of Npc1-/- mice (Lloyd-Evans et 
al., 2008). 
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1.3.8 NP-C Animal Models 
Animal models are crucial tools used for understanding disease biology and 
therapeutic testing. Due to the highly conserved nature of the NPC1 gene (Blom et 
al., 2003), a variety of NP-C models from yeast to cats have been characterised or 
developed for analysis. The most commonly used and well-characterised NP-C 
model is the Npc1nih mouse (BALB/cNctr‐Npc1m1N/J, referred throughout this study 
as Npc1-/- mouse) (Pentchev et al., 1980). Genetic analysis of these mice revealed a 
large spontaneous frameshift mutation, via an insertion of 1,100bp and deletion of 
800bp from the Npc1 gene, ultimately knocking out the majority of the Npc1 gene 
(Loftus et al., 1997). This mutation results in minimal expression of truncated Npc1 
mRNA and no measurable levels of murine NPC1 expression in the Npc1-/- mouse 
model (Elrick et al., 2010). The Npc1-/- mouse model recapitulates many of the 
neuropathological features of human NP-C disease, with a rapid disease progression 
suggesting late infantile or juvenile form of NP-C disease. Npc1-/- mice exhibit no 
apparent symptoms until 4 weeks of age, however initial locomotor and behavioural 
deficits develop from 5 weeks of age. Disease progress is characterised by impaired 
gait, noticeable tremor and significant loss in weight from 7 - 10 weeks of age and 
death occurs from 10 - 12 weeks of age (Smith et al., 2009). Human neuropathology 
is also mirrored on the cellular level, with severe neurodegeneration and 
neuroinflammation, particularly in the cortex, thalamus, substantia nigra and the 
cerebellum (Elrick et al., 2010, Pressey et al., 2012). Accumulation of cholesterol 
and glycosphingolipids comparable to the human form of NP-C has been reported in 
the Npc1-/- mouse, with extreme elevation of sphingoid bases, ceramide and GM2 
gangliosides in the liver, compared to sphingoid bases and GM2 and GM3 
gangliosides in the brain (Pentchev et al., 1980, Fan et al., 2013). 
 
Recently other variant NP-C mouse models have been created or identified in an 
attempt to reflect other forms of the disease, such as the C57BL/6J-Npc1-/-, where the 
transferring of the BALB/c Npc1nih mutation to a C57BL/6 background resulted in a 
more severe form of the disease, particularly in the viscera (Parra et al., 2011). As a 
high amount of NP-C cases occur due to missense mutations in the NPC1 gene 
(Carstea et al., 1997, Bauer et al., 2002, Park et al., 2003), several NP-C mouse 
models with common missense mutations have been created (Maue et al., 2012, 
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Praggastis et al., 2015). These mutations result in misfolding of the NPC1 protein, 
rather than a complete loss of NPC1 expression, allowing the testing of proteostatic 
therapies such as chaperone therapy or histone deacetylase inhibition (Praggastis et 
al., 2015). These models are characterised by slower disease progression, comparable 
to later onset forms of NP-C. A range of studies has also been carried out in 
conditional Npc1 mutant mice, with the aim of analysing the effect of NPC1 loss in 
specific cell populations or organ compartments. These studies have lead to the 
conclusion of cell autonomous neurodegenration, where expression of NPC1 in 
neurons was critical for cell survival and isolated NPC1 expression in glial cells 
demonstrated no or minimal effect on neurodegeneration (Ko et al., 2005, Elrick et 
al., 2010, Lopez et al., 2011, Yu et al., 2011). 
 
A feline model of NP-C has also been characterised (Lowenthal et al., 1990, Brown 
et al., 1994), which is the result of a spontaneous missense mutation (2864G-C) 
(Somers et al., 2003) to Npc1, leading to neurovisceral pathology and lipid 
accumulation comparable to human NP-C (Vite et al., 2008). Other available NP-C 
models include yeast (Malathi et al., 2004), Caenorhabditis elegans (Sym et al., 
2000), Drosophila melanogaster (Huang et al., 2005) and zebrafish (Schwend et al., 
2011). 
1.4 Gene Therapy 
Gene therapy is defined by the European Medicines Agency as a therapy generally 
consisting of a vector or delivery system containing a genetic construct. This 
construct may be engineered to express a specific sequence or protein responsible for 
the regulation, repair, addition or deletion of a genetic sequence. Additionally, the 
therapeutic, prophylactic or diagnostic effects relate directly to either the 
recombinant nucleic acid sequence or to the protein product of the genetic construct. 
Recent rapid advances and successes in the field of nucleic acid delivery have 
attracted substantial scientific and commercial interest. The potential use of gene 
therapy is vast, from genetic disorders such as haemophilia or lysosomal storage 
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disorders, acquired diseases such as cancer or neurodegenerative disorders, to use in 
vaccinations (Del Pozo-Rodriguez et al., 2016). Over 1,800 ongoing or completed 
gene therapy clinical trials have been approved and while the majority focus on 
cancer therapy, the second largest disease group is monogenic disorders (Wirth et al., 
2013, Abedia.com, 2017). Monogenic disorders are in theory ideal candidates for 
gene therapy, as the delivery and subsequent expression of the single defective gene 
will result in the treatment of the disease. Successes have been fuelled by 
improvements in our understanding of the defective mechanisms and pathology of 
these disorders, combined with advances in genetic engineering and virology. Gene 
delivery is achieved by the use of a vector system, categorised as either viral or non-
viral, where the aim is efficient gene delivery to the correct site of action, while also 
minimising potential adverse affects. The following sections aim to introduce the 
field of viral vector mediated gene therapy and the use of viral vectors for the 
treatment of neurovisceral lysosomal storage disorders, including its potential use for 
Niemann-Pick Type C. 
1.5 Viral Vectors 
Viruses naturally represent appealing tools for gene delivery as they have evolved to 
efficiently deliver their genes in the form of either ribonucleic acid (RNA) or 
deoxyribonucleic acid (DNA) into mammalian cells. Viruses can differ by their viral 
particle structure, genome structure and composition, replication cycle and method of 
immune system evasion. Depending on the virus, the ultimate aim of infection may 
also differ, from hijacking host cell machinery for replication, killing the host cell in 
the process, such as with adenoviruses or herpes simplex viruses, to laying dormant 
in cells by integrating into the host genome, such as with adeno-associated viruses or 
lentiviruses. As viruses are ultimately pathogenic agents, their use for gene delivery 
requires their attenuation to be safely used in clinical applications. The results are 
known as recombinant viral vectors, where pathogenic and viral sequences 
unnecessary for viral vector transduction are removed, allowing the replacement with 
a therapeutic expression cassette. Despite the large number of viral families only a 
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small number of viruses have been extensively characterised and utilised for gene 
delivery. Currently, the most commonly used viral vectors are adenoviral, retroviral 
or lentiviral and adeno-associated viral vectors, each with their own advantages and 
disadvantages depending on the gene therapy target and requirement (Table 2). The 
efficiency of viral vectors is reflected by the fact that over 70% of all gene delivery 
vectors in gene therapy clinical trials are viral vector based (Ginn et al., 2013, 
Abedia.com, 2017). Early setbacks in the field of viral vector mediated gene therapy 
have forced the advancement in understanding the risks, characteristics and 
capabilities of viral vector gene delivery. These lessons have led to a series of 
successful and clinically promising clinical trials and commercialisation of the first 
viral vector gene therapy product. 
 
Vector Adenoviral γ-Retroviral Lentiviral 
Adeno-associated 
viral 
Family Adenoviridae Retroviridae Retroviridae Parvoviridae 
Particle size (nm) 70 - 120 100 100 20 - 25 
Genome dsDNA RNA RNA ssDNA 
Packaging 
capacity (kb) 
8 - 10 7 - 8 7 - 9 4.7 
Vector yield 
(vp/ml) 
1 x 1012 1 x 109 1 x 109 1 x 1013 
Chromosomal 
integration ? 
No Yes Yes Minimal 
Infects post-
mitotic cells? 
Yes No Yes Yes 
Immunogenicity High Low Low Low 
Insertional 
mutagenesis risk 
None High Medium Low 
Table 2: Summary of the characteristics of the most commonly used viral vectors 
for gene therapy. 
Adapted from (Choudhury et al., 2016). 
1.5.1 Adenoviral vectors 
In terms of the overall number of clinical trials, adenovirus based vectors have been 
the most widely used viral vectors, with a total of 23% of trials until 2012 utilising 
adenoviral vectors (Ginn et al., 2013). Adenoviruses are a family of non-enveloped 
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viruses with a relatively large, linear and double stranded DNA genome, which is 
packaged inside an icosahedral nucleocapsid. With over 57 distinct serotypes, 
adenoviruses have a wide range of tropism with the ability to infect an extensive 
range of organisms, often characterised by moderate to severe pathogenicity 
(Arnberg, 2012). Adenoviral vectors have been a popular choice as certain serotypes 
such as hAd2 and hAd5 are well characterised, they do not integrate into the host 
genome (Harui et al., 1999), are easily purified to high titres, can transduce a wide 
variety of both dividing and non-dividing cells and have a packaging capacity of up 
to 37 kilobase (kb) (Bett et al., 1993). Studies directly delivering adenoviral vectors 
to the brain also demonstrated promising long-term transduction in both neurons and 
glial cell populations (Akli et al., 1993, Davidson et al., 1993, Barcia et al., 2007). A 
major limitation associated with adenoviral administration in vivo is their capsid 
immunoreactivity, shown to be a result of their strong activation of host innate 
immune system (Appledorn et al., 2008, Tian et al., 2009). Additionally, due to the 
ubiquitous nature of wild-type adenoviral infections within populations, pre-existing 
neutralising antibodies can be a major obstacle and risk (Burgert et al., 2002). 
Although this antigenicity may be beneficial for adenoviral vector use as an 
immunogenic adjuvant, the high doses required for in vivo delivery can result in 
extreme inflammation and cytotoxicity. These dangers were demonstrated in an 
extreme case, where administration of an adenoviral vector for the treatment of 
ornithine transcarbamylase deficiency resulted in the death of a patient (Marshall, 
1999). Additionally, these host immune responses can often result in transient 
transgene expression in vivo (Stein et al., 1998, Yang et al., 1996). 
 
While adenoviral vectors remain popular for use in certain situations, such as cancer 
therapy, the development of new strategies limiting the extent of immunogenicity for 
direct gene delivery in vivo is crucial (Sheridan, 2011). Examples of such approaches 
include development of ‘gutted’ helper-dependent adenoviral vectors that lack all 
viral genes (Palmer and Ng, 2005), and the identification of alternative serotype-
based vectors shown to evade pre-existing immunity. Canine adenovirus serotype 2 
(CAV-2) is a promising alternative adenovirus serotype that has shown non-
significant levels of pre-existing neutralising antibodies in 98% of samples from a 
randomised cohort and also does not show cross-reactivity with ubiquitously present 
human adenovirus neutralising antibodies (Kremer et al., 2000). CAV-2 vectors have 
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also been reported to reduce innate immunoreactivity, compared to human Ad5 
vectors (Soudais et al., 2004). The potential use of CAV-2 for the treatment of 
Niemann-Pick Type C1 via direct cerebrospinal fluid administration is evaluated in 
this study. 
1.5.2 Lentiviral and retroviral vectors 
Lentiviruses and γ-retroviruses are part of the Retroviridae family, where a linear 
single stranded RNA genome (Figure 5A) is packaged into an isometric capsid 
surrounded by a spherical envelope consisting of a combination of glycosylated viral 
proteins (Burns et al., 1993, Tang et al., 1999). Following entry into a cell, the RNA 
genome is translated to produce viral reverse transcriptase and integrase proteins, 
which combine to synthesis double stranded DNA copies of the RNA viral genome 
that is subsequently integrated into the host genome. On the one hand, this stable 
integration into the host genome can be of great advantage, as integration leads to 
long-term expression in both the originally transduced cell and any resulting 
progeny. Ex vivo gene therapy modification of hematopoietic stem cells with 
retroviral and lentiviral vectors utilises this system for therapeutic effect (Cavazzana-
Calvo et al., 2000, Aiuti et al., 2013, Biffi et al., 2013). On the other hand, 
integration events can also result in insertional mutagenesis by disrupting or 
upregulating host genes. Where these two viruses differ is their preferred sites of 
integration and their ability to transduce dividing and non-dividing cells (Matrai et 
al., 2010). γ-retroviral vectors are only capable of transducing and integrating into 
dividing cells and their integration has been shown to preferentially target active 
genes and regional hotspots, specifically within a 5-kilobase pair window either side 
of the transcription start site (Schroder et al., 2002, Schwarzwaelder et al., 2007). 
The potential extreme dangers of such integration were demonstrated by the 
development of a leukaemia-like disorder in 4 patients administered with γ-retroviral 
based vectors for the treatment of X-linked severe combined immune deficiency 
(Hacein-Bey-Abina et al., 2003, Hacein-Bey-Abina et al., 2008). Analysis showed 
that these leukaemia-like disorders were the result of uncontrolled clonal T cell 
proliferation, due to integration events near proto-oncogenes LMO2 and BMI1.  
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In comparison, lentiviral vectors are capable of transducing both dividing and non-
dividing cells, and while integration into the host genome does occur, they 
demonstrate a relatively randomised integration preference (Schroder et al., 2002, 
Montini et al., 2006). Although lentiviral integration events are still more likely to 
occur around actively transcribed areas, they have been reported to not show any 
preference for integration in the immediate proximity of transcription start sites. 
Additionally the development of self-inactivating vectors has further reduced the 
potential side effects of insertion (Miyoshi et al., 1998, Zufferey et al., 1998). In self-
inactivating vectors a deletion in the 3’ lentiviral long terminal repeat (LTR region) 
results in the loss of intrinsic LTR promoter activity, which previously may have 
interfered with host gene regulation (Figure 5B). This modification also 
demonstrated a reduction of vector genomic RNA generation in host cell and viral 
insert silencing in vivo. While the risk of insertional mutagenesis remains present 
with integrating lentiviral vectors, the statistical probability of such events are 
significantly reduced, as demonstrated by their common and therapeutic use in ex 
vivo clinical trials and in vivo preclinical studies (Biffi, 2016). Recently, integrase-
defective non-integrating lentiviral vectors have been designed, which eliminate the 
danger for insertional mutagenesis at the potential cost of stable long-term transgene 
expression (Vargas et al., 2004, Yanez-Munoz et al., 2006). 
 
 
Figure 5: Illustrations of the HIV-1 viral genome and recombinant lentiviral 
vector genome. 
(A) Illustration of HIV-1 (lentiviral) genome organisation with all proviral-coding 
sequences. 
(B) Illustration of a current generation self-inactivating recombinant lentiviral vector, 
with LTR modifications, crucial cis-acting elements and inserted transgene 
cassette. ORF, open reading frame; WPRE, woodchuck hepatitis virus post-
transcriptional regulatory element; polyA, polyadenylation signal sequence. 
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Current generation non-replicating lentiviral vectors are based on the HIV-1 virus, 
but have been extensively modified for optimal transgene expression and safety, by 
the removal of specific viral genome sequences associated with pathogenicity. This 
includes the removal of lentiviral genes essential for replication (pol), capsid 
production (gag) and envelope packaging (env), along with a combination of 
accessory genes (vpu, vif, vpr, nef and tat). The resulting vector backbone only 
contains the modified 5’ and 3’ LTR, and packaging signal element (ψ) as remaining 
HIV-1 elements, with a moderate packaging capacity of 11kb (Kumar et al., 2001). 
These vectors can only replicate and produce fully functioning viral particles in the 
presence of these removed genes, which are provided in trans to cells during viral 
vector production. The viral envelope plays a crucial role in the tropism and 
transduction efficiency of lentiviral vectors. One of the most widely used lentiviral 
envelope is pseudotyped and contains the gag sequence from the completely 
independent vesicular-stomatitis virus. The resulting lentiviral pseudotyped 
vesicular-stomatitis virus G-protein (VSV-G) envelope produces a combination of 
broad tissue and cell tropism following in vivo administration, while also allowing 
high viral titre purification during vector production (Burns et al., 1993, Mochizuki 
et al., 1998, Sena-Esteves et al., 2004). During this study the potential use of a VSV-
G pseudotyped self-inactivating lentiviral vector for NP-C therapy is evaluated 
following in vivo administration directly into the cerebrospinal fluid. 
1.5.3 Adeno-associated viral vectors 
Adeno-associated virus (AAV) was originally identified as a contaminant during a 
laboratory production of adenovirus (Atchison et al., 1965) and has been 
subsequently classified as part of the Parvoviridae family, a family that is 
characterised by their relatively small and simplistic nature. Within the Parvoviridae 
family, AAV belong to the genus Dependoparvovirus, which for replication and 
virion production are dependent on a co-infection with a helper virus, such as 
adenovirus or herpesvirus (Casto et al., 1967, Buller et al., 1981). In the absence of a 
helper virus, wild-type AAV may remain quiescent by site specific integration at a 
targeted locus on human chromosome 19 (Kotin et al., 1992). No human pathology 
has been reported to be associated with AAV infection (Dismuke et al., 2013). 
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AAVs contain a relatively small 4.7kb single stranded (ss) DNA genome, which is 
packaged within an icosahedral, non-enveloped capsid. The wild-type AAV genome 
structure contains two 145bp short inverted terminal repeat (ITR) sequences at the 5’ 
and 3’ ends of the viral genome, which flank the two multi-cistronic coding regions 
rep and cap (Koczot et al., 1973). Base-pairing between the palindromic regions in 
AAV ITRs results in a T-shaped secondary structure, which is crucial for both AAV 
origin of replication and conversion of viral ssDNA genome into double-stranded 
(ds) DNA necessary for viral gene for expression (Weitzman and Linden, 2011). The 
rep gene encodes a group of 4 Rep proteins (Rep78, Rep68, Rep52 and Rep40), 
which are expressed via alternative promoters and as splice variants (Qiu and Pintel, 
2008). The Rep proteins are involved in viral genome replication, integration and 
genome packaging into readily synthesised empty capsids (Surosky et al., 1997, King 
et al., 2001). Both the sense and antisense ssDNA strands of the replicated viral 
genome are packaged into separate virions with identical efficiency (Berns and 
Adler, 1972). The cap gene encodes AAV capsid proteins VP1, VP2 and VP3 
(Becerra et al., 1988), together with a group of other viral proteins that traffic and 
assemble these capsid proteins during capsid synthesis (Naumer et al., 2012). The 
final icosahedral capsid consists of 60 copies of the three AAV capsid proteins 
VP1:VP2:VP3 in a 1:1:10 ratio, with variations to the VP3 protein structure thought 
to determine AAV receptor usage and viral serotype (Weitzman and Linden, 2011) 
(Table 3). 
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AAV1 NHP α2,3/α2,6 N-linked SA ? 83 67 










AAV4 NHP α2,3/α2,3 O-linked SA ? 60 ? 
AAV5 Human α2,3/α2,3 N-linked SA PDGFR 57 40 
AAV6 Human 
α2,3/α2,6 N-linked SA, 
SA/HSPG 
EGFR 83 46 
AAV7 NHP ? ? 82 ? 
AAV8 NHP ? LamR 83 38 
AAV9 Human N-linked Galactose LamR 82 47 
Table 3: Summary of principle characteristics for AAV serotypes 1 - 9. 
NHP, non-human primate; ?, unknown; HGFR; hepatocyte growth factor receptor; 
LamR, laminin receptor; FGFR1, fibroblast growth factor receptor 1; HSPG, heparin 
sulphate proteoglycan; EGFR, epidermal growth factor receptor; PDGFR, platelet-
derived growth factor receptor; NAbs, neutralising antibodies. Adapted from 
(Lisowski et al., 2015) and (Saraiva et al., 2016). 
 
The ubiquitous nature of AAV in humans is demonstrated by the identification of 12 
natural serotypes and over 100 distinct AAV isolates from human or non-human 
primate origins (Gao et al., 2004). These 12 serotypes, defined by motifs in the 
capsid proteins that can be identified by specific neutralising antibodies, share 
between 51% and 99% identity in capsid amino acid sequence (Lisowski et al., 2014) 
(Table 3) and the general organisation of the viral genome is also maintained. The 
variation in the structure of exposed regions of the viral capsid proteins defines the 
interaction with the principal AAV receptors (Table 3) and intracellular trafficking 
pathways, which are central to viral tropism (Gao et al., 2003, Nonnenmacher and 
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Weber, 2012). Following cell surface receptor binding, the successful infection of 
AAV depends on a series of steps including endocytosis, escape from 
endosomal/lysosomal compartments, translocation to the nucleus and viral capsid 
uncoating, whereby the ssDNA genome is released for complementary strand 
synthesis and ultimately transcription from the now dsDNA viral genome (Weitzman 
and Linden, 2011, Balakrishnan and Jayandharan, 2014). Characterisation stuides of 
these naturally occurring AAV variants have demonstrated extremely diverse organ, 
tissue and cell tropism (White et al., 2011, Asokan et al., 2012). 
 
The relatively simplistic structure of the wild-type AAV genome facilitated the 
production of recombinant AAV (rAAV) gene delivery vectors (Figure 6) (Daya and 
Berns, 2008). This is accomplished by the removal of viral coding sequences rep and 
cap, and replacing them with a desired expression cassette. Only the flanking ITRs 
remain from the original genome, as they contain the cis-acting sequences required 
for vector genome replication and packaging. Despite the removal of all viral genes, 
the packaging capacity of rAAV vectors remains extremely limited, as an expression 
cassette containing the minimum of a promoter, transgene and polyadenylation 
signal sequence together with flanking ITRs should not exceed the wild-type AAV 
genome length of 4.7kb to avoid packaging or truncation problems. The resulting 
viral vectors are non-replicating, so to achieve the necessary replication during 
vector production, the rep and cap genes are provided in trans together with other 
necessary adenoviral helper functions. As these vectors lack the viral Rep proteins 
necessary for host genome integration, the viral genome persists in an extra-
chromosomal episomal form (Nakai et al., 2001). Insertional mutagenesis risk is 
therefore thought to be minimal, although these episomal vector genomes may be 
lost over time in actively replicating cell populations (Cunningham et al., 2008). 
Recent studies have reported that a small yet significant percentage of rAAV vector 
genomes can still achieve integration into the host genome, demonstrated by 
integration events within the liver of rAAV administered animals being associated 
with an increased occurrence of hepatocellular carcinoma (Donsante et al., 2007, 
Chandler et al., 2015). The potential seriousness of this risk in human patients 
currently remains unclear, however this factor should be taken into consideration, 
especially with higher dose administration. 
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Figure 6: Illustrations of wild-type AAV genome and rAAV vector genome. 
(A) Illustration of wild-type AAV genome organisation with all proviral coding 
sequences. Arrows depict start of VP1, VP2 and VP3 open reading frames. 
(B) Illustration of current recombinant AAV vector, with cricual cis-acting inverted 
terminal repeat (ITR) regions flanking inserted transgene cassette. ORF, open 
reading frame; WPRE, woodchuck hepatitis virus post-transcriptional regulatory 
element; polyA, polyadenylation signal sequence. 
The development of recombinant AAV vectors has allowed the cross-packaging of 
rAAV vector genomes into different AAV capsids, thereby creating pseudo-
serotyped rAAV vectors (Rabinowitz et al., 2002). As capsid structure is a major 
factor in AAV tropism, the use or modification of different capsids can greatly 
benefit vector efficiency. This process has lead to the AAV vector toolkit metaphor, 
where different rAAV vectors can be chosen for their specific tropism or properties, 
depending on organ, tissue or cell target (Asokan et al., 2012). The availability of 
capsids for selection is rapidly increasing, due to both continual isolation of naturally 
occurring AAV variants and the creation of engineered capsids. Capsid engineering 
in particular is thought to show promise for increased clinical benefit, as vectors can 
be tailored by rational design or directed evolution to specifically address the 
relevant aim or challenge. This can result in enhanced vector efficiency and 
specificity, thereby reducing both the administration dose necessary for clinical 
benefit and potential dose-related toxicity. 
 
The combination of a lack in AAV associated pathogenicity, low integration rate, 
ability to purify rAAV at a high titer and wide vector tropism, has lead to the 
emergence of rAAV vectors as extremely promising and extensively used viral 
vectors for in vivo gene delivery, in both preclinical studies (Mingozzi and High, 
2011) and clinical trials (Ginn et al., 2013, Lisowski et al., 2015). In some 
successfully regarded recent trials, the use of rAAV resulted in the treatment of 3 
distinct genetic disorders, including retinal degenerative disease Leber congential 
amaurosis with rAAV2 (Maguire et al., 2008), blood clotting disorder haemophilia B 
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with rAAV2/8 (Nathwani et al., 2011) and lipoprotein lipase deficiency with rAAV1 
(Stroes et al., 2008, Gaudet et al., 2013), which became the product Glybera, the first 
EU authorised and commercially available gene therapy treatment. 
 
Although rAAV are non-pathogenic and show low immune activation compared to 
other viral vectors (Zaiss et al., 2002), certain clinical trial results have revealed 
potential immune challenges and how they affect transgene expression efficiency. As 
demonstrated in a phase I/II dose escalation study for haemophilia B, rAAV2 
administration only resulted in transient expression of Factor IX for approximately 6 
weeks (Manno et al., 2006). Further analysis revealed loss of expression was due to a 
capsid-specific CD8+ T-cell response in transduced hepatocytes in a dose dependent 
manner (Mingozzi et al., 2007), which was mirrored by several other trials (Brantly 
et al., 2009, Mingozzi et al., 2009). This response may be a result of either pre-
existing immunity in the form of neutralising antibodies or vector-induced cellular 
and humoral immunity (Hareendran et al., 2013). Natural exposure to wild-type 
AAVs lead to the generation of anti-AAV antibodies, with sero-positivity levels 
varying depending on the prevalence of certain serotypes (Table 3). Studies have 
also suggested possible cross-reactivity between closely related serotypes in terms of 
structural capsid homology (Calcedo et al., 2009). Relative titers of individual pre-
existing neutralising antibodies can correlate with levels of transgene expression 
following rAAV administration (Manno et al., 2006). Interestingly for paediatric 
diseases, such as early infantile NP-C, comparative analysis of AAV2 and AAV8 
neutralising antibody titers in humans revealed that titers were lowest from 7-11 
months of age and increased significantly at adolescence (Calcedo et al., 2011). In 
comparison, adaptive immune responses to AAV can be targeted against either the 
viral capsid or against the protein being expressed from the vector. As part of vector 
internalisation, degradation of the viral capsid reveals antigenic peptides that can 
activate adaptive immunity via cross-presentation to major histocompatibility 
complex I molecules (Li et al., 2013). Targeting and presentation of epitopes within 
the viral vector encoded protein has also been shown to influence CD8+ T-cell 
reactivity (Li et al., 2009).  
 
The success or failure of a clinical trial and therapeutic efficacy may be affected by 
these factors, which has subsequently led to the development of strategies to avoid 
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immune responses against AAV vectors. Pre-screening of patients for the presence of 
neutralising antibodies is carried out for all trials, however this can lead to the 
exclusion of significant numbers of patients, which is especially problematic in rare 
diseases where patient numbers are limited. Transient immune-suppression of 
patients has been proposed as a potential approach (Adriouch et al., 2011, Sack et al., 
2014), which may even allow secondary AAV administration (McIntosh et al., 
2012). During the haemophilia B clinical trial, asymptomatic elevations in AAV 
capsid-induced aminotransferase levels following rAAV2/8 administration in two 
patients were controlled by a short course of glucocorticoids, without any apparent 
loss in transgene expression (Nathwani et al., 2011). The targeted delivery of vectors 
to immune-privileged sites, such as the eye, brain and to a certain extent the liver can 
also reduce potential adaptive immune response (Maguire et al., 2008, Breous et al., 
2009, LeWitt et al., 2011). Tissue or cell specific promoters have also been used to 
reduce expression of the transgene to the specific target, thereby reducing antigen 
presentation for adaptive immunity (Ziegler et al., 2004, Nathwani et al., 2006). 
Finally modification or shielding of neutralising antibody epitopes on the viral capsid 
have also shown promise in reducing possible immune response, however this may 
affect vector tropism (Hareendran et al., 2013). 
1.6 Non-viral gene delivery systems 
Despite the recent successes in viral vector mediated gene therapy, the development 
of non-viral gene delivery systems remains attractive, due to their relatively simple 
and cheap production process, combined with a low safety profile. Additionally, 
there is no limitation to the size of genetic material that can be encapsulated and 
delivered. However, the major problem with current non-viral gene delivery systems 
is their extremely limited transfection efficacy in vivo. Despite these disadvantages, 
advances in efficiency, specificity and gene expression have resulted in an increase 
in the number of non-viral gene delivery systems entering clinical trials 
(Ramamoorth and Narvekar, 2015). The simplest form of a non-viral gene delivery 
approach is the use of naked DNA or RNA via physical methods, such as 
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electroporation, sonoporation or ballistic DNA. However, these methods are 
associated with poor transfection efficiency, rapid degradation and possible tissue 
damage. Other approaches use chemical carrier vectors to protect the nucleic acid 
cargo and promote gene delivery. These include inorganic particles, such as calcium 
phosphate and silica (Al-Dosari and Gao, 2009), and biodegradable compounds, such 
as lipid based, polymer based and peptide based vectors (Jin et al., 2014). 
 
Lipid nanoparticles have recently become popular, due to their composition of 
physiological lipids that are already approved in pharmaceutical preparation for 
human use, complex stability and solvent-free production techniques (Del Pozo-
Rodriguez et al., 2016). Hundreds of lipids have been developed, however they share 
a common structure of a positively charged hydrophilic head and a hydrophobic tail. 
Together with DNA or RNA, these lipid nanoparticles form compact lipoplexes and 
protect the cargo, as the positively charged head binds to the negatively charged 
nucleic acid. These lipoplexes then interact with negatively charged cell membrane 
proteins to induce cellular uptake (Rehman et al., 2013). The structure and ratio of 
lipids to nucleic acids determines the stability, toxicity and potential release of cargo 
upon endocytosis. Assuming uptake into the cell, these lipoplexes must overcome 
significant barriers in terms of endosomal escape, intracellular trafficking and access 
to the nucleus for transgene expression to occur. Recent studies with lipoplex-
mediated gene delivery have demonstrated early indications of potential in vivo 
transfection efficacy, following direct administration at the target area in mouse 
models of retinal degeneration (Apaolaza et al., 2015) and neuroblastoma tumour 
(Tagalakis et al., 2011). Despite the current lack of efficiency demonstrated by these 
non-viral vectors in vivo, a novel non-viral cationic lipid nanoparticle complex was 
evaluated in this study, in the context of direct cerebrospinal fluid administration.  
1.7 Gene therapy for lysosomal storage disorders 
Lysosomal storage disorders are generally considered as favourable candidates for 
gene therapy, due to a number of factors. Firstly, lysosomal storage disorders are 
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monogenic by nature, therefore the efficient delivery and expression of only a single 
gene should be necessary for treatment. This has also resulted in the development or 
identification of a wide range of animal models that accurately mimic human 
lysosomal storage disease pathology and progression, allowing critical preclinical 
gene therapy evaluation. Secondly, relatively minimal amelioration in the level of 
functional lysosomal enzymes beta-hexosaminidase A and arylsulfatase A (from 1 - 
10%) has been shown to have significant therapeutic benefit on disease progression 
(Leinekugel et al., 1992). Patient data further supports this theory, as more severe 
infantile forms of lysosomal storage diseases generally demonstrate extremely low 
levels of enzyme activity (<1%), compared to the higher levels of enzyme activity (< 
10%) exhibited in milder adult onset forms (Polten et al., 1991, Mechtler et al., 
2012). The final factor is the mechanism of cross-correction therapy, whereby 
functional extracellular lysosomal protein secreted by transduced cells can be 
absorbed and subsequently trafficked to late endosomes and lysosomes in other cells, 
directly at their site of action (Fratantoni et al., 1968). The same principle is taken 
advantage of by enzyme replacement therapy, which is currently used for significant 
therapeutic effect in several lysosomal storage disorders. Therefore, although the 
hallmark of lysosomal storage disorders is the ubiquitous accumulation of storage 
material, the treatment of relatively small amounts of cells in certain organs or 
tissues could result in widespread benefits. These targeted tissues or organs could act 
as factories for functional lysosomal protein, which is subsequently released and 
delivered to diseased tissues and cells. Examples of the use of this mechanism are 
liver-directed gene delivery, resulting in distribution via the bloodstream following 
in vivo administration, or the ex vivo treatment of hematopoietic stem cells, which 
are then replanted back into patients and the subsequent differentiated cells 
containing the functional protein can be delivered directly to multiple organs (Biffi, 
2016). 
 
However, the mechanism of cross-correction is limited to soluble lysosomal enzymes 
found within the lumen of late endosomes/lysosomes. This is due to the process that 
endogenously synthesised lysosomal enzymes undergo for delivery to acidic 
compartments (Kaplan et al., 1977). The correct trafficking of lysosomal enzymes 
requires a series of post-translational modifications and protein-protein interactions 
(Kornfeld, 1992). After glycosylation in the endoplasmic reticulum, newly 
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synthesised lysosomal enzymes are phosphorylated in the Golgi apparatus at the 6 
position of the terminal mannose residues (mannose-6-phosphate). Within the Golgi 
apparatus at standard physiological pH, mannose-6-phosphate receptors subsequently 
bind these phosphorylated lysosomal enzymes. These enzyme-receptor complexes 
are then trafficked to late endosomes/lysosomes, where the decrease in pH results in 
their dissociation, thereby releasing the protein into the late endosomal/lysosomal 
lumen for maturation. The isolated mannose-6-phosphate receptors are then either 
trafficked back to the Golgi apparatus for recycling or to the plasma membrane. A 
small portion of lysosomal enzyme has been shown to escape endosomal sorting and 
is subsequently sent to the cell membrane for exocytosis, resulting in its release into 
the extracellular space. Free mannose-6-phosphate receptors on the plasma 
membrane of cells can bind extracellular lysosomal proteins, which subsequently 
undergo endocytosis leading to their direct delivery to the site of action in late 
endosomal and finally lysosomal compartments (Achord et al., 1978, Dahms, 1996).  
 
This secretion-recapture mechanism represents the basis of cross-correction therapy, 
which can be utilised by therapeutic strategies for lysosomal storage disorders caused 
by lysosomal enzyme deficiency. While certain non-enzyme soluble lysosomal 
proteins are sorted and trafficked via the mannose-6-phosphate receptor system 
(Hahn et al., 1998, Leimig et al., 2002), all membrane-bound and transmembrane 
lysosomal proteins, such as NPC1, are not (Sands and Davidson, 2006). This lack of 
cross-correction is thought to represent a major challenge for the development of 
effective gene therapy in these diseases, as correction of a cell would depend on 
direct transduction and gene expression. Ultimately, in the absence of cross-
correction, amelioration of pathology is thought to require gene delivery to large 
numbers of cells. 
 
Following the identification of lysosomal storage disorders as ideal candidates for 
the development of gene therapy, a vast number of preclinical studies utilising 
different approaches have been carried out in a range lysosomal storage disorder 
animal models. The therapeutic effects demonstrated in a number of these studies 
have resulted in a series of both completed and currently ongoing clinical trials 
within the field of gene therapy treatment for lysosomal storage disorders (Table 4). 
Initial preclinical studies in mouse models utilised the ex vivo gene therapy approach, 
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with retroviral and lentiviral vectors for lysosomal storage disorder treatment via 
gene therapy. The potential benefit of ex vivo gene therapy for these disorders is 
demonstrated by the fact that transplantation of haematopoietic stem cells from 
compatible donors has been carried out in patients with certain lysosomal storage 
disorders for over 20 years (Lund, 2013). In addition to therapeutic enzyme delivery 
in the viscera, these haematopoietic stem cells can also differentiate into cells that 
can cross the blood-brain barrier for therapeutic protein delivery to the central 
nervous system (CNS). Along with avoiding the challenge of finding a compatible 
donor, there are two other main advantages to the use of modified autologous cells 
rather than donor cells. Firstly, the significant reduction in the risk of graft-versus-
host disease and secondly, enhanced therapeutic potential as viral gene delivery can 
result in supraphysiological levels of therapeutic lysosomal enzyme expression 
(Biffi, 2016). Preclinical studies in a variety of models have shown promising results 
in the clearance of storage material from both haematopoietic and non-
haematopoietic cells, which translated to amelioration of neurological and visceral 
disease manifestations (Liang et al., 2007, van Til et al., 2010, Visigalli et al., 2010, 
Harrison et al., 2013, Wakabayashi et al., 2015). These studies also demonstrated 
that therapeutic efficacy correlated with enzyme expression levels and genetically 
engineered cells expressed higher therapeutic protein levels compared to standard 
donor cells, which was identified as a crucial factor in the prevention of neurological 
deficits.  
 
Several early clinical trials utilised retroviral vector transduced autologous cells to 
treat Type I Gaucher disease (ClinicalTrials.gov Identifier: NCT00001234 and 
NCT00004294), Fabry disease (ClinicalTrials.gov Identifier: NCT00001234) and 
MPSII (ClinicalTrials.gov Identifier: NCT00004454) (Dunbar et al., 1998, 
Alexander et al., 2007, Byrne et al., 2012). While the relative safety of the procedure 
was confirmed with no severe adverse affects, low levels of therapeutic protein 
expression resulted in no improvement to disease pathology or progression. 
Following promising early studies in the mouse model for metachromatic 
leukodystrophy using novel lentiviral vectors (Biffi et al., 2004), a phase I/II clinical 
trial was carried out in three presymptomatic patients, where the lentiviral vector was 
used to deliver a functional copy of the ARSA gene (Biffi et al., 2013). The treated 
haematopoietic stem cells successfully engrafted within the patients, resulting in 
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stable ARSA protein expression at supraphysiological levels in haematopoietic 
lineages and in the cerebrospinal fluid. Assessment 24 months post-treatment in 
these patients suggested that the onset of disease had not progressed and further 
long-term evaluation will determine the complete clinical potential of this treatment. 
Combined with no adverse effects related to vector use, no significant immune 
response was observed against the transgene and therapeutic protein. This trial 
demonstrated the first successful use of ex vivo gene therapy for the treatment of a 
lysosomal storage disorder. 
 
Taking the promise of this trial into account, there are still significant challenges for 
the treatment of lysosomal storage disorders by ex vivo gene therapy. The patients 
treated in the trial were diagnosed with the late infantile form of metachromatic 
leukodystrophy and treated before the development of disease manifestations. 
Previous experience with cell transplantation (Rovelli, 2008) indicates that this form 
of treatment in patients with more aggressive forms of lysosomal storage disorders or 
patients with prior disease progression may not be as effective, as therapeutic protein 
levels in visceral and central nervous system tissues can take months to increase 
following treatment. Toxicity or immune response to high levels of the therapeutic 
protein systemically must also be taken into account (Gentner et al., 2010), as 
supraphysiological levels of the therapeutic protein are needed for the amelioration 
of both visceral and especially neurological pathology. As therapeutic efficacy is 
linked to enzymes levels, lysosomal storage disorders with severer neurological 
disease may require high levels of transgene expression, although there have been 
attempts at restricting therapeutic protein expression to specific tissues (Sergijenko et 
al., 2013). For optimal engraftment of haematopoietic stem cells, preconditioning of 
the host also has to be carried out to a certain degree. Finally, as with enzyme 
replacement therapy, only diseases due to a deficiency in a soluble lysosomal 
enzyme that can take advantage of cross-correction will be viable targets for ex vivo 
gene therapy. Disorders caused by the loss of other lysosomal protein functions, such 
as NPC1 for Niemann-Pick Type C, will require in vivo administration. 
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Disease Vector Gene Delivery Phase Clinical Trial 
Metachromatic 
leukodystrophy 
Lentivirus ARSA HSCT I/II NCT01560182  
Fabry Retrovirus GLA HSCT I NCT00001234 
MPSII Retrovirus L2SN HSCT I/II NCT00004454 
Gaucher Type I Retrovirus GBA PBSC I NCT00004294 
MPS IIIa AAV9 SGSH IV I/II NCT02716246 
MPS IIIa AAVrh10 SGSH, SUMF1 IC I/II 
NCT01474343 
NCT02053064 
MPSIIIb AAV5 NAGLU IC I/II ISRCTN19853672 
Metachromatic 
leukodystrophy 
AAVrh10 ARSA IC I/II NCT01801709 
Neuronal Ceroid 
Lipofuscinosis 
AAV2 CLN2 IC I NCT00151216 
Neuronal Ceroid 
Lipofuscinosis 





AAV9 CLN6 IT I/II NCT02725580 
Pompe AAV9 GAA IM I NCT02240407 
Pompe AAV1 GAA IM I/II NCT00976352 
Table 4: Completed and ongoing clinical trials using gene therapy for the 
treatment of lysosomal storage disorders. 
Data collected from the U.S. National Institutes of Health clinical trial database 
(https://clinicaltrials.gov/ on 20-12-2016). HSCT, ex vivo transduction and 
haematopoietic stem cell transplant; PBSC, ex vivo transduction and peripheral blood 
stem cell transplantation; IV, intravenous; IC, intracerebral; IT, intrathecal; IM, 
intramuscular. 
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In vivo gene therapy refers to the direct injection of a gene delivery vector to a 
certain tissue or circulatory system and has been successfully applied in a series of 
lysosomal storage disorder animal models and is also currently being translated into 
clinical trials (Table 4). Early studies demonstrated the potential of this approach 
with the delivery of lentiviral or rAAV vectors targeted towards the liver, either via 
intravenous or direct tissues administration. Therapeutic efficacy was due to the liver 
acting as a source of the therapeutic protein, which resulted in significant therapeutic 
protein expression throughout other peripheral organs via cross-correction (Gao et 
al., 2000, Mango et al., 2004, Liu et al., 2005b, Ma et al., 2007). A comparison study 
in a mouse model of MPSVI revealed this gene therapy approach to be as effective 
as enzyme replacement therapy, with the added benefit of only a single 
administration (Ferla et al., 2014). However, pathology in MPSVI is limited to the 
viscera, unlike the majority of lysosomal storage disorders that are also characterised 
by progressive neurological disease. The major disadvantage to liver directed gene 
therapy, as with enzyme replacement therapy, is the limited movement of therapeutic 
protein across the blood-brain barrier to allow delivery to the CNS. While there have 
been efforts to enhance the transit of therapeutic protein across the blood-brain 
barrier, such as fusion with trans-blood-brain barrier active motifs (Boado et al., 
2013), liver directed gene therapy approach may not be sufficient for the 
amelioration of the severe neurological pathology exhibited by most lysosomal 
storage disorders. 
1.7.1 Gene delivery to the CNS 
The crossing of therapeutic protein across the blood-brain barrier following either 
enzyme replacement therapy, ex vivo or liver targeted gene in vivo gene therapy is 
inefficient. As a result, there are many neurovisceral lysosomal storage disorders 
with no or limited treatment options and the main obstacle in treating this class of 
disorders is overcoming the blood-brain barrier (BBB) to deliver therapeutic protein 
to cells in the central nervous system. Although there are exceptions, the majority of 
viral vectors have also been shown to be ineffective at crossing the mature BBB 
following intravenous administration, which has resulted in the development of a 
series of different approaches for effective gene delivery to the CNS. 
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The most obvious approach at bypassing the BBB and treating neurological 
pathology by gene therapy is the direct administration of recombinant viral vectors 
into CNS compartments, which can be accomplished by injection into the brain 
parenchyma or into the cerebrospinal fluid. Although direct administration of viral 
vectors via intracranial injections into the parenchyma of the brain is an intrusive and 
complex procedure, its use has been investigated in the context of treating lysosomal 
storage disorders, which has also progressed into several clinical trials (Table 4). 
Early studies utilised lentiviral, rAAV2 and rAAV5 vectors, due to their known 
neurotropic tropism, with injections targeting specific brain regions, such as the 
hippocampus, putamen and striatum. The rationale behind this approach was cross-
correction of both nearby and distal cells from secretion of the therapeutic lysosomal 
enzyme from locally transduced cells. Certain AAV serotypes have also been 
demonstrated to undergo axonal transport allowing even broader distribution 
(Salegio et al., 2013).  Although successful transduction of both neuronal and glial 
cells was observed, the spread from the site of injection was limited with rAAV2, 
rAAV5 and to an even lesser extent with lentiviral vectors (Consiglio et al., 2001, 
Brooks et al., 2002, Cressant et al., 2004, Sevin et al., 2006). Cells at the site of 
injection demonstrated some form of correction, however the lack of spread resulted 
in a therapeutic gradient (Cachon-Gonzalez et al., 2006). The identification and 
characterisation of other AAV serotypes has led to significant improvements in viral 
vector spread following intracranial injection. AAV9 and AAVrh10 based vectors in 
particular have shown promise, due to not only improved spread, but also their 
highly efficient axonal transport (Cearley and Wolfe, 2007, Piguet et al., 2012). 
Administration into areas with divergent connections, including the thalamus, 
cerebellar nuclei and ventral tegmental area have also reportedly shown enhancement 
of vector spread (Dodge et al., 2005, Cearley and Wolfe, 2007, Salegio et al., 2010, 
Bu et al., 2012). Despite these improvements, multiple bilateral intraparenchymal 
injection sites have been necessary to show therapeutic efficacy in lysosomal storage 
disease animal models (Cheng, 2014). These lessons have been carried through to 
clinical trials (Table 4), such as where patients treated for MPSIIIa with an 
AAVrh10 vector received 12 simultaneous intracranial injections into the white 
matter of the basal ganglia (Tardieu et al., 2014). This trial demonstrated 
significantly improved safety profile compared to previous trials for neuronal ceroid 
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lipofuscinosis (CLN2) (Worgall et al., 2008), with no adverse outcomes, however the 
numbers were too small to show significant therapeutic benefit. The question 
remains whether this approach will be or can be adapted to be sufficient for treating 
the neurological manifestations of lysosomal storage disorders. The practicality of 
additional injection sites if necessary must also be taken into account, as each further 
site adds potential risk to the procedure (Souweidane et al., 2010). 
 
A less invasive and less spatially restricted approach for CNS delivery is the infusion 
of vector into the cerebrospinal fluid, either via intracerebroventricular (ICV) or 
intrathecal (IT) injection. Transduction of cells within the ventricular system, 
including ependymal cells, would result in the constant secretion of therapeutic 
protein throughout the cerebrospinal fluid (CSF) and neighbouring tissue, allowing 
widespread cross-correction potential similar to direct ERT delivery to the CSF 
(Kakkis et al., 2004, Chang et al., 2008, Dodge et al., 2009). The eventual drainage 
of the CSF into the venous system may also promote further systemic distribution 
(Haurigot et al., 2013). However, exclusive transduction of cells in the ventricular 
system would not be effective for non-soluble lysosomal proteins, such as NPC1 in 
Niemann-Pick Type C. The use of rAAV vectors that have demonstrated improved 
distribution following intraparenchymal injections, such as AAV9, results in the 
escape of vector out of the CSF into nearby tissue for even broader correction 
potential. Intracerebroventricular administration into neonatal mice has been reported 
to result in extensive widespread gene delivery in both neuronal and glial cell 
populations (Kim et al., 2014, McLean et al., 2014). Studies in adult and larger 
animal models have also demonstrated promising results of widespread gene delivery 
in multiple brain regions, following ICV rAAV9 vector administration (Samaranch 
et al., 2012, Haurigot et al., 2013, Meyer et al., 2015). ICV rAAV vector 
administration has also been evaluated in lysosomal storage disease animal models, 
demonstrated by rAAV1, rAAV2 and rAAV4 induced reduction in storage material 
throughout the brain of MPSVII mice (Elliger et al., 1999, Passini et al., 2003, Liu et 
al., 2005a), and amelioration of MPSIIIA neurovisceral pathology in both a murine 
(Ribera et al., 2015) and canine model (Haurigot et al., 2013), following ICV rAAV9 
administration. 
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Direct delivery to the CSF can also be achieved by intrathecal administration into the 
intervertebral cistern of the spinal cord or the subarachnoid space in the cisterna 
magna. The rationale behind these approaches is identical to ICV administration, 
however the clinical procedures are less invasive. Intrathecal administration of rAAV 
has been reported to result in widespread and efficient transduction of motor neurons 
and dorsal root ganglia in the spinal cord, in both smaller and larger animal models 
(Bevan et al., 2011, Snyder et al., 2011, Dayton et al., 2012, Federici et al., 2012, 
Gray et al., 2013, Hordeaux et al., 2015). Promisingly, transduction of both neurons 
and glial cell populations could also be observed throughout the brain, with the 
brainstem demonstrating the highest transduction efficiency. In the context of 
lysosomal storage disorders, preclinical studies in mouse models of MPSI and MPSII 
administered intrathecally with rAAV2 and rAAV9 vectors respectively, resulted in 
regional reduction of storage material and brain pathology (Watson et al., 2006, 
Hinderer et al., 2016). Widespread CNS correction was also reported in a larger 
feline model of MPSI following intrathecal administration of rAAV9 (Hinderer et 
al., 2014), further supporting translation into the clinic. 
 
Finally, an alternative and non-invasive strategy in delivering a viral vector to the 
CNS is the intravenous administration of vectors that have been demonstrated to 
cross the BBB. Studies have identified AAV serotypes AAV9 and AAVrh10 as the 
currently most effective serotypes at crossing the BBB, with widespread neuronal 
transduction in the CNS following intravenous administration in neonatal mice 
(Foust et al., 2009, Zhang et al., 2011). Subsequent studies demonstrated the 
successful transduction of neurons and astrocytes in both adult mice and non-human 
primates injected systemically with AAV9, however the efficiency was significantly 
reduced compared to neonatal animals (Duque et al., 2009, Gray et al., 2011b, 
Samaranch et al., 2012). Intravenous administration of rAAV9 has also been 
evaluated in lysosomal storage disorder models, with MPSIIIA and MPSIIIB treated 
adult mice and neonatally treated MPSI dogs demonstrating correction of 
neurological disease (Fu et al., 2011, Ruzo et al., 2012, Hinderer et al., 2015). While 
these studies have demonstrated therapeutic efficacy, it remains to be seen how 
effective this approach will be in upcoming clinical trials (Table 4). As the level of 
therapeutic protein has been shown to be crucial for CNS treatment efficacy, high 
systemic doses may be required to achieve the necessary influx of vector into the 
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CNS. This factor will be especially crucial for the treatment of lysosomal storage 
disorders that can’t take advantage of cross-correction, such as Niemann-Pick Type 
C. The need for higher systemic vector doses subsequently increases the cost of trials 
and therapy, with the added the potential for immune response challenges, due to 
high levels of both vector and encoded protein in the viscera. Recent advances in the 
targeted evolution of AAV capsid variants has resulted in the development of a series 
of next generation rAAV vectors that show increased tissue specificity and 
transduction efficiency, which may reduce required doses (Lisowski et al., 2015). 
One variant in particular, AAV-PHP.B, demonstrated a 40-fold increase in CNS 
transduction efficiency compared to AAV9 when administered intravenously into 
adult mice (Deverman et al., 2016). While extremely promising, the tropism and 
efficiency of these novel rAAV vector variants in larger non-human primate models 
and ultimately patients remains to be evaluated. 
1.8 Gene therapy for Niemann-Pick Type C disease 
Following these promising results of viral vector mediated gene therapy in 
preclinical studies for several lysosomal storage disorders and their current 
translation into clinical trials, the potential use of gene therapy is expanding to other 
and more challenging disorders. The therapeutic application of gene therapy to 
Niemann-Pick Type C1 has generally been considered to be especially challenging, 
as the NPC1 protein is a large non-secreted transmembrane protein that can’t take 
advantage of mannose-6-phosphate receptor based secretion and recapturing (Vanier, 
2010). In the absence of cross-correction, the amelioration of pathology in individual 
cells can only be achieved through direct viral vector transduction. Any gene therapy 
approach is therefore expected to require both efficient and extensive transduction of 
diseased tissue to demonstrate therapeutic potential. 
 
Although NP-C is characterised by neurovisceral pathology, extremely severe and 
fatal visceral pathology is generally only observed in a minority of patients, such as 
neonatal cases with acute liver failure. Otherwise visceral pathology is mainly 
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limited to hepatosplenomegaly and is completely absent in 15% of patients at the 
time of diagnosis (Vanier, 2010). Apart from severe neonatal or adult-onset cases, all 
NP-C patients will ultimately develop a progressive and fatal neurological disease 
(Vanier, 2013). Taking these factors into consideration, the first prioritisation of gene 
therapy for NP-C should therefore be the focus on amelioration of the neurological 
pathology. Limiting the majority of the viral vector dose to the CNS will also have 
the additional benefit reducing potential immune response in the relatively immune 
privileged brain (Sack and Herzog, 2009, Muldoon et al., 2013), compared to the 
extremely high systemic doses that may be required for sufficient vector to cross the 
blood-brain barrier. 
 
Several complementary studies have suggested that neurodegeneration in NP-C is 
cell-autonomous, with the isolated loss of NPC1 in neurons responsible for 
neurodegeneration and progressive neurological disease manifestations (Lopez and 
Scott, 2013). An early chimeric mouse study revealed that Npc1-/- Purkinje cell loss 
was not affected by Npc1+/+ glial cells, whereas Npc1+/+ Purkinje cells survived and 
were not affected by surrounding Npc1-/- glial cells (Ko et al., 2005). These findings 
were mirrored by studies in other conditional knockout animal models, where the 
loss of NPC1 function in neurons only was sufficient in recapitulating 
neurodegeneration and neurological disease progression (Elrick et al., 2010, Yu et 
al., 2011). Finally, in a Tet-inducible Npc1-/- mouse model, NPC1 activity in neurons 
resulted in the correction of neurodegeneration, whereas disease progression was not 
significantly affected by astrocytic NPC1 activity (Lopez et al., 2011). Interestingly, 
the selective reconstitution of NPC1 in Purkinje neurons only resulted in a delay of 
neurological disease onset, with the rescue of other neuronal populations in other 
brain regions such as the thalamus crucial for further reducing disease progression 
rate and improving survival (Lopez et al., 2011). In combination, these studies 
demonstrate the priority of strong and widespread neuronal transduction, if a gene 
therapy approach for Niemann-Pick Type C is to be successful in treating the 
neurological manifestations of the disease. 
 
An additional challenge in the development of gene therapy for NP-C1 is linked to 
the relatively large size of the human NPC1 complementary DNA (cDNA), which 
will have to be integrated into a functional and efficient viral vector. As previously 
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discussed, while rAAV are currently considered the optimal approach for gene 
delivery to the CNS (Section 1.5.3), their limited packaging capacity potentially 
affects the viability of their use for effective NPC1 delivery. Other viral vectors 
reviewed in previous sections, such as adenoviral vectors (Section 1.5.1) or lentiviral 
vectors (Section 1.5.2) have sufficient packing capacity, however their transduction 
spread and efficiency throughout the CNS may not be sufficient for NP-C. 
1.9 Aims: Rationale and Significance 
Although preclinical evaluation in the NP-C mouse model has identified several 
treatment options that can slow disease progression, there is currently no major 
disease modifying or curative treatment available for Niemann-Pick Type C. 
Advances in the field of gene therapy and viral vector technology have recently led 
to a surge of promising preclinical studies in a range of lysosomal storage disorder 
animal models, with clinical translation now moving forward in the form of a series 
of clinical trials (Table 4).  
 
The overall aim of this project is the development and evaluation of gene therapy in 
the Npc1-/- mouse model, in the context of a potential future therapy for Niemann-
Pick Type C1. As discussed in the previous section (Section 1.8), this gene delivery 
approach will aim to primarily focus on treating the neurological pathology of NP-C, 
via widespread and efficient neuronal transduction. The gene delivery vector will 
therefore be administered directly to the CSF via intracerebroventricular 
administration for optimal spread throughout the brain. For this proof of concept 
study, administration will be carried out in neonatal mice to achieve the best possible 
spread of gene delivery vector. 
 
The chosen gene delivery vector will have to incorporate the relatively large human 
NPC1 cDNA. Homology is relatively conserved between the human and murine 
NPC1 protein and cDNA, at 86% and 84% respectively (Supplementary Figure S1 
and Supplementary Figure S2). Therefore the human version of NPC1 
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(Supplementary Figure S3) will be used throughout the study to aid potential 
downstream clinical translation. Due to the large size of the NPC1 cDNA, the 
optimal vector for incorporating, delivering and expressing the transgene throughout 
the brain will have to be evaluated. This vector will then be used in a series of studies 
in wild-type mice, investigating tropism, transgene expression and potential vector 
related toxicity.  
 
The evaluated vector will subsequently be used in an initial preclinical study in the 
Npc1-/- mouse model, with the aim of primarily analysing safety but also potential 
therapeutic efficacy in the form of survival, weight and various parameters of motor 
function throughout their lifespan. Additionally, gene therapy treated Npc1-/- mice 
brains will be examined for amelioration of neurodegenration, inflammation and 
lipid storage. 
 
Finally, gene therapy will be compared in certain parameters with other small 
molecule drugs shown to have efficacy in the Npc1-/- mouse model, including the 
European Medicines Agency approved miglustat and HP-β-CD that is currently in 
clinical trails, to put into context the therapeutic potential that gene therapy may have 
in the current NP-C arena. 
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 Materials and Methods 
2.1 AAV vector construct design 
During the design of the hNPC1 construct to be used for rAAV vector production 
certain factors were taken into consideration to strike a balance between maximising 
AAV-hNPC1 production efficiency and AAV-hNPC1 expression efficacy. The 
combination of large hNPC1 transgene size and limited rAAV packaging capacity 
resulted in a series of major changes to the template rAAV, which are presented in 
detail in Chapter 3. The template construct containing the human synapsin I 
promoter expression cassette flanked by AAV2 ITRs was kindly provided by Dr. J. 
Tordo (Department of Infectious Diseases, King’s College London, UK). Through 
subsequent rounds of cloning described in Sections 3.4-3.5 enhanced green 
fluorescent protein (eGFP), Woodchuck hepatitis virus posttranscriptional regulatory 
element (WPRE) and human growth hormone polyadenylation signal (hGHpA) 
sequences were removed and replaced with Kozak, hNPC1 and Simian virus 40 
polyadenylation signal (SV40pA) sequences to produce the final 
pAAV.hSynI.hNPC1.SV40pA construct used for AAV2/9-hSynI-hNPC1-SV40pA 
(AAV9-hNPC1) vector production and subsequent in vitro and in vivo testing. 
Sources and details for the other plasmids used in this study can be found in Table 5. 
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2.2 Cloning 
2.2.1 Bacterial transformation 
Plasmid DNA was transformed into competent Escherichia coli bacteria for 
subsequent amplification and cloning. To reduce the risk of recombination events 
resulting from the highly repetitive inverted terminal repeats regions, recombinase 
negative (recB and recJ deficient) SURE competent cells (Agilent Technologies, 
Santa Clara, USA) were used for the cloning of rAAV constructs. Per transformation 
reaction, 50µl of bacterial suspension was thawed on ice and the sample DNA was 
subsequently added to the suspension and incubated on ice for 30 minutes. Samples 
were then heat-shock treated for 45 seconds at 42°C and incubated on ice again for 2 
minutes. The transformation mix was transferred into 150µl of S.O.C. medium 
(ThermoFisher Scientific, Paisley, UK) and incubated for 1 hour at 37°C and shaking 
at 225rpm. This culture was spread on to lysogeny broth (LB) agar (ThermoFisher) 
plates containing either ampicillin (100µg/ml, Sigma-Aldrich, Dorset, UK) or 
kanamycin (50µg/ml, Sigma-Aldrich) and incubated overnight at 37°C to select for 
positive colonies. The DNA from resulting colonies was analysed by restriction 
enzyme digest, polymerase chain reaction (PCR) or Sanger sequencing to confirm 
successful and correct plasmid transformation for downstream applications. 
2.2.2 Plasmid amplification and purification 
Positive colonies were inoculated in 5ml of LB broth (Sigma-Aldrich) with the 
relevant antibiotic and grown overnight at 37°C with shaking at 225rpm. The culture 
was then centrifuged at 6,000 x g (Eppendorf 5415D, Stevenage, UK) for 10 minutes 
and the resulting bacterial pellet was used for plasmid DNA purification with a 
‘QIAprep Spin Miniprep Kit’ (QIAGEN, Hilden, Germany), as per manufacturers 
protocol. For larger scale plasmid amplification and purification 500µl of overnight 
culture was added to 500ml of LB broth with selective antibiotic and grown 
overnight at 37°C with shaking at 225rpm. Plasmid DNA was purified from this 
culture using ‘Plasmid Maxi Kit’ (QIAGEN) following the manufacturer’s 
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instructions. The resulting DNA pellet was resuspended in dH2O and the final DNA 
concentration and purity was determined by spectrophotometry through 
measurements of absorbance at 260nm and 280nm (NanoDrop 1000, Thermo 
Scientific). 
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Plasmid Name Relevant Characteristics Source 
pCMV6.hNPC1.Neo CMV promoter driving human 
NPC1 cDNA 
Platt FM, Department of 
Pharmacology, Oxford, UK 
pSUB201-Caggs-
GFP 
Contains eGFP and SV40pA 
sequences 
Tordo J., Department of 
Infectious Diseases, King’s 
College London, UK 
pAAV.hSynI.flox.eG
FP.WPRE.hGHpA 
AAV2 ITRs flanking cassette 
containing human synapsin I 
promoter, eGFP transgene and 
WPRE element. 
Tordo J., Department of 
Infectious Diseases, King’s 
College London, UK 
pAAV.hSynI.hNPC1.
hGHpA 
AAV2 ITR construct with hSynI 
driving hNPC1 cDNA and 





AAV2 ITR construct with hSynI 
driving hNPC1 cDNA and the 




hNPC1 replaced by eGFP 
reporter gene. 
This Study 
pU57.NPC1O Codon optimised NPC1 
sequence 
Genscript, China 
pHGTI Adenovirus helper plasmid (Streck et al., 2006) 
pDG9 AAV9 cap and AAV2 rep genes Tordo J., Department of 
Infectious Diseases, King’s 
College London, UK 
pCCL.SIN.cPPT.CM
V.eGFP.WPRE 
Lentiviral construct with CMV 
promoter driving eGFP reporter 
Howe S., Institute for Child 
Health, London, UK 
pMDG2 Vesicular stomatitis virus 
envelope expression plasmid 
Plasmid Factory, Bielefeld, 
Germany 
pCMVdR.8.74 Encapsidation plasmid lacking 
Vif-, Vpr-, Vpu-, and Nef- 
accessory HIV-1 proteins 
Plasmid Factory, Bielefeld, 
Germany 
Table 5: Plasmids used in this study 
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2.2.3 Polymerase Chain Reaction 
All polymerase chain reactions were carried out with high fidelity proof reading Pfu 
DNA polymerase (Promega, Madison, USA). Desired sequences were amplified 
from 50-75ng of plasmid template DNA using primer pairs (Sigma-Aldrich) flanking 
these regions at the 5’ and 3’ ends, introducing additional restriction enzyme sites if 
necessary, and a mix of equimolar deoxynucleotide triphosphates (dNTPs, VWR, 
Leicestershire, UK). The sets of primers used for the amplification of each sequence 
are listed in Table 6. PCR products were subsequently analysed by DNA 
electrophoresis to confirm correct size or purified using ‘QIAquick PCR Purification 
Kit’ (QIAGEN), following manufacturers protocol, for further downstream cloning. 
 
Example of PCR reaction mix (30µl reaction volume): 
template DNA 50-75ng 
dNTPs 200µM 
Forward Primer (5’ > 3’) 1µM 
Reverse Primer (3’ > 5’) 1µM 
10X Pfu Buffer 3µl 
Pfu DNA polymerase 0.125u (unit) 
dH2O to final volume 30µl 
 
Example of standard cycle conditions (35 cycles of denaturation, annealing and 
extension): 
Initial denaturation 95°C 5 minutes 
Denaturation 95°C 1 minutes 
Annealing Tm (melting temperature 
adapted for each primer set) 
30 seconds 
Extension 72°C 2 minutes/kb 
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PCR Product Forward Primer Reverse Primer Template Source 















Gift from J.Tordo 








Gift from J.Tordo 
Table 6: List of oligonucleotides used in this study 
2.2.4 Restriction enzyme digest 
Plasmid DNA and PCR amplicons were digested with restriction enzymes sourced 
from New England Biolabs Inc. (Ipswich, USA), where 1µg of DNA was digested 
for a minimum of 1 hour at 37°C unless stated otherwise. Resulting DNA fragments 
were separated by size on an agarose gel via electrophoresis. 
 
Example of restriction enzyme reaction (25µl reaction volume): 
DNA 1µg 
10X Restriction Buffer 2.5µl 
Enzyme 0.5µl (1u) 
dH2O to final volume of 25µl 
 
2.2.5 DNA electrophoresis 
DNA fragments were separated on a 0.8-2% (w/v) agarose gel (Invitrogen), 
depending on fragment size, using 1X Tris-acetate-ethylenediaminetetraacetic acid 
(TAE) buffer. Safeview (Applied Biological Materials, Richmond, Canada) was 
added to the agarose at a dilution of 1:10,000 for DNA visualisation. Samples were 
loaded onto the gel using 1X Orange G gel-loading buffer (Sigma-Aldrich) with 
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either 1kb Plus (ThermoFisher Scientific) or HyperLadder 1kb (Bioline, London, 
UK) molecular weight markers to determine DNA fragment size. Gels were run at 
100V (PowerPac Basic, Biorad, California, USA) for 30-90 minutes, depending on 
fragment size, and visualised under a ultraviolet (UV) transilluminator (Ingenius, 
Syngene, Cambridge, UK). 
 
1X TAE: 
Tris (pH 7.6) 40mM 
Ethylenediaminetetraacetic acid (EDTA) 1mM 
Acetic acid 20mM 
 
2.2.6 DNA extraction 
Desired DNA fragments were isolated from agarose gel under low level UV light 
and subsequently extracted and purified using a ‘QIAquick Gel Extract Kit’ 
(QIAGEN) following manufacturer’s protocol. DNA was eluted in a final volume of 
30µl of dH2O and resulting DNA concentration and purity was determined by 
spectrophotometry through measurement of absorbance at 260nm and 280nm. 
2.2.7 Ligation 
Purified DNA fragments were ligated overnight at 4°C using bacteriophage T4 DNA 
ligase (Promega), following manufacturer’s protocol with insert to vector ratios of 
1:1 or 3:1. 
 
Example of ligation reaction (10µl reaction volume): 
vector 100ng 
insert 1:1 or 3:1 (ratio of insert to vector) 
10X T4 DNA Ligase Buffer 1µl 
T4 DNA Ligase 1u (unit) 
dH2O to final volume of 10µl 
2.3 Tissue Culture 84 
2.2.8 DNA sequencing 
Plasmid DNA and sequencing primers were sent externally to SourceBioscience for 
Sanger sequencing (www.lifesciences.sourcebioscience.com, Nottingham, UK). 
Resulting DNA electropherograms were visualised and analysed using MacVector 
v15.0. 
2.3 Tissue Culture 
2.3.1 Culture of cell lines 
The human embryonic kidney (HEK) 293T cell line, a variant of the HEK-293 cell 
line expressing the late SV40 large T antigen to enhance protein and viral production 
(DuBridge et al., 1987), and neuroblastoma cell line SH-SY5Y were used in this 
study. Cell lines were grown in standard growth medium of Dulbecco’s modified 
Eagle’s medium (DMEM; Gibco, ThermoFisher Scientific) with: high glucose (4.5 
mg/ml), GlutaMAX (0.8 mg/ml), pyruvate (0.1 mg/ml) and supplemented with 10% 
heat-inactivated foetal bovine serum (FBS; Sigma-Aldrich), penicillin (100 units/ml) 
and streptomycin (100 µg/ml). All cells were grown on poly-D-lysine coated 6-well 
plates, T75 and T175 flasks and 100mm dishes to maintain adherence (Nunc, 
ThermoFisher Scientific). Cells were incubated at 37°C in 5% CO2 for an average of 
48-72 hours between passaging.  
 
2.3.2 Cell culture passaging 
After 48-72 hours cells were passaged at 80-90% confluency. Cells were washed 
with Dulbecco's Phosphate-Buffered Saline (DPBS, Gibco) and detached with a 
trypsin and EDTA (Gibco) mix. The culture containing the detached cells was spun 
at 200 x g for 5 minutes and the resulting pellet was gently resuspended in fresh 
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growth media. The culture was regularly split at a 1:5 ratio into a new flask or dish. 
To avoid genetic drift, cells beyond passage 20 were discarded and freshly thawed 
passage 3 cells were allowed to recover until passage 5, before being utilised. 
2.3.3 Transfection 
Cells were seeded in a 6 well plate (Nunc) at a ratio of 200,000 cells/well with 
standard growth media and incubated for 24 hours. Plasmid DNA was mixed with 
the transfection agent linear polyethylenimine MAX (PEI MAX Mw ~40000, 
Polysciences Inc., Warrington, USA) at a ratio of 1:3 in reduced serum media Opti-
MEM (Gibco). Transfection mix was incubated at room temperature for 15 minutes 
to allow DNA-PEI complex formation and was subsequently added to the cells in the 
standard growth media. After 24 hours the media was replaced with fresh standard 
growth media and incubated for a further 24 - 48 hours at which point cells were 
either imaged or collected for downstream protein analysis.  
2.3.4 In vitro protein expression analysis 
To confirm successful overexpression of the transgene from the construct following 
transfection in vitro, Western blotting against the expressed transgene protein was 
carried out.  48 - 72 hours post-transfection cells were collected for protein 
extraction. 100µl of cold radioimmunoprecipitation assay buffer (RIPA) lysis buffer 
(ThermoFisher Scientific) with 1X protease inhibitor cocktail (ThermoFisher 
Scientific) was added per well and incubated on ice for 5 minutes, swirling the plate 
every minute. Cells were then scraped and collected at the bottom of the well and the 
lysate was transferred to 1.5ml microcentrifuge tubes. Resulting lysates were 
incubated on ice for 30 minutes, after which debris was pelleted by centrifugation at 
14,000 x g, 4°C for 20 minutes. Lysate was carefully extracted and overall protein 
concentration was determined by Pierce BCA Protein Assay (LifeTechnologies, 
ThermoFisher Scientific). Sample protein concentrations were normalised to 1µg/µl 
to standardise loading volumes. 1X LDS Sample buffer (LifeTechnologies) and 1X 
Sample Reducing agent (LifeTechnologies) were added to the samples, which were 
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then incubated at 37°C for 30 minutes to denature proteins, while simultaneously 
avoiding clumping of transmembrane proteins. 20 - 40µg of protein was 
subsequently loaded per well on a NuPAGE Bis-Tris 4 - 12% polyacrylamide gel, 
with 10µl of molecular weight marker RPN800E (Amersham, GE Healthcare, 
Buckinghamshire, UK) to confirm molecular weight of visualised bands. Proteins 
were separated via sodium dodecyl sulphate (SDS) PAGE electrophoresis with 1X 
MES running buffer (LifeTechnologies) run at 120V for 2 hours. 
 
Proteins were transferred on to methanol activated polyvinyl difluoride membrane 
(Millipore, Watford, UK) via semi-dry transfer. Filter paper and activated membrane 
were soaked in transfer buffer and placed in the semi-dry transfer unit (Biorad 
Transblot SD, Biorad), before carefully placing the gel on top. Additional filter paper 
was used to cover the gel before closing the unit, which clamped the filter, 
membrane and gel together. Semi-dry transferring was run at 400mA for 1 hour, 
after which the membrane, now containing the transferred proteins, was briefly 
washed in phosphate-buffered saline (PBS) before blocking endogenous protein 
binding by incubating in 1X tris-buffered saline (TBS) with 3% Tween20 and 5% 
bovine serum albumin (BSA) for 1 hour at 4°C. Membranes were subsequently 
incubated overnight at 4°C with primary antibodies for NPC1 (1:10,000, ab134113, 
Abcam, Cambridge, UK) and β-Tubulin (1:2,000, ab6161, Abcam) in 1X TBS with 
3% Tween20 and 3% BSA overnight at 4°C. After three 5 minute washes in 1X TBS 
with 3% Tween20, horseradish peroxidase conjugated secondary antibodies goat 
anti-rabbit IgG (1:2,000, ab6721, Abcam) and goat anti-rat IgG (1:10,000, ab97057, 
Abcam) were added to 1X TBS with 3% Tween20 and 3% BSA and incubated with 
the membrane for 2 hours at room temperature. Membranes were washed a final 
three times and developed using the enhanced chemiluminescence system 
SuperSignal West Pico kit (LifeTechnologies), as per manufacturers protocol. 
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1X TBS (1000ml): 
Tris 6.04g 
NaCl 8.5g 
1M HCl 3.2ml 
dH2O to final volume of 1000ml 
 
 
Transfer Buffer (1000ml): 
methanol (100%) 200ml 
Tris 3g 
glycine 14.2g 
dH2O to final volume of 1000ml 
 
2.4 Virus Production 
2.4.1 Lentiviral vector preparation 
A 2nd generation lentiviral vector packaging system was used to produce the VSV-
G.CCL.SIN.cPPT.CMV.eGFP.WPRE lentiviral vector. 100mm dishes (Nunc) were 
seeded with 1 x 107 HEK-293T cells per dish and grown to 70-80% confluence. 
Cells were then triple transfected with 40µg of pCCL.SIN.cPPT.CMV.eGFP.WPRE 
lentiviral vector construct, 10µg of vesicular stomatitis virus envelope glycoprotein 
(VSV-G) encoding envelope plasmid pMDG2 and 30µg of packaging plasmid 
pCMVdR8.74 per dish. Plasmids and transfection agent PEI (branched Mw ~25,000, 
Sigma-Aldrich) at a final concentration of 1mM were added to 10ml of serum free 
Opti-Modified Eagle’s medium (Opti-MEM, Gibco), mixed and incubated at room 
temperature for 20 minutes to allow for PEI-DNA complex formation. HEK-293T 
cells were washed with Opti-MEM, before adding 10ml of the transfection mix per 
dish and incubated at 37°C, 5% CO2 for 4 hours, after which the mix was replaced 
with fresh standard growth media. Supernatant was subsequently collected 48 and 72 
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hours post-transfection, centrifuged at 3,000 x g for 10 minutes and filtered through a 
0.22µm filter (Millipore) to remove cell debris. Virus was pelleted by centrifugation 
overnight (16 - 18 hours) at 3,500 x g, 4°C, with the resulting pellet being 
resuspended in Opti-MEM and stored at -80°C.  
2.4.2 Lentiviral vector titration 
Lentiviral titer was obtained by quantification of the viral envelope protein p24. The 
ZeptoMetrix p24 antigen enzyme-linked immunosorbent assay was used as per 
manufacturers protocol (ZeptoMetrix, Buffalo, USA), where quantity of sample viral 
envelope protein p24 is determined by comparison to a standard curve, created by 
standards of known p24 concentration. The resulting titre for the VSV-
G.CCL.SIN.cPPT.CMV.eGFP.WPRE vector used in this study was 9.2 x 108 vp/ml. 
 
2.4.3 AAV vector preparation 
To produce recombinant AAV2/9 vectors, HEK-293T cells were transiently triple 
transfected with the ITR-containing plasmid carrying the transgene cassette, a helper 
plasmid expressing both AAV2 Rep and AAV9 Cap and a third construct containing 
the adenovirus helper functions. The combined transfection and resulting viral 
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Figure 7: Representative diagram of triple transfection in HEK293T cells, 
resulting in AAV2/9 vector production.  
 
5 x 108 HEK-293T cells were added to a total volume of 1L of standard growth 
media, seeded in a 10 layered CellSTACK (Corning, 6360 cm2, ThermoFisher 
Scientific) and incubated at 37°C in 5% CO2 for 16 to 30 hours. 160µg of AAV 
transgene plasmid, 160µg of capsid plasmid AAV2/9 (pDG9) and 480µg of 
adenovirus helper plasmid (pHGTI) were added to serum free DMEM, to which 
2.8ml of 3.5mg/ml PEI MAX was added. The transfection mixture was subsequently 
mixed and incubated at room temperature to allow DNA-PEI complex formation, 
after which 1L of fresh standard growth media was added. CellSTACK media was 
replaced with completed transfection media and incubated for 72 hours at 37°C in 
5% CO2.  
 
After 72 hours, the resulting AAV particles were collected and purified from both 
cells and supernatant. The supernatant was removed from the CellSTACK and 
centrifuged at 1,800 x g for 10 minutes to collect dislodged cells. Simultaneously 
cells remaining in the CellSTACK were washed with sterile PBS, detached via 
2.4 Virus Production 90 
trypsinisation and pelleted by centrifugation at 1,800 x g for 10 minutes. The 
resulting cell pellets were resuspended in 20ml of AAV lysis buffer and lysed by 3 
freeze-thaw cycles (-80°C to 37°C) with regular 5 minute vortexing at each interval. 
Viral particles were precipitated from the collected supernatant by adding 31.3g of 
ammonium sulphate (Sigma-Aldrich) per 100ml of supernatant, which was shaken 
vigorously until dissolved and subsequently incubated on ice for 30 minutes. The 
mixture was centrifuged at 8,300 x g and the resulting pellet was resuspended in 
20ml of AAV lysis buffer. Cell and supernatant lysates then underwent benzonase 
treatment to degrade cellular DNA and RNA by adding MgCl2 to a final 
concentration of 1mM and 5000 units of benzonase (Sigma-Aldrich) and were 
incubated at 37°C for 1 hour. The lysates were then cleared by centrifugation at 




Figure 8: Image of completed iodixanol gradient in ultracentrifuge tube prior to 
centrifugation.  
Extracted indicates fraction containing packaged AAV particles post-centrifugation, 
which were extracted for downstream concentration. 
 
The gradient was carefully created in ultracentrifuge tubes (Beckman Instruments, 
High Wycombe, UK) by overlaying the supernatant to slowly pipetted Optiprep 
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iodixanol (Sigma-Aldrich) solutions of increasing steps (15%, 25%, 40% and 60%). 
Completed tubes were centrifuged (Sorvall Discovery 90SE, ThermoFisher 
Scientific) for 3 hours at 200,000 x g using a TH641 (ThermoFisher Scientific) rotor. 
As a result the viral particles concentrated to the 40% band, which was extracted 
with a 19G11/2 needle attached to a 3ml syringe (Figure 8). The extracted sample 
was diluted in sterile PBS to a total volume of 50ml, 0.22µm filter sterilised and 
concentrated. The viral particles were concentrated in a Vivaspin20 with a 100,000 
Mw cut-off centrifugal concentrator (Sartorious Stedim Biotech, Epsom, UK) with 
repeated spins at 3,000 x g until a final volume of 500 - 1000µl was achieved. 
Concentrated virus was finally titered and stored at -80°C for further use.  
 
1X AAV lysis buffer: 
NaCl 150mM 
Tris pH 8.5 50mM 
 
2.4.4 AAV vector titration 
A combination of two methods was used to determine AAV titer, quantifying either 
viral capsid protein or number of viral genomes in a sample. In the first method AAV 
viral capsid proteins were separated by SDS page gel electrophoresis and the VP3 
protein was quantified using a standard curve created by known quantities of bovine 
serum albumin (BSA, Sigma-Aldrich) standards (Kohlbrenner et al., 2012). AAV 
samples were diluted in 6X AAV SDS loading buffer and heated at 95°C for 5 
minutes to breakdown the capsid and denature proteins. BSA standards (250ng, 
500ng, 750ng and 1000ng) and AAV samples were run on a NuPAGE Bis-Tris 4 - 
12% polyacrylamide gel (LifeTechnologies) at 120V for 2 hours. The gel was fixed 
in gel fix solution for 30 minutes, before staining for 3 hours at room temperature 
with ‘SYPRO Ruby’ (LifeTechnologies) for protein visualisation. Band visualisation 
and quantification was performed using a UV transilluminator (Ingenius, Syngene). 
VP3 band volume was analysed using the BSA standard curve, resulting in titration 
of viral protein per ml. 
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6X AAV SDS loading buffer (10ml): 
SDS 0.8g 
Tris pH 6.8 5ml 
glycerol 5ml 
bromophenol blue 4mg 
β-mercaptoethanol 5% 
 
Gel fix solution (500ml): 
Methanol 250ml 
Glacial acetic acid 35ml 
dH2O 215ml 
 
Concentrated vector genome content was determined using alkaline agarose gel 
electrophoresis (Fagone et al., 2012). AAV sample dilutions were mixed with 8.5µl 
of 4X alkaline sample buffer, which were then loaded on a 0.8% agarose gel made 
with alkaline running buffer. The gel was run with 1X alkaline running buffer 
overnight at 20V and 4°C. Gels were washed in 0.1M Tris (pH 8.0) for 1 hour, 
stained post-electrophoresis for 2 hours with 4X GelRed stain (Biotium, Fremont, 
USA) and subsequently visualised on a UV transilluminator (Ingenius, Syngene). 
Band quantification was carried out and compared against a HyperLadder 1kb 
(Bioline Reagents, London, UK) standard curve. 
 
50X Alkaline running buffer (500ml): 
NaOH 2.5M 
EDTA pH 8.0 50mM 
dH2O to a final volume of 500ml 
 
4X alkaline sample loading buffer (1ml): 
glycerol 200µl 
50X alkaline running buffer 80µl 
SDS (20% w/v) 60µl 
xylene cyanol 10mg 
dH2O to a final volume of 1ml 
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2.5 In vivo experiments 
2.5.1 Animals 
Wild-type CD-1 mice were used for preliminary vector testing and expression 
analysis in collaboration with Dr. S. Waddington (Institute for Women’s Health, 
Univeristy College London, UK). Wild-type and Npc1-/- BALB/c mice (Pentchev et 
al., 1984) were used for AAV9-hNPC1 vector efficacy studies in collaboration with 
A. Colaco, D. Smith and Prof. FM. Platt (Department of Pharmacology, University 
of Oxford, UK).  Any mice that lost 1g of body weight within a 24-hour period were 
considered to have reached their humane end-point and were sacrificed. All animal 
studies were approved by the UK Home Office for the conduct of regulated 
procedures under license (Animal Scientific Procedures Act, 1986) and according to 
ARRIVE guidelines and recommendations. 
2.5.2 Vector administration 
All vector administrations were carried out on P0/1 neonatal pups as previously 
described (Kim et al., 2014). Vectors were administered via bilateral 
intracerebroventricular (ICV) injection, targeting the anterior horn of the lateral 
ventricle (Figure 9). Prior to procedure, pups were incubated on ice for 1 minute to 
anesthetise and were placed on a cold flat surface during injection. Injection sites 
were identified at 2/5 of the distance directly from the lambda suture to the eye and a 
loaded 33-gauge needle (Hamilton, Reno, USA) with syringe was inserted 
perpendicular to the surface of the skull at a depth of 3mm from the tip of the needle. 
A maximum of 5µl was then slowly injected, after which the needle was carefully 
withdrawn and the procedure was repeated on the contralateral ventricle. Injected 
neonates were subsequently warmed and returned to the dam. For preliminary vector 
testing injected and uninjected control CD-1 mice underwent terminal 
exsanguination at 1-month (P30) post-injection. Npc1-/- and AAV9-hNPC1 treated 
Npc1-/- BALB/c mice were also sacrificed via terminal exsanguination at their 
respective humane end-point.  
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Figure 9: Illustration of injection sites (red arrows) used for P0/1 neonatal 
bilateral ICV administration. 
2.5.3 Drug administration 
Small molecule drugs hydroxypropyl-β-cyclodextrin (HP-β-CD, Sigma-Aldrich) and 
miglustat shown to have therapeutic efficacy in the Npc1-/- model were analysed to 
compare AAV9-hNPC1 therapeutic efficacy. Upon weaning at 3 weeks of age, 
cohorts of Npc1-/- mice began receiving either treatments. HP-β-CD was 
administered by weekly intraperitoneal injection at a dose of 4,000mg/kg. Miglustat 
was supplemented as a dry admixture to powdered RM1 mouse chow at a dose of 
1,200mg/kg/day (Actelion Pharmaceuticals Ltd., Basel, Switzerland) as previously 
described (Williams et al., 2014). Treatment continued until the treated Npc1-/- mice 
reached their humane end-points. 
2.5.4 Behavioural analysis – Rearing 
From 5 weeks of age, weekly rearing measurements were carried out on control 
wild-type mice, untreated Npc1-/- and treated Npc1-/- cohorts in an open field setting. 
Mice were individually placed in an open and empty cage and rears were counted 
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manually during a 5-minute period. A rear was recorded when a mouse reared on its 
hind legs using the side of the cage as support. 
2.5.5 Behavioural analysis – Tremor 
Tremor analysis was carried out on control, untreated and treated cohorts weekly, 
starting at 5 weeks of age using a commercial tremor monitor (San Diego 
Instruments, San Diego, USA) as previously described (Smith et al., 2009). 
Individual mice were placed inside the apparatus on an anti-vibration table and 
monitored for 256 seconds, after 30 seconds of acclimatisation time. The output 
(amplitude/time) was analysed using LabView software, to give a measurement of 
power at each monitored frequency (0-64Hz). Npc1-/- mice demonstrate an age-
dependent increase in 32-55hz high frequency tremor (Lloyd-Evans et al., 2008) and 
data within this range was analysed in detail in this study. 
2.5.6 Behavioural analysis – Gait 
Gait monitoring was performed by using the automated gait analysis CatWalk 
system (Noldus, Wageningen, Netherlands). From 5 weeks of age, mice were 
monitored weekly by being individually placed at one end of the CatWalk and were 
filmed freely walking across a filmed section with a backlit stage. A minimum of 
five successful runs were recorded per session, where a run across the stage was 
deemed successful if standard run criteria were met, including: speed, duration of 
run, direction and minimum number of steps. Paw prints during successful runs were 
checked, assigned and analysed using the CatWalk XT software v10.6 (Noldus) to 
produce footprint, stride and overall run measurements.  
2.5.7 Tissue harvest 
Mice to be sacrificed underwent terminal exsanguination by transcardial perfusion 
with sterile PBS under isoflurane-induced anaesthesia. A lateral incision through the 
2.6 Expression Analysis 96 
skin and abdominal wall was made below the rib cage to expose the pleural cavity. 
The sternum was lifted to reveal the diaphragm, which was cut to access the heart, 
where a small incision to the right atrium was made. 10 - 20ml of PBS was then 
slowly injected into the left ventricle with a 24 gauge needle, where liver and organ 
blanching indicated successful perfusion. Brains and visceral organs were 
subsequently extracted and either fixed in PBS with 4% paraformaldehyde for 
immunohistochemistry or snap frozen on dry ice and stored at -80°C for protein and 
glycosphingolipids analysis. 
2.6 Expression Analysis 
2.6.1 Double gelatine coating of slides 
To increase tissue adhesion and allow downstream washes, all microscope slides 
(Superfrost, VWR) were double coated with a fine layer of gelatine. 2.5g of gelatine 
powder (VWR) and 0.25g of chromium (III) potassium sulphate 12-hydrate (VWR) 
were added to 500ml of dH2O, which was subsequently warmed to 45°C with 
constant stirring. While maintaining the mix at 45°C, slides were briefly immersed in 
slide racks and then left to dry overnight at 56°C. The process was repeated a second 
time to produce double coated microscope slides, which were used for histology, 
immunohistochemistry and immunofluorescent studies. 
2.6.2 Immunohistochemistry 
After 48 hours of fixation in PBS with 4% (w/v) paraformaldehyde, tissues were 
transferred into 30% sucrose (Sigma-Aldrich) in PBS for cryoprotection. Brains were 
subsequently cryosectioned in the coronal or sagittal plane at -20°C using a Leica 
CM3050 cryostat microtome to a 40µm thickness. Resulting sections were stored at 
4°C in TBSAF in a 96-well (Nunc) consecutive format by rows, from dorsal to 
ventral. 3,3’- diaminobenzidine (DAB, Sigma-Aldrich) mediated 
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immunohistochemistry (IHC) was used for transgene expression and pathological 
marker analyses. Representative sections were chosen by selecting brain sections in 
the 96-well plates in 6 column intervals (e.g. columns 2, 8, 14, etc.) and were washed 
in 1X TBS. Endogenous peroxidase activity was depleted by incubating sections 
with 1% hydrogen peroxide (H2O2, Sigma-Aldrich) in 1X TBS for 30 minutes, 
followed by three 5 minute washes in 1X TBS. Non-specific protein binding was 
blocked via incubation in 15% normal serum (Sigma-Aldrich) in TBS-T for 30 
minutes. Sections were incubated overnight at 4°C in 10% normal serum in TBS-T 
with primary antibodies (Table 7). Following washes in 1X TBS, sections were 
incubated in 10% normal serum in TBS-T with corresponding biotinylated secondary 
antibodies (Table 7) at room temperature for 2 hours. Following washes, sections 
were incubated with Vectastain avidin-biotin solution (ABC, Vector Laboratories, 
Peterborough, UK), where reagents A and B were diluted 1:1,000 in 1X TBS, mixed 
and incubated for 2 hours at room temperature. Staining was visualised with 0.05% 
DAB (Sigma-Aldrich) and 0.003% H2O2 in 1X TBS in limited light conditions.  
 
The completed staining reaction was stopped via the addition of ice cold 1X TBS, 
after which the sections were washed three times for 5 minutes in 1X TBS, mounted 
on to double gelatine-coated slides and air-dried overnight. To further dehydrate and 
clean sections, dried slides were dipped in 100% ethanol (EtOH) for 30 seconds and 
transferred into Histo-Clear (National Diagnostics, Hessle, UK) for 30 minutes. 
Mounting agent DPX (VWR) was used to coverslip (VWR) the slides, which were 
then left to dry for 3 days. Sections were analysed by light microscopy on a Nikon 
Eclipse E600 light microscope and representative images were captured using a 
Nikon DS-Fi1 camera (Nikon, New York, USA). 
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Primary antibody Host Source Dilution 
Anti - eGFP Rabbit Abcam (ab290) 1:10,000 
Anti - NPC1 Rabbit Abcam (ab134113) 1:500 
Anti - GFAP Mouse Millipore (MAB3402) 1:2,000 
Anti - CD68 Rat AbD Serotech (MCA1957) 1:100 
Anti - Calbindin Rabbit Swant (CB38) 1:10,000 
Anti - LAMP1 Rabbit Abcam (ab24170) 1:2,000 
 
 
   
Secondary antibody Host Source Dilution 
Biotinylated Anti - Rabbit IgG Goat Vector Lab Inc. (BA-1000) 1:1,000 
Biotinylated Anti - Rat IgG Goat Vector Lab Inc. (BA-9400) 1:1,000 
Biotinylated Anti - Mouse IgG Goat Vector Lab Inc. (BA-9200) 1:1,000 
Table 7: List of antibodies used for IHC in this study 
 
1X TBS (1000ml): 
Tris 6.04g 
NaCl 8.5g 
1M HCl 3.2ml 
dH2O to final volume of 1000ml 
 
1X TBS-T (1000ml): 
1X TBS 997ml 
TRITON X-100 3ml 
 
1X TBSAF (1000ml): 
1X TBS 545ml 
sodium azide 10 % (w/v) 5ml 
ethylene glycol 300ml 
sucrose 150g 
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2.6.3 Quantitative analysis of immunohistochemical staining 
Levels of glial fibrillary acidic protein (GFAP), cluster of differentiation 68 (CD68), 
lysosomal-associated membrane protein 1 (LAMP1) and calbindin 
immunohistochemical staining were measured by quantitative thresholding image 
analysis, as previously described (Rahim et al., 2012). For each region of interest 10 
non-overlapping images were captured using a live video camera (Nikon, DS-Fil) 
mounted onto a Nikon Eclipse E600 light microscope at x40 magnification with 
constant light intensity. Images were analysed using Image-Pro Premier (Media 
Cybernetics, Cambridge, UK), where immunoreactivity was measured using a 
constant darkness threshold that is applied to all images within that set of antigen 
staining. Data is presented as the mean percentage area of immunoreactivity per unit 
area ± standard deviation (S.D.) for each region. 
2.6.4 Immunofluorescence and scanning confocal microscopy 
Immunofluorescence (IF) was used for the analysis of cell tropism and subcellular 
localisation of NPC1 following AAV9-hNPC1 administration. 40µm brain 
cryosections were initially stained as described for IHC (Section 2.6.2), however 
different primary antibody concentrations were used (Table 8). Secondary antibodies 
with Alexa Fluor conjugates were used to differentiate between co-stained proteins. 
Following incubation with the secondary antibodies, sections were washed three 
times for 5 minutes with 1X TBS and subsequently counterstained with 4′,6-
diamidino-2-phenylindole (DAPI, Sigma-Aldrich) for nuclear visualisation. A 
1mg/ml stock solution of DAPI in dH2O was further diluted 1:1,000 with 1X TBS 
and applied to the sections in limited light conditions for 5 minutes. After, sections 
were washed three times for 5 minutes in 1X TBS and mounted on to double 
gelatine-coated slides. Mounted sections were briefly dried, then coverslipped with 
Fluoromount G (SouthernBiotech, Birmingham, USA) and visualised with a Zeiss 
LSM 710 laser scanning confocal microscope (Carl Zeiss AG, Cambridge, UK). 
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Primary Antibody Host Source Dilution 
Anti - NPC1 Rabbit Abcam (ab134113) 1:100 
Anti - NeuN Mouse Millipore (MAB377) 1:500 
Anti - CD68 Rat AbD Serotech (MCA1957) 1:100 
Anti - GFAP Mouse Millipore (MAB2402) 1:2,000 
Anti - LAMP1 Rat Abcam (ab25245) 1:500 
    
Secondary Antibody Host Source Dilution 
Alexa488 conjugated 
Anti - Rabbit IgG 
Goat LifeTechnolgies (A-11008) 1:200 
Alexa568 conjugated 
Anti - Mouse IgG 
Goat LifeTechnolgies (A-11004) 1:200 
Alexa568 conjugated 
Anti - Rat IgG 
Goat LifeTechnolgies (A-11077) 1:200 
Table 8: List of antibodies used for IF in this study 
2.6.5 Brain section histology 
Nissl staining was carried out for the visualisation of general brain and neuronal 
cytoarchitecture (Scott and Willett, 1966). Every sixth 40µm section from a 
cryosectioned brain was mounted on double gelatine-coated slides and left to dry 
overnight, before staining with cresyl violet. Sections were incubated in filtered 
0.05% cresyl fast violet with 0.05% acetic acid (VWR) in distilled water for 30 
minutes at 60°C, followed by brief rinses in ascending series of graded alcohol from 
50% to 100%. Slides were subsequently incubated in Histo-Clear for 30 minutes and 
coverslipped with DPX for imaging and stereology. 
 
Filipin staining was carried out on mounted 40µm brain cryosections to analyse 
unesterified cholesterol accumulation observed in Npc1-/- mice (Kruth et al., 1986). 
Filipin (Sigma-Aldrich) was diluted in PBS to a working concentration of 100µg/ml 
and applied to brain sections for 1 hour at room temperature in limited light 
conditions. Sections were then washed at room temperature with PBS three times for 
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5 minutes. Staining was visualised with a Zeiss LSM 710 laser scanning confocal 
microscope (Carl Zeiss AG) under DAPI settings. 
2.6.6 Stereology  
Neuronal counts, cortical thickness measurements and regional volume estimates 
were carried out on 40µm Nissl stained brain sections using StereoInvestigator 
software (MBF Bioscience, Vermont, USA) on a Nikon Optiphot light microscope 
(Nikon) attached to a Q-Imaging Model 01-MBF-2000R-CLR-12 camera (MBF 
Bioscience). 
 
Regional volumes for the ventral posterior medial and lateral nuclei (VPM/VPL) of 
the thalamus and the substantia nigra pars reticulate (SNR) were obtained via 
Cavalieri estimator probe (Kielar et al., 2007) using a 10x objective, where a 50µm2 
sampling grid was superimposed on every sixth section over each region of interest 
and number of points within the area were counted. 
 
Cortical thickness in the somatosensory barrelfield cortex (S1BF) region was 
obtained by calculating the mean of 10 perpendicular line measurements from the 
corpus callosum white matter to the pial surface on every sixth section within the 
region of interest (Kielar et al., 2007). 
 
Neuronal cell number within the S1BF, VPM/VPL and SNR regions was estimated 
using the optical fractionator probe (West et al., 1991). Using a 100x objective, only 
Nissl stained cells with a neuronal morphology and clearly identifiable nucleus were 
counted (Figure 10). A border was traced around the region of interest, a grid was 
then superimposed and neurones were counted within a series of 50µm x 50µm 
dissector frames, which were automatically arranged according to the sampling grid 
size. Every sixth section containing the region of interest was analysed and grid sizes 
were used as followed: S1BF, 225µm x 225 µm; VPM/VPL, 175µm x 175µm; SNR 
150µm x 150µm. A coefficient of error (CE) between 0.05 and 0.1 was obtained for 
all counts indicating sufficient sampling efficiency (Gundersen et al., 1999). 
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Figure 10: Example of cells identified as neurons for neuronal quantification 
Representative image within the S1BF region of the cortex from a Nissl stained brain 
section from a wild-type mouse. Arrows signal cells identified and counted as 
neurons. Scale bar: 20µm. 
2.6.7 Western blotting of tissue protein extract 
Tissues were homogenized using an Ultra-Turrax TP (IKA Labortechnik, 
Wasserburg, Germany) on ice in 300µl of RIPA lysis buffer (ThermoFisher 
Scientific) per 100mg of tissue with 1X protease inhibitor cocktail (ThermoFisher 
Scientific). Lysates were subsequently treated as previously described in Section 
2.3.4. 
2.7 Biochemical glycosphingolipid analysis 
Glycosphingolipids (GSL) were analysed in collaboration with M. Huebecker as 
described by Neville and co-workers (2004). Lipids from tissue homogenates were 
extracted with chloroform:methanol (1:2, v/v) overnight at 4°C. GSLs were further 
purified using solid phase C18 columns (Kinesis, St Neots, UK). After elution, the 
GSL fractions were dried down under a stream of nitrogen and treated with ceramide 
glycanase (prepared in house from the medicinal leech Hirudo medicinalis/verbena) 
to obtain oligosaccharides from GSLs. Liberated glycans were then fluorescently-
labelled with anthranillic acid (2-AA). Excess 2AA-label was removed using DPA-
6S SPE columns (Supelco, PA, USA). Purified 2AA-labelled oligosaccharides were 
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separated and quantified by normal phase high-performance liquid chromatography 
(NP-HPLC) as previously described by Neville et al. (2004). The NP-HPLC system 
consisted of a Waters Alliance 2695 separations module and an in-line Waters 2475 
multi λ fluorescence detector set at Ex λ360nm and Em λ425nm. The solid phase 
used was a 4.6 x 250mm TSK gel-Amide 80 column (Anachem, Luton, UK). A 
standard 2AA-labelled glucose homopolymer ladder (Ludger, Oxfordshire, UK) was 
included to determine the glucose units (GU) of the HPLC peaks. Individual GSL 
species were identified by their GU values and quantified by comparison of 
integrated peak areas with a known amount of 2AA-labelled BioQuant chitotriose 
standard (Ludger). Results were normalised to protein content. 
2.8 Statistical Analysis 
All statistical analyses were carried out with GraphPad Prism software (Version 
6.0e). Two-sample comparisons were performed using Student’s t test and multiple 
comparisons were analysed by two-way analysis of variance (ANOVA) followed by 
Tukey’s honest significant difference (HSD) test. All graphs are plotted as the mean 
± the standard deviation (S.D.) unless stated otherwise and statistical significance 
was assumed for p < 0.05. ns - non significant, * p < 0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001. 
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 Development of a 
functional and efficient 
hNPC1 viral vector 
3.1 Introduction 
As detailed in the previous chapters, although recombinant AAV (rAAV) vectors are 
currently the standard vector of choice for efficient and widespread delivery to the 
CNS, the integration of the relatively large hNPC1 cDNA of 3.8kb in to a size 
limited rAAV construct of 4.7kb would be challenging. Initial rAAV-hNPC1 
construct variations conceived at the start of this study utilising standard rAAV 
templates would have resulted in a final oversized construct of ~5kb and over. While 
relatively larger genes have previously been integrated into functional rAAV vectors, 
which result in an oversized rAAV genome, the packaging efficiency and resulting 
viral production and transduction efficiency were significantly reduced (Dong et al., 
1996, Lai et al., 2010, Wu et al., 2010, Choi et al., 2014). Lower viral titers and 
potential truncation of oversized viral genomes would result in reduced numbers of 
cells being successfully transduced with the complete construct. Major adjustments 
to a standard rAAV construct would therefore have to be made in order to reduce 
vector genome size, thereby maximising packaging and production efficiency, while 
also attempting to maintain high levels of transgene expression. Due to the 
previously described lack of cross-correction potential of the NPC1 protein (Section 
1.8), the transduction of the highest number of cells possible will be crucial for 
maximum therapeutic efficacy. While other viral and non-viral vectors with larger 
packaging capacity can be utilised, their transduction spread and efficiency within 
the brain may not be sufficient for NP-C. Taking these points into consideration, the 
delivery of hNPC1 would have to balance a variety of factors including transduction 
3.2 Chapter Aims 105 
spread, expression levels and production efficiency in the context of realistic clinical 
potential. 
3.2 Chapter Aims 
This chapter aims to start with the presentation of the results of a gene delivery 
vector study, which was carried out to determine the optimal vector to be used for 
widespread delivery of hNPC1 throughout the brain, after ICV administration. This 
is followed by the development and synthesis of a rAAV construct capable of 
efficiently expressing the complete human NPC1 protein to supraphysiological 
levels. The results of in vitro testing of the hNPC1 plasmid construct and eGFP 
reporter equivalent are subsequently presented to justify the continuation of these 
variants for AAV9-hNPC1 vector production, used in initial in vivo testing. Vector 
production analysis is followed by results of transgene expression, vector tropism 
and toxicity studies in vivo, where wild-type mice were administered neonatally with 
the produced vector. In combination, the results presented in this chapter validate the 
use of the produced AAV9-hNPC1 vector for subsequent preclinical studies in the 
Npc1-/- mouse model. 
3.3 Vector Study  
Although AAV is currently the vector of choice for gene delivery to the brain, one of 
its major limitations is the restricted packaging size that it has. This can be 
problematic for larger genes such as NPC1. Other commonly used vectors do not 
have such a restricted packaging capacity. Therefore, before committing to a 
potentially more complex AAV-based approach, a side-by-side evaluation of 
different vectors was conducted. All vectors were designed to express an eGFP 
reporter gene, under the control of the strong and constituently active 
cytomegalovirus promoter (Damdindorj et al., 2014), to allow a direct comparison of 
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vector spread and eGFP expression (Rahim et al., 2012). Administration of 
individual vectors was carried via intracerebroventricular injection to the neonatal 
mouse brain at the highest possible dose for each respective vector, to compare the 
efficiency of transduction. As AAV9 vectors have previously shown to result in 
extensive transgene expression throughout the brain following ICV injection 
(McLean et al., 2014), an AAV2/9.CMV.eGFP.WPRE vector was sourced from the 
Penn Vector Core facility (Univeristy of Pennsylvania, Philadelphia, PA, US) at a 
titre of 6 x 1013 vg/ml and a total dose of 6 x 1011 vg was administered. Due to the 
previously mentioned issue of immunogenicity associated with human adenoviral 
serotypes (Jooss and Chirmule, 2003, Bessis et al., 2004), the canine adenovirus 
serotype 2 (CAV-2), shown to have a low rate of pre-existing neutralising antibodies 
in mice and humans compared to hAd5 vectors (Kremer et al., 2000) was evaluated. 
CAV-2 was kindly provided by Dr. E. Kremer (Institut de Génétique Moléculaire de 
Montpellier, France) at a titre of 1 x 1012 vp/ml and a total dose of 1 x 1010 vp was 
administered. The lentiviral LV.VSV-G.CCL.SIN.cPPT.CMV.eGFP.WPRE vector 
used in this study was produced in collaboration with Dr. S. Howe (UCL Institute of 
Child Health, London, UK) to a titer of 9.2 x 108 vp/ml and a total dose of 9.2 x 106 
vp was administered. Finally a non-viral vector was also evaluated, although as 
previously stated (Section 1.6) these vectors have shown poor and short-term 
transfection efficiency (Kenny et al., 2013). A novel non-viral vector cationic 
complex containing a CMV.eGFP construct was kindly provided by Prof. S. Hart 
(Institute of Child Health, London, UK) and a total of 10µl of nanocomplex 
formulation was administered.  
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Figure 11: Vector study comparing eGFP expression in mouse brains following 
P0 bilateral intracerebroventricular administration of gene delivery vectors. 
Vectors expressing eGFP driven by the CMV promoter were administered at their 
highest possible dose into P0 wild-type mice via bilateral ICV injection (n = 3 for each 
group). Brains were harvested 14 (non-viral) or 30 (viral) days post-injection, 
sectioned and analysed by anti-eGFP IHC. Gene delivery vectors and doses: 
AAV2/9.CMV.eGFP.WPRE (AAV9, 6 x 1011 vg), canine adenoviral vector CAV-
2.CMV.eGFP (CAV-2, 1 x 1010 vp), lentiviral vector LV.VSV-
G.CCL.SIN.cPPT.CMV.eGFP.WPRE (LV.VSV-G, 9.2 x 106 vp) and 10µl of non-
viral cationic complex containing CMV.eGFP (NV-Cat).  
(A) Images of whole brain representative sections presented rostral to caudal, 
exhibiting eGFP expression. 
(B) Representative images from the S1BF region of the cerebral cortex. Scale bar: 
100µm. 
(C) Higher magnification images from the S1BF region of the cerebral cortex. Scale 
bar: 20µm. 
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P0/1 CD-1 wild-type pups were administered with the individual vectors via bilateral 
ICV injection. Viral vector injected and non-injected control mice were sacrificed 30 
days post-injection to analyse sustained transgene expression into adulthood. 
However, mice injected with the non-viral vector were sacrificed at 14 days post-
injection, due to the previously observed transient expression resulting from these 
complexes (Kenny et al., 2013).  
 
Immunohistochemistry with anti-eGFP antibody was carried out on whole-brain 
sections and representative images were captured by light microscope (Figure 11A). 
No significant background staining was present in the brains of uninjected P30 
control mice, however widespread rostrocaudal eGFP expression was observed 
throughout the entire brain of age-matched mice injected with 
AAV2/9.CMV.eGFP.WPRE. eGFP expression was extensive enough in brains 
injected with AAV2/9.CMV.eGFP.WPRE, that identification of clear cellular 
morphology was challenging at higher magnifications (Figure 11B-C). Age-
matched brains injected with other viral vectors showed both extremely limited 
efficiency of transduction and distribution through the brain, when compared to the 
AAV2/9 vector. No eGFP positive cells could be identified in mice injected with the 
non-viral cationic complex at 14 days post-injection, indicating short transient 
expression or limited transfection efficiency. However, as anticipated following ICV 
administration directly in to the cerebral spinal fluid, eGFP positive ependymal cells 
lining the luminal surface of the ventricle walls could be observed following CAV-2 
administration. Positive eGFP staining was also observed around the site of injection 
and at higher magnifications these cells appeared to show a neuronal morphology. 
However, in remaining areas of the brain the spread of transduction was either 
severely limited or absent.  
 
A similar transduction profile was also observed in brains injected with VSV-
G.CCL.SIN.cPPT.CMV.eGFP.WPRE, as ependymal cells throughout the ventricles 
in the brain exhibited positive eGFP staining and the distribution of transduced cells 
in the brain was anatomically limited. At higher magnification individual eGFP 
positive cells with neuronal and glial morphology could be observed. Interestingly, 
extensive levels of eGFP expression were observed in the olfactory bulbs of P30 
mice injected neonatally with VSV-G.CCL.SIN.cPPT.CMV.eGFP.WPRE, compared 
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to the relatively limited transduction in all other brain areas (Figure 12A). In 
combination with high levels of ependymal cell transduction around the lateral 
ventricle, it was hypothesised that the lentiviral vector had transduced cells in the 
rostral migratory stream. The rostral migratory stream is a migratory route of neural 
progenitors known as neuroblasts, from the subventricular zone surrounding the 
lateral ventricle towards and into the olfactory bulb (Pencea et al., 2001). These 
migrating neuroblasts subsequently mature into neurons and in certain situations can 
migrate to sites of damage, where they may play a role in regeneration (Capilla-
Gonzalez et al., 2015). To analyse the potential transduction of the rostral migratory 
stream, sagittal sections from the brains of P30 mice injected neonatally with VSV-
G.CCL.SIN.cPPT.CMV.eGFP.WPRE underwent immunohistochemistry against 
eGFP (Figure 12B). Imaged under light microscopy, a distinct line of eGFP positive 
cells could be observed originating from subventricular zone of the lateral ventricle 
and extending into the olfactory bulb (Figure 12C). Additionally, in collaboration 
with Prof. T. McKay and Ms. L. Fitzpatrick (St. George’s University of London), 
immunofluorescent co-staining of eGFP and Nestin, an intermediate filament protein 
expressed in neuronal precursor cells (Wang et al., 2011), was carried out (Figure 
12D). Confocal microscopy imaging revealed that the previously observed stream of 
eGFP positive cells also exhibited positive Nestin expression, confirming neuroblast 
transduction within the rostral migratory stream. 
 
Although this observation may or may not be of direct interest or benefit for the 
treatment of NP-C, the subventricular zone is one of only two areas of active and 
proliferating stem cell niches in the central nervous system (Gage, 2000) and the 
ability to target and transduce these neural progenitors with a viral vector may in the 
future be of novel therapeutic benefit. 
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Figure 12: Lentiviral vector transduction of neuroblasts in the rostrol migatory 
stream.  
(A) Representative coronal sections of olfactory bulbs from a P30 mouse brain 
administered P0 with VSV-G.CCL.SIN.cPPT.CMV.eGFP.WPRE  
(WT + LV-eGFP) and age-matched uninjected control (WT). Scale bar: 250µm. 
(B) Representative sagittal sections of a P30 mouse brain administered at P0 with 
VSV-G.CCL.SIN.cPPT.CMV.eGFP.WPRE and age-matched uninjected control.  
Scale bar: 1000µm. 
(C) Magnification of the lateral ventricle subventricular zone exhibited in (B). Scale 
bar: 50µm. 
(D) Co-localisation of eGFP positive cells from the RMS with neural progenitor cell 
marker Nestin. Scale bar: 50µm. [Performed in collaboration with Prof. T. 
McKay and Ms L. Fitzpatrick at St. George’s University of London.] 
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The transgene expression levels and spread of transduction resulting from neonatal 
ICV AAV2/9 administration compared to the other delivery vectors was clearly 
superior. As previously stated (Section 1.8) widespread and efficient transduction of 
as many cells possible will be crucial for maximal therapeutic efficacy for Niemann-
Pick Type C. While adenoviral and lentiviral vectors may have potential for 
treatments able to take advantage of cross-correction to amplify therapeutic efficacy, 
the lack of transduction efficiency would most likely be too limited for therapeutic 
hNPC1 delivery. As a result of the vector study, despite the obstacles of rAAV 
packaging capacity and potential downstream production challenges, an AAV2/9 
vector based approach was chosen as the delivery mechanism for hNPC1 gene 
delivery. 
3.4 Incorporating hNPC1 into an rAAV construct 
Following the highly efficient transduction of neural cells throughout the brain 
demonstrated by the AAV2/9 vector in the vector study, a strategy to incorporate the 
relatively large human NPC1 cDNA into a functional and clinically relevant rAAV 
construct was devised, as appropriate for use in a preclinical study. Furthermore, the 
constructs and vectors used and tested in the murine Npc1-/- model throughout this 
study therefore express the clinically relevant human NPC1 cDNA and human NPC1 
protein, as opposed to the murine variants. Human and murine NPC1 cDNA and 
protein sequences share an 84% and 86% homology respectively (Supplementary 
Figure S1 and Supplementary Figure S2), so the functionality of human NPC1 was 
expected to be conserved in the murine model. Due to the susceptibility of neuronal 
loss in NP-C disease, the transduction of the maximum number of neurons possible 
was prioritised. Additionally, a previous study demonstrated in a chimeric mouse 
model of NP-C, that neuronal loss is primarily a cell-autonomous defect (Ko et al., 
2005). Npc1-/- Purkinje cells were not rescued by surrounding Npc1+/+ glial cells, 
however Npc1+/+ Purkinje cells were not lost when surrounded by Npc1-/- glial cells. 
Consequently the decision to prioritise maximal AAV-mediated NPC1 production in 
neurons led to the decision of choosing the strong human neuronal promoter 
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synapsin I (SynI) to drive hNPC1 expression. A rAAV construct containing the 
hSynI.flox.eGFP.WPRE.hGHpA expression cassette flanked by AAV2 ITRs was 
kindly provided by Dr. J. Tordo (Department of Infectious Diseases, King’s College 
London, UK). To accommodate the large NPC1 gene, the first consideration was the 
removal from the template construct of as much DNA as possible, deemed non-
essential for basic transgene expression. These non-essential sequences included the 
original eGFP transgene, flanking loxP sites and the woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) sequence. The WPRE sequence is 
frequently added to viral expression cassettes to enhance transgene expression 
(Zufferey et al., 1999), though the extent of enhancement can vary with different 
promoters and cell types (Klein et al., 2006). However, due to the WPRE sequence 
length of 609bp and limited rAAV packaging capacity, it was chosen not to be 
included in the hNPC1 construct. 
 
Removal of these sequences and incorporation of the hNPC1 gene was carried out by 
restriction enzyme digest and subsequent ligation. The template plasmid 
pAAV.hSynI.flox.eGFP.WPRE.hGHpA was digested with restriction enzymes KpnI 
and BglII, which cut directly downstream of the SynI promoter and directly upstream 
at the start of the hGHpA sequence (Figure 13A). The products of this digest 
underwent agarose gel electrophoresis, where the predicted 3.9kb segment consisting 
of the remaining construct and plasmid backbone was observed (Figure 13D). The 
human NPC1 cDNA was amplified via PCR from the pCMV6neo.hNPC1 template 
plasmid kindly provided by Prof. FM Platt (Department of Pharmacology, University 
of Oxford, Oxford, UK). Primers were additionally designed to incorporate the 
translation enhancing Kozak consensus sequence (Kozak, 2005) and the KpnI and 
BglII restriction enzyme sites directly at the 5’ and 3’ end of the hNPC1 cDNA 
respectively (Figure 13B). The resulting PCR product was subsequently digested 
with KpnI and BglII restriction enzymes to produce sticky ends compatible to the 
previously digested backbone and underwent agarose gel electrophoresis, where the 
predicted 3.8kb hNPC1 cDNA segment was observed (Figure 13D). The 3.9kb 
rAAV backbone and 3.8kb hNPC1 insert were then extracted from the gel, purified 
and ligated at a molar ratio of 1:3 backbone to insert respectively, to produce 
pAAV.hSynI.hNPC1.hGHpA (Figure 13C). Incorporation of the insert was initially 
confirmed by KpnI restriction enzyme digest and agarose gel electrophoresis, which 
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revealed the predicted clear single band of pAAV.hSynI.hNPC1.hGHpA at ~7.8kb 
(Figure 13E). 5’ ITR to 3’ ITR automated Sanger sequencing (Source Biosciences) 
was additionally carried out to confirm complete and un-mutated hNPC1 
incorporation and correct integration at the desired ligation sites (Figure 13F-G). 
The completed pAAV.hSynI.hNPC1.hGHpA construct had an oversized 5’ ITR to 3’ 
ITR viral genome of 5,154bp. To further reduce the rAAV-hNPC1 construct size, the 
human growth hormone polyadenylation signal sequence, at 496bp in length, was 
identified as the next modification target. 
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Figure 13: Summary of hNPC1 cDNA integration into a rAAV construct to 
produce pAAV.hSynI.hNPC1.hGHpA.  
(A) Illustration of pAAV.hSynI.flox.eGFP.WPRE.hGHpA template construct.  
(B) Illustration of pAAV.hSynI.flox.eGFP.WPRE.hGHpA template following KpnI and 
BglII restriction enzyme digest.  
(C) Illustration of resulting pAAV.hSynI.hNPC1.hGHpA construct.  
(D) Image of KpnI and BglII double digest of 1 – 
pAAV.hSynI.flox.eGFP.WPRE.hGHpA template, 2 – hNPC1 cDNA PCR product. 
L – Ladder.  
(E) Image of KpnI confirmation digest of 1 – pAAV.hSynI.flox.eGFP.WPRE.hGHpA 
template, 2 – pAAV.hSynI.hNPC1.hGHpA construct. L – Ladder. 
(F) Section of Sanger sequencing electropherogram verifying 5’ ligation site. 
(G) Section of Sanger sequencing electropherogram verifying 3’ ligation site. 
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3.5 Introduction of SV40pA signal sequence 
Significant reductions in efficient viral genome packaging and subsequent viral 
vector production efficiency have been observed in rAAV vectors with genomes 
exceeding 4.9-5kb. In an attempt to further reduce problems with downstream vector 
packaging and production efficiency, the 496bp human growth hormone 
polyadenylation signal sequence was replaced with the commonly used 193bp SV40 
late polyadenylation signal sequence (Fitzgerald and Shenk, 1981). This change 
shortened the viral genome to 4,858bp, under the 4.9kb threshold (Figure 14).  
 
The hGHpA signal sequence was removed from the pAAV.hSynI.hNPC1.hGHpA 
construct via restriction enzyme digest with BglII and PmlI restriction enzymes, 
cutting directly downstream of the hNPC1 cDNA stop codon and upstream of the 
3’ITR respectively (Figure 14A). Digest products were analysed by agarose gel 
electrophoresis, where the predicted 7.2kb band, consisting of the remaining 
construct and plasmid backbone, was observed (Figure 14D). The SV40pA signal 
sequence was amplified from the pSUB201-Caggs-GFP template plasmid via PCR, 
utilising primers designed to incorporate BglII and PmlI restriction enzyme sites 
directly at the 5’ and 3’ ends of the SV40pA signal sequence respectively (Figure 
14B). The products of this PCR reaction were digested with restriction enzymes 
BglII and PmlI, to produce the sticky ends necessary for ligation with the digested 
backbone and were analysed by agarose gel electrophoresis, where the predicted 
200bp band was observed (Figure 14D). The required 7.2kb backbone band and 
0.2kb SV40pA band were subsequently extracted, purified and ligated to produce 
pAAV.hSynI.hNPC1.SV40pA (Figure 14C). The produced construct was verified by 
ITR to ITR automated Sanger sequencing (Figure 14E-F), confirming a final vector 
genome size of 4,858bp. 
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Figure 14: Summary of SV40pA signal sequence integration to produce 
pAAV.hSynI.hNPC1.SV40pA.  
(A) Illustration of pAAV.hSynI.hNPC1.hGHpA template construct.  
(B) Illustration of pAAV.hSynI.hNPC1.hGHpA template following BglII and PmlI 
restriction enzyme digest.  
(C) Illustration of resulting pAAV.hSynI.hNPC1.SV40pA construct.  
(D) Image of BglII and PmlI double digest of 1 – pAAV.hSynI.hNPC1.hGHpA 
template with extracted band, 2 – SV40pA PCR product. L – Ladder.  
(E) Section of Sanger sequencing electropherogram verifying 5’ ligation site.  
(F) Section of Sanger sequencing electropherogram verifying 3’ ligation site. 
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The pAAV.hSynI.hNPC1.SV40pA construct remains over the standard AAV wild-
type genome size of 4.7kb, however under the 4.9kb threshold at which vector 
production and transduction efficiency have been observed to be significantly 
affected (Wu et al., 2010, Choi et al., 2014). Alterations or minimising of either the 
promoter or polyadenylation signal sequences to reduce construct size further would 
have required changes to the wild-type sequences, which may potentially have 
impacted transgene expression. As a result, the pAAV.hSynI.hNPC1.SV40pA viral 
vector construct was used for basic in vitro and in vivo testing before being used for a 
preclinical study in the Npc1-/- mouse model.  
3.6 Synthesis of eGFP reporter construct 
Following discussion with collaborators and others researchers working in the NP-C 
field, we were advised that the commercial antibodies available against the NPC1 
protein were not highly efficient. Therefore, to facilitate initial in vitro and in vivo 
analysis of the novel pAAV.hSynI.hNPC1.SV40pA viral vector, a clone replacing the 
hNPC1 cDNA with an eGFP reporter gene was created (Figure 15). The hNPC1 
cDNA was extracted via the previously utilised KpnI and BglII restriction enzymes 
from the pAAV.hSynI.hNPC1.SV40pA plasmid (Figure 15A). PCR was used to 
amplify the eGFP reporter gene from the pSUB201-Caggs-GFP template plasmid, 
utilising primers introducing a Kozak consensus sequence and the KpnI and BglII 
restriction enzyme sites at the 5’ and 3’ ends of the eGFP gene respectively (Figure 
15B). The PCR product was also digested with KpnI and BglII restriction enzymes 
and was analysed by agarose gel electrophoresis together with the backbone digest 
products. The predicted 3.6kb backbone band and 0.7kb eGFP insert band were 
extracted from the gel, purified and underwent ligation to produce the 
pAAV.hSynI.eGFP.SV40pA (Figure 15C). Confirmation of complete eGFP 
integration was carried out by automated Sanger sequencing (Figure 15D-E). 
Produced viral vector plasmids pAAV.hSynI.eGFP.SV40pA and 
pAAV.hSynI.hNPC1.SV40pA subsequently underwent in vitro testing, to confirm 
vector functionality.  




Figure 15: Summary of hNPC1 replacement with eGFP reporter gene to produce 
pAAV.hSynI.eGFP.SV40pA.  
(A) Illustration of pAAV.hSynI.hNPC1.SV40pA template construct.  
(B) Illustration of pAAV.hSynI.hNPC1.SV40pA template following KpnI and BglII 
restriction enzyme digest.  
(C) Illustration of resulting pAAV.hSynI.eGFP.SV40pA construct.  
(D) Section of Sanger sequencing electropherogram verifying 5’ ligation site.  
(E) Section of Sanger sequencing electropherogram verifying 3’ ligation site. 
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3.7 In vitro testing confirms functional hNPC1 and eGFP 
constructs 
To verify if the pAAV.hSynI.eGFP.SV40pA and pAAV.hSynI.hNPC1.SV40pA 
plasmids were capable of expressing their transgenes and respectively encoded 
proteins, a series of transfections in wild-type HEK-293T cells was carried out 
(Figure 16). The amount of NPC1 protein 72 hours post-transfection was analysed 
by Western blot in cells transfected with pAAV.hSynI.hNPC1.SV40pA plasmid. 
NPC1 levels were compared to cells transfected with the original hNPC1 expression 
plasmid pCMV6.hNPC1.Neo as a positive control and endogenous levels of NPC1 in 
the untransfected control cells (Figure 16). 
 
Staining with an anti-NPC1 antibody revealed that a single band at the predicted size 
of 170kDa was present in all groups, representing the NPC1 protein (Figure 16A). A 
statistically significant overexpression of NPC1 was observed in samples transfected 
with both expression plasmids compared to endogenous control levels, indicating 
successful expression of the hNPC1 transgene (Figure 16B). The eGFP reporter 
construct pAAV.hSynI.eGFP.SV40pA was also transfected into human neuroblastoma 
SH-SY5Y cells to confirm functional transgene expression (Figure 16C). 48 hours 
post-transfection cells were imaged using fluorescent microscopy, where no 
background eGFP expression was observed in untransfected control cells. Cells 
transfected with the construct exhibited positive whole cell eGFP fluorescence, 
indicating functional transgene and downstream protein expression.  
 
As a result of in vitro confirmation of the pAAV.hSynI.eGFP.SV40pA and 
pAAV.hSynI.hNPC1.SV40pA transgene expression capability, both constructs were 
used to produce AAV2/9 viral vectors for subsequent in vivo testing. 
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Figure 16: In vitro hNPC1 and eGFP expression.  
(A) Western blot analysis of NPC1 levels in HEK-293T cells following transfection 
with positive control pCMV6.hNPC1.Neo (CMV) and 
pAAV.hSynI.hNPC1.SV40pA (SYN) compared to endogenous NPC1 in 
untransfected negative control (Control). 170kDa band represents NPC1 protein. 
50kDa band represents the β-tubulin loading control.  
(B) Densitometric quantification of NPC1 bands normalised against loading control 
and expressed as fold change of endogenous control NPC1 levels. Data 
represented as mean ± S.D., compared by One-way ANOVA. * p < 0.05; ** p < 
0.01; n = 2 blots with 3 samples per group.  
(C) Fluorescent microscopy images of untransfected control SH-SY5Y cells and cells 
transfected with pAAV.hSynI.eGFP.SV40pA construct (n = 3 per group) resulting 
in eGFP expression. Scale bar: 40µm. 
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3.8 No elevation in NPC1 following codon optimisation of 
hNPC1 cDNA 
With the aim of increasing NPC1 protein expression efficiency of the newly 
produced rAAV construct, codon optimisation of the human NPC1 cDNA was 
carried out. The final NPC1 amino acid sequence was not modified, however specific 
changes to the cDNA sequence and resulting codon distribution were made with the 
aim of improving the rate and stability of translation (Plotkin and Kudla, 2011). In 
total 30% of the wild-type hNPC1 nucleotide sequence was changed however the 
resulting NPC1 amino acid sequence remained conserved. Design and synthesis of 
the optimised NPC1 sequence (NPC1O) was outsourced to Genscript (China), with a 
Kozak sequence and KpnI restriction enzyme site incorporated directly at the 5’ end 
of NPC1O and a BglII restriction enzyme site directly after the stop codon. The 
synthesised NPC1O sequence was extracted from the pU57.NPC1O template via 
KpnI and BglII restriction enzyme digest. The wild-type NPC1 cDNA was 
simultaneously removed from the pAAV.hSynI.hNPC1.SV40pA with identical 
restriction enzymes. Digest products were then separated by agarose gel 
electrophoresis, where the desired bands were extracted purified and ligated to 
produce the pAAV.hSynI.hNPC1O.SV40pA construct (Figure 17A). 
 
A series of transfections in HEK-293T cells with the original hNPC1 construct 
pAAV.hSynI.hNPC1.SV40pA and codon optimised NPC1O construct 
pAAV.hSynI.hNPC1O.SV40pA were carried out, to compare resulting NPC1 
expression by Western blot (Figure 17B). Wild-type non-transfected control samples 
showed low-level endogenous hNPC1. As previously presented in Section 3.7, cells 
transfected with the pAAV.hSynI.hNPC1.SV40pA construct exhibited significantly 
higher expression of NPC1, compared to endogenous levels (Figure 17C). 
Transfection of the codon optimised pAAV.hSynI.hNPC1O.SV40pA construct also 
resulted in significantly higher NPC1 expression, compared to untransduced control 
cells. However, no significant difference in NPC1 amount was observed in cells 
transfected with the two constructs, indicating that this specific codon optimised 
variant did not further enhance NPC1 expression. As a result of these findings, the 
original pAAV.hSynI.hNPC1.SV40pA construct was chosen for vector production, as 
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the function of the NPC1 protein produced by wild-type cDNA expression did not 
have to be tested and confirmed. 
 
 
Figure 17: In vitro testing of codon optimised hNPC1O cDNA in HEK-293T cells.  
(A) Illustration of codon optimised pAAV.hSynI.hNPC1O.SV40pA construct.  
(B) Western blot analysis of NPC1 levels in HEK-293T cells following transfection 
with wild-type NPC1 cDNA construct pAAV.hSynI.hNPC1.SV40pA (NPC1) and 
codon optimised construct pAAV.hSynI.hNPC1O.SV40pA (NPC1O), compared to 
endogenous NPC1 in untransfected negative control (Control). β-tubulin staining 
used for loading control.  
(C) Densitometric quantification of NPC1 bands normalised against loading control 
and expressed as fold change of endogenous NPC1 levels. n = 2 blots with 3 
samples per group. Data represented as mean ± S.D., compared by One-way 
ANOVA. ns - non significant, *** p < 0.001 
3.9 Successful production of oversized AAV2/9-hNPC1 viral 
vector 
The aim of the initial round of AAV9-hNPC1 viral vector production was to identify 
whether fully packaged and functional viral particles could be produced from the 
oversized pAAV.hSynI.hNPC1.SV40pA construct, at a titer viable for further 
preclinical studies. AAV2/9-SynI-hNPC1-SV40pA (AAV9-hNPC1) was produced in 
HEK-293T cells that were harvested and lysed 72 hours post-transfection. Viral 
particles were then purified by iodixanol gradient ultracentrifugation, where viral 
particles accumulate and are extracted from a band of known iodixanol density. 
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Iodixanol gradient ultracentrifugation also results in the beneficial sorting of lighter 
empty capsids from packaged capsids (Lock et al., 2010), thereby increasing dose 
efficiency by reducing the administration of non-functional empty capsids. 
Concentrated viral titer was determined by viral genome and viral particle 
quantification analysis, where viral capsid protein ratios and complete packaging of 
the oversized viral genome were simultaneously analysed (Figure 18). 
 
 
Figure 18: AAV2/9-SynI-hNPC1-SV40pA titration and vector genome analysis.  
(A) Viral capsid protein VP3 quantification via SDS-PAGE gel electrophoresis. Titer 
of concentrated sample was subsequently quantified by densitometric comparison 
with known BSA quantity standards (S1000 – 1000ng, S750 – 750ng, S500 – 
500ng, S250 – 250ng). Resulting viral particle titer of 4.63 x 1011 vp/ml.  
(B) Vector genome quantification against Hyperladder I standard by alkaline gel 
electrophoresis. Single viral vector genome band at 5kb. Resulting viral genome 
titer of 4.21 x 1011 vg/ml. 
The amount of viral capsid protein VP3 in samples of concentrated AAV9-hNPC1 
was quantified against a set of known quantity bovine serum albumin standards, via 
SDS PAGE gel electrophoresis and subsequent band visualisation by SYPRO Ruby 
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staining (Figure 18A). The resulting titer from the first round of AAV9-hNPC1 
production was significantly lower than the standard expected titer of at least 1 x 1013 
vp/ml, at 4.63 x 1011 viral particles per ml. Bands representing the remaining larger 
and less abundant VP1 and VP2 capsid proteins were also observed. Alkaline gel 
electrophoresis of viral DNA followed by GelRed band visualisation was carried out 
to quantify the amount of viral genome in a concentrated sample against the 
Hyperladder I standard (Figure 18B). Using this method, the resulting titer of 
AAV9-hNPC1 was 4.21 x 1011 viral genome copies per ml, comparable to the 4.63 x 
1011 vp/ml measured by viral capsid quantification. As anticipated, reductions in final 
viral titer may have been related to the oversized viral genome of 
pAAV.hSynI.hNPC1.SV40pA. However, crucially the analysis of the AAV9-hNPC1 
viral genome confirmed complete packaging of the oversized viral genome, without 
any indications of major truncation variants, as indicated by a clean single band at 
4.9kb.  
 
Although the final titer of AAV9-hNPC1 was 22-fold lower than the titer expected 
during a standard AAV preparation, the production of viral particles containing the 
fully packaged AAV.hSynI.hNPC1.SV40pA genome was successful. Further 
optimisation of vector production protocol can be carried out, in attempt to boost 
viral titer. However as a starting point, this vector was used to carry out initial in vivo 
studies, to confirm functionality of the vector following administration.  
3.10 AAV2/9-eGFP viral vector production 
The eGFP reporter variant of AAV9-eGFP was produced in an identical fashion, 
using the pAAV.hSynI.eGFP.SV40pA construct. Quantification of the viral capsid 
VP3 in a sample of concentrated AAV9-eGFP, resulted in a viral titer of 4.8 x 1013 
vp/ml (Figure 19). As transgene and resulting viral genome size was the only 
differentiating factor between both constructs and the production process, the over 
100-fold titer difference in concentrated viral particle yield supported the previously 
suggested affect of oversized viral genome on vector production efficiency. The 
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produced AAV9-eGFP vector was subsequently used for in vivo dose testing, 
compared with the AAV9-hNPC1 vector. 
 
Figure 19: AAV2/9-SynI-eGFP-SV40pA titration 
AAV titration by quantification of viral capsid protein VP3 via SDS-PAGE gel 
electrophoresis. Subsequent densitometric comparison with known BSA quantity 
standards (S1000 – 1000ng, S750 – 750ng, S500 – 500ng, S250 – 250ng) resulted in a 
viral particle titer of 4.8 x 1013 vp/ml. 
3.11 Overexpression of NPC1 following low dose AAV9-
hNPC1 administration 
To confirm the production of a functional AAV9-hNPC1 vector, a low dose of 4 x 
109 viral particles of AAV9-hNPC1 was administered via bilateral 
intracerebroventricular injection to P0/1 wild-type mice. At P30, injected mice (n = 
3) and uninjected age-matched wild-type control mice (n = 3) were sacrificed and the 
brains were harvested and processed for anti-NPC1 immunohistochemistry (Figure 
20). Analysis of stained brain sections via light microscopy revealed minimal and 
diffuse positive staining of endogenous NPC1 in the brains of uninjected control 
brains (Figure 20A-B). However, in comparison, the AAV9-hNPC1 administered 
brains exhibited strong staining in brain regions including the cerebral cortex, 
thalamus, substantia nigra, cerebellum and brain stem. As expected with low dose 
vector administration, transduction was not ubiquitous, yet distinct populations of 
cells showed clear NPC1 expression. Analysis at higher magnification revealed that 
NPC1 staining was limited to within the soma, specifically in the cytoplasm, of 
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transduced cells and was punctate in distribution, suggesting localisation to within 
late endosomes/lysosomes (Figure 20B). The robust nature of NPC1 staining also 
suggested the presence of supraphysiological levels of NPC1 (Millard et al., 2000) in 
cells following AAV9-hNPC1 administration, compared to the minimal staining of 
endogenous NPC1 observed in uninjected control mice. Cells exhibiting positive 
NPC1 staining appeared neuronal in morphology, within all examined brain regions. 
The brains of mice administered with AAV9-hNPC1 and age-matched uninjected 
controls were also homogenised and examined for NPC1 levels via Western blot 
(Figure 20C). Wild-type control mice exhibited low level staining of endogenous 
NPC1, however brains administered with AAV9-hNPC1 again demonstrated 
supraphysiological levels of NPC1. Critically AAV mediated expression of the 
NPC1 protein was of the expected ~170kDa size with a clear single band visible, 
suggesting NPC1 truncation had not occurred despite the oversized viral genome.  
 
These initial results confirmed that the produced AAV9-hNPC1 vector was 
functional in vivo and despite low dose administration, AAV9-hNPC1 was capable 
of NPC1 delivery and NPC1 expression in regions throughout the brain to 
supraphysiological levels. Following the observation of inefficient staining of 
endogenous murine NPC1, additional in vivo testing with the eGFP reporter 
equivalent AAV9-eGFP was also carried out. The aim of AAV9-eGFP 
administration analysis was to evaluate whether low-level NPC1 expression was 
being accurately identified with the utilised NPC1 antibodies and additionally gauge 
transgene expression following higher dose administration. 
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Figure 20: hNPC1 expression to supraphysiological levels in various brain 
regions following low dose AAV9-hNPC1 administration to neonatal wild-type 
mice. 
(A) hNPC1 expression detected by IHC within the brains of P30 wild-type mice, 
injected neonatally via ICV administration with a low dose of 4 x 109 GC of AAV-
hNPC1. Selected regions reflect areas significantly affected by NP-C pathology. Scale 
bar: 100µm.  
(B) Higher magnification images from selected regions. Scale bar: 60µm.  
(C) High magnification image of cell demonstrating punctate staining of 
overexpressed NPC1. Scale bar: 10µm 
(D) Western blot analysis of NPC1 levels in full brain lysates of wild-type uninjected 
and AAV9-hNPC1 administered wild-type mice. 170kDa band represents NPC1 
protein. 50kDa band represents the β-tubulin loading control. 
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3.12 Dose dependent increase of eGFP expression following 
AAV9-eGFP administration 
To compare the transduction profile of low dose AAV9-hNPC1 administration, a 
titre-matched low dose of 4 x 109 viral particles of AAV9-eGFP was administered 
via bilateral intracerebroventricular injection to P0/1 wild-type mice. An additional 
group of pups were injected with a higher dose of 5 x 1011 viral particles, to evaluate 
the spread of expression achievable at the currently highest possible doses for 
neonatal administration. Uninjected littermates were used as age-matched controls. 
After 30 days, low dose administered (n = 3), high dose administered (n = 3) and 
uninjected age matched wild-type control mice (n = 3) were sacrificed, brains were 
harvested and processed for anti-eGFP immunohistochemistry (Figure 21). Stained 
brain sections were analysed and imaged via light microscopy, which revealed 
extensive and widespread eGFP expression in identical areas of the brain, as 
previously observed following titer-matched AAV9-hNPC1 administration, for both 
low and high dose AAV9-eGFP administration (Figure 21A-B). Minimal 
background staining was observed in uninjected control sections. Brains 
administered with low dose AAV9-eGFP exhibited increased levels of eGFP positive 
staining, relative to the NPC1 positive staining observed following identical low dose 
AAV9-hNPC1 administration. The cortex and substantia nigra in particular showed 
more ubiquitous positive staining, following low dose AAV9-eGFP administration. 
This may be explained by higher efficiency of the anti-eGFP antibody, allowing the 
positive staining of lower eGFP levels. However the fact that eGFP expresses not 
just in the soma, but also throughout all cellular processes must be taken in to 
account. This was confirmed at higher magnification (Figure 21B), where clear 
axonal staining was observed in the cortex and cerebellum.  
 
As expected, brains administered with a higher dose of 5 x 1011 vp AAV9-eGFP 
exhibited increased levels of eGFP expression throughout the observed areas, 
compared to low dose administration. Again, eGFP expression in the cortex, 
thalamus and substantia nigra was extremely high. eGFP staining in these areas was 
so extensive that at higher magnification individual cells bodies and cell morphology 
could not be identified (Figure 21B). Additionally, a further increase in individual 
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eGFP positive cells was observed in the cerebellum and brain stem. As a result of the 
saturation of positive staining observed following AAV9-eGFP administration, 





Figure 21: Widespread eGFP expression following low and high dose AAV9-
eGFP administration to neonatal wild-type mice. 
(A) eGFP expression detected by IHC within the brains of P30 wild-type mice, 
injected neonatally via ICV administration with a low dose of 4 x 109 vp or a high 
dose of 5 x 1011 vp. Selected regions reflect areas significantly affected by NP-C 
pathology. Scale bar: 100µm.  
(B) Higher magnification images from selected regions. Scale bar: 60µm. 
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3.13 Neuronal tropism of AAV9-hNPC1 vector 
To investigate the tropism and confirm previous observations of neuronal cell 
transduction with the AAV9-hNPC1 vector, a series of immunofluorescence studies 
utilising cell lineage specific markers was carried out. Brain sections from P30 mice 
administered as neonates with low dose AAV9-hNPC1 and age-matched uninjected 
control mice were labelled with the nucleic acid marker DAPI and antibodies against 
the neuron-specific marker NeuN and NPC1 (Figure 22). Sections were examined 
by scanning confocal microscopy, which revealed minimal staining of endogenous 
murine NPC1 in uninjected control mice. However, brain sections from injected 
mice revealed supraphysiological levels of NPC1 within the cytoplasm of transduced 
cells, as shown in representative images taken from the S1BF region of the cerebral 
cortex. As previously observed, the staining appeared punctate and limited to the 
soma, suggesting late endosomal/lysosomal localisation of the overexpressed NPC1 
protein. NPC1 positive cells were crucially also found to be expressing neuron-
specific NeuN on the nuclear membrane, confirming successful neuronal 
transduction and NPC1 expression following AAV9-hNPC1 administration. 
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Figure 22: Neuronal overexpression of hNPC1 protein following AAV9-hNPC1 
administration. 
Representative confocal images showing immunofluorescence staining of the cortical 
S1BF region from P30 wild-type mice following neonatal AAV9-hNPC1 
administration (n = 3). AAV9-hNPC1 induced overexpression of hNPC1 (green) in 
cells positive for neuronal marker NeuN (red), confirming neuronal vector tropism. 
Nuclei were counterstained with DAPI (blue). Arrows signal neurones with clear 
perinuclear staining of hNPC1, indicating hNPC1 localisation within late 
endosomal/lysosomal vesicles. Scale bar: 20µm. 
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Expression of hNPC1 following AAV9-hNPC1 administration was expected to be 
limited to neurons, due to the use of the strong neuronal promoter hSynI. However, 
to conclusively evaluate potential NPC1 expression in glial cells, immunofluorescent 
labelling with the fibrillary astrocyte marker GFAP and pan-macrophage marker 
CD68 was carried out in combination with NPC1 staining (Figure 23). Analysis by 
confocal microscopy again revealed strong hNPC1 expression in the S1BF region, 
following AAV9-hNPC1 administration. However, no NPC1 positive cells were also 
found to be labelled with GFAP, confirming the lack of astrocyte tropism of the 
AAV9-hNPC1 vector (Figure 23A). Similarly, labelling of microglia with CD68 
could not detect overexpression of NPC1 in CD68 positive cells (Figure 23B). CD68 
positive cells were few in number and displayed a resting morphology in both 
uninjected controls and AAV9-hNPC1 administered mice. The absence of hNPC1 
overexpression in astrocytes and microglia confirmed the expected strong neuronal 
tropism of the AAV9-hNPC1 vector. Although ubiquitous expression of NPC1 in 
other non-neuronal cell populations within the CNS may be beneficial and explored 
in the future, the initial aim of strong neuronal transduction had been achieved. 
 
It was crucial to investigate whether the exogenously expressed hNPC1 protein was 
undergoing correct intracellular trafficking to within late endosomal/lysosomal 
compartments. Immunofluorescence studies were conducted using antibodies against 
the lysosomal specific protein LAMP1, which resides within the membrane of late 
endosomes/lysosomes (Howe et al., 1988, Viitala et al., 1988), and antibodies against 
the NPC1 protein. Confocal imaging revealed co-localisation of LAMP1 and NPC1 
within late endosomal/lysosomal vesicles in neurons within brains administered with 
AAV9-hNPC1 (Figure 24). LAMP1 staining in administered brain sections appeared 
similar to the staining observed in uninjected wild-type control sections. Although 
trafficking of AAV9-hNPC1 induced NPC1 specifically to the lysosomal membrane 
could not be confirmed at this resolution using conventional scanning confocal 











Figure 23: Glial cells do not exhibit overexpression of hNPC1 protein following 
AAV9-hNPC1 administration. 
Representative confocal images showing immunofluorescent staining of the cortical 
S1BF region from P30 wild-type mice following neonatal AAV9-hNPC1 
administration (n = 3).  
(A) Astrocytes identified via anti-GFAP (red) staining demonstrated lack of AAV9-
hNPC1 induced overexpression of hNPC1 (green). Nuclei were counterstained 
with DAPI (blue). Arrows signal astrocytes exhibiting endogenous levels of 
murine NPC1. Scale bar: 20µm.  
(B) Resting microglia demonstrated by positive CD68 staining (red) did not exhibit 
hNPC1 overexpression following AAV9-hNPC1 administration. Nuclei were 
counterstained with DAPI (blue). Arrows indicate resting microglia. Scale bar: 
20µm. 
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Figure 24: Lysosmal localisation of hNPC1 protein following AAV9-hNPC1 
administration. 
Representative confocal images showing immunofluorescent staining of the cortical 
S1BF region from P30 wild-type mice following neonatal AAV9-hNPC1 
administration (n = 3). Confirmation of hNPC1 (green) localisation to late 
endosomal/lysosomal vesicles, via co-localisation with lysosomal-associated 
membrane protein 1 (LAMP1, red), compared to uninjected wild-type control. Nuclei 
were counterstained with DAPI (blue). Arrows indicate cells with clear hNPC1 
overexpression co-localising with LAMP1. Scale bar: 20µm. 
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3.14 No toxicity associated to supraphysiological levels of 
NPC1 following AAV9-hNPC1 administration  
Brain sections of mice administered with low dose AAV9-hNPC1 were evaluated for 
potential cytotoxicity or inflammatory response, resulting from the administration of 
AAV9-hNPC1 or downstream NPC1 overexpression to supraphysiological levels. 
This was carried out by immunohistochemical analysis of sections stained with 
antibodies against the astrocytic marker glial flibrillary acid protein (GFAP) and the 
microglial marker CD68, to screen for astrogliosis and a microglia-mediated 
inflammatory response respectively (Figure 25). No change in resting astrocyte and 
microglial cell morphology, or increase in staining intensity was observed when 
compared to brain sections from uninjected control mice in any of the brain regions 
examined, such as within the cerebral cortex (Figure 25A). Brain sections from a 
mouse model of the neuronopathic Gaucher disease (Enquist et al., 2007), known to 
display an acute inflammatory response, was used as a positive control (Gba1-/-) for 
both markers.  
 
Thresholding analysis was carried out on a series of representative images from 3 of 
the most well transduced regions of the brain, to quantify GFAP and CD68 positive 
staining (Figure 25B-C). Sections from low dose AAV9-hNPC1 administered wild-
type mice (n = 3), age-matched uninjected wild-type control mice (n = 3) and 
positive control Gba1-/- mice (n = 3) were analysed. No statistically significant 
difference was measured between AAV9-hNPC1 administered mice and uninjected 
control mice for both GFAP (Figure 25B) and CD68 (Figure 25C) positive staining 
in all brain regions. As expected, the positive control sections from Gba1-/- mice 
showed a statistically significant increase in both GFAP and CD68 staining, when 
compared to brain sections from AAV9-hNPC1 administered and uninjected wild-
type mice (p < 0.0001). These results confirm that neither the administration of 
AAV9-hNPC1, or subsequent overexpression of hNPC1 to supraphysiological levels 
does not trigger an astrocyte- or microglia-mediated immune response. In conclusion 
the produced AAV9-hNPC1 viral vector was suitable for the use in preclinical 
therapeutic efficacy studies in the Npc1-/- mouse model.  




Figure 25: No astrocyte- or microglia-mediated immunge response, as a result of 
hNPC1 overexpression in wild-type mice. 
Analysis of brain sections subjected to anti-CD68 and -GFAP immunohistochemistry 
and resulting quantification of P30 wild-type mice administered neonatally with 
AAV9-hNPC1 (n=3), age-matched uninjected control mice (n=3) and positive control 
Gba1-/- mice (n=3).  
(A) Representative images from the somatosensory barrelfield cortex region of CD68 
and GFAP stained brain sections. Scale bars: 50µm.  
(B/C) Quantification of positive anti-GFAP (B) and anti-CD68 (C) immunoreactivity 
from regions with high levels of AAV9-hNPC1 induced hNPC1 overexpression. Data 
presented as mean ± S.D., compared by two-way ANOVA and Tukey’s HSD test. ns, 
non significant, *** p < 0.001, **** p < 0.0001. 
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3.15 Summary 
The results presented in this chapter aim to demonstrate why a recombinant adeno-
associated viral vector gene delivery system was chosen for the development of NP-
C gene therapy. rAAV vectors are currently considered the ideal method for 
widespread and efficient transduction of the CNS, as reflected by their frequent use 
in clinical trials for other lysosomal and neurodegenerative disorders, such as 
mucopolysaccharidosis type IIIA (Tardieu et al., 2014). The initial vector study 
carried out in this project further emphasised this point, where an AAV2/9 vector 
resulted in transgene expression throughout the brain following neonatal ICV 
administration, compared to the limited spread around the site of injected observed 
with lentiviral and adenoviral vectors. However, as a result of rAAV vector’s 
restricted packaging capacity, the integration of the relatively large hNPC1 cDNA 
into a functional and efficient construct was challenging. Several cloning steps were 
carried out to remove or replace essential transgene expression enhancer elements 
with shorter variants, to produce the final pAAV.hSynI.hNPC1.SV40pA construct. 
Although still oversized, this construct was shown to express hNPC1 in vitro and 
was used to successfully produce fully packaged AAV9-hNPC1 viral vector 
particles, albeit at a lower than expected titer. 
 
Preliminary in vivo testing demonstrated that low dose neonatal ICV administration 
of AAV9-hNPC1 resulted in NPC1 overexpression in wild-type mice to 
supraphysiological levels within brain regions associated with severe NP-C 
neurodegeneration. The vector exhibited a strong neuronal tropism and 
overexpressed hNPC1 successfully localised to within late endosomal/lysosomal 
compartments. Additionally, comparison studies with an eGFP variant showed the 
potential further spread and expression levels that could be achieved with a higher 
dose administration. Crucially, the administration of AAV9-hNPC1 and resulting 
overexpression of hNPC1 in murine brains to supraphysiological levels was proven 
to not cause toxicity, or an astrocyte- or microglia-mediated immune response. It was 
therefore decided to undertake a preclinical study with low dose AAV9-hNPC1 in 
the Npc1-/- mouse model, while simultaneously optimising vector production to 
increase viral titer to allow further studies with higher dose administration. 
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 Preclinical low dose  
AAV9-hNPC1 study in the 
Npc1-/- mouse model 
4.1 Introduction 
To evaluate the potential therapeutic efficacy of the AAV9-hNPC1 vector produced 
in the previous chapter, a preclinical study of neonatal low dose gene therapy was 
carried out in the Npc1-/- mouse model. As previously described, the Npc1-/- mouse 
model accurately mimics the behavioural, neuropathological and biochemical defects 
seen in human patients, including weight loss, tremor and ataxic gait symptoms. To 
gauge potential therapeutic efficacy of the tested therapy, a range of behavioural and 
locomotor studies were carried out on the animal cohorts, including monitoring of: 
survival, weight, rearing in an open field environment, tremor and gait. As the 
human and murine sequences of NPC1 cDNA and encoded NPC1 protein share a 
respective homology of 84% and 86% (Supplementary Figure S1 and 
Supplementary Figure S2), it was hypothesised that hNPC1 would retain its 
functionality in the Npc1-/- mouse model. All in vivo studies were carried out in 
collaboration with D. Smith, L. Morris, A. Colaçao and F. Platt (Department of 
Pharmacology, University of Oxford). The same low titer preparation of AAV9-
hNPC1 vector produced in the previous chapter was given via ICV administration 
into P0 Npc1-/- pups, at a total dose of 4.6 x 109 GC. Mice deemed to have reached 
their humane endpoint, by loosing 1g during a 24-hour period, were sacrificed for 
detailed neuropathology examination outlined in Chapter 5.  
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4.2 Chapter aims 
The aim of this chapter is to present the results of the first preclinical study with 
neonatal low dose AAV9-hNPC1 via ICV administration in the Npc1-/- mouse 
model. This chapter will focus on the therapeutic efficacy of low dose AAV9-hNPC1 
on survival, weight, behaviour, locomotor, neurodegenerative and coordination 
deficiencies associated with the Npc1-/- mouse model. Additionally for several of 
these parameters the therapeutic efficacy of low dose gene therapy is also compared 
to miglustat, the only currently licensed treatment for NP-C in Europe (Santos-
Lozano et al., 2015) and HP-β-CD, a promising therapy currently being evaluated in 
clinical trials (Liu et al., 2009). Summary of the animal cohorts and doses for this 
study can be found in Table 9. The aim of this comparison is to evaluate where this 
initial study of low dose gene therapy lies on the current NP-C treatment spectrum. 
 
Cohort N (Male/Female) Dose Administration 
Wild-type 6 (3/3) - - 
Npc1-/- 8 (4/4) - - 
Npc1-/- + AAV9-
hNPC1 
8 (4/4) Single dose of 4.6 x 109 GC 
at P0/1 
ICV 
Npc1-/- + miglustat 8 (4/4) 1,200mg/kg/day from P21 Oral 
Npc1-/- + HP-β-CD 11 (6/5) 4,000mg/kg/week from P21 IP 
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4.3 Extension of lifespan in Npc1-/- mice following low dose 
AAV9-hNPC1 treatment 
Wild-type, untreated Npc1-/-, gene therapy treated Npc1-/-, miglustat treated Npc1-/- 
and HP-β-CD treated Npc1-/- mice were monitored daily and any mice deemed to 
have reached their humane endpoint of 1g weight loss in a 24-hour period were 
sacrificed (Figure 26). Consistent with previous studies, untreated Npc1-/- mice had 
an average lifespan of 75 days, with 7 out of 8 mice sacrificed between 70-80 days. 
Npc1-/- mice treated daily from P21 with the glucosylceramide synthase inhibitor 
miglustat had an average lifespan of 108 days and consistent with previous reports 
lived significantly longer than untreated Npc1-/- mice (p < 0.0001). Npc1-/- mice 
treated with a single administration of low dose AAV9-hNPC1 had an average 
lifespan of 116.5 days and also lived significantly longer than untreated Npc1-/- mice 
(p < 0.0001). There was no significant difference between the average survival of 
Npc1-/- mice following treatment with miglustat or low dose gene therapy (p = 0.09). 
Npc1-/- mice treated weekly with HP-β-CD had an average lifespan of 168 days with 
a significant increase in survival compared to untreated Npc1-/- (p < 0.0001), 
miglustat treated Npc1-/- mice (p < 0.0001) and AAV9-hNPC1 treated Npc1-/- mice 
(p < 0.0001). Considerable variance was observed in the lifespan of these HP-β-CD 
treated Npc1-/- mice, with a range of 135 to 210 days. 
 
These initial results demonstrate that even low dose treatment of Npc1-/- mice with 
AAV9-hNPC1 results in a 55.3% increase in the lifespan of Npc1-/- mice. This 
duration of survival is comparable to Npc1-/- mice treated with the only current NP-C 
approved drug in Europe, miglustat. However, continual treatment with HP-β-CD 
resulted in a 124% increase in lifespan of Npc1-/- mice, significantly higher than a 
single low dose AAV9-hNPC1. 
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Figure 26: Efficacy of low dose gene therapy and competing therapies on the 
lifespan of Npc1-/- mice. 
Kaplan-Meier survival curve of wild-type (n=6), untreated Npc1-/- mice (n=8, 75 
days), Npc1-/- mice with daily oral administration of 1,200mg/kg of miglustat (n=8, 
108 days), Npc1-/- mice treated with weekly intraperitoneal administration of 
4,000mg/kg of HP-β-CD (n=11, 168 days) and Npc1-/- mice treated neonatally with a 
single ICV administration of 4 x 109 GC of AAV9-hNPC1 (n=8, 116.5 days). Logrank 
test (Mantel-Cox) comparing survival curves results in significant increases in the life 
span of the treated Npc1-/- mice compared to untreated Npc1-/- (p < 0.0001). 
4.4 Improved weight gain in Npc1-/- mice treated with low 
dose AAV9-hNPC1 
The weight of untreated and treated mice was tracked until 19 weeks of age, or until 
their humane endpoint had been reached (Figure 27). Untreated Npc1-/- mice 
demonstrated initial weight gain until 5 weeks of age, at which point their weights 
plateaued (Figure 27A). From 7 weeks of age, the time point at which NP-C 
symptoms become apparent in this model, a constant reduction in weight was 
observed until their humane endpoint had been reached. In agreement with previous 
reports, a significant reduction in body weight gain was observed in Npc1-/- mice 
treated with miglustat, which is known to cause osmotic diarrhoea and suppress 
appetite (Priestman et al., 2008). This significant loss of weight gain was present 
throughout the duration of their lifespan, compared to both untreated Npc1-/- mice 
and all other treatment cohorts, and as a result mice had a consistently lower average 
weight of approximately 8g ± 1.2g. HP-β-CD treated Npc1-/- mice exhibited weight 
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gain comparable to untreated Npc1-/- mice until 7 weeks of age, after which their 
weight was maintained and ultimately started to decline at week 13. However, 
compared to age-matched wild-type controls, significant differences in the weight of 
HP-β-CD treated Npc1-/- mice were observed at all monitored time points. In 
comparison, no significant difference in weight was observed in AAV9-hNPC1 
treated Npc1-/- mice compared to wild-type weights up until 12 weeks of age. The 
weight of gene therapy treated Npc1-/- mice subsequently decreased to within the HP-
β-CD treated weight range, with a comparable slow decline in weight until their 
humane endpoint had been reached.  
 
When the weights of the monitored cohorts were separated by gender, considerable 
differences between male (Figure 27B) and female (Figure 27C) cohorts was 
observed (Voikar et al., 2002). The weight gap between untreated Npc1-/- and age-
matched wild-type mice was reduced in male mice compared to female mice, with no 
significant difference between wild-type and untreated Npc1-/- male mice until 7 
weeks of age. In comparison, there was a significant difference in weight between 
untreated Npc1-/- and wild-type female mice throughout their life span. The 
difference between the weights of wild-type and Npc1-/- female mice treated with 
HP-β-CD and low dose AAV9-hNPC1 was also significantly reduced. As a result, no 
statistical difference was observed between wild-type and gene therapy treated Npc1-
/- female mice until 14 weeks of age. 
 
Low dose gene therapy treatment of Npc1-/- mice resulted in significantly improved 
initial weight gain and continued steady weight maintenance until approximately 15 
weeks of age, after which a steady weight decline was observed. While no significant 
difference in lifespan was observed between miglustat and AAV9-hNPC1 therapy, a 
substantial difference in weight between the two treatments was seen. Combined 
with the severe gastrointestinal side effects associated with the use of miglustat in 
patients, these results demonstrate a clear benefit of gene therapy treatment, even at 
this very low dose. 
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Figure 27: Improvement in weight loss in Npc1-/- mice following low dose AAV9-
hNPC1 treatment. 
Weekly weight monitoring of wild-type (n=6), untreated Npc1-/- mice (n=8), Npc1-/- 
mice with daily oral administration of 1,200mg/kg of miglustat (n=8), Npc1-/- mice 
treated with weekly intraperitoneal administration of 4,000mg/kg of HP-β-CD (n=11) 
and Npc1-/- mice treated neonatally with a single ICV administration of 4 x 109 GC of 
AAV9-hNPC1 (n=8). Male to female ratio of 1:1 in each monitored cohort. Data 
represented as weekly weight mean ± SEM. 
(A) Male and female combined weekly weight data. 
(B) Male weekly weight data. 
(C) Female weekly weight data. 
(D) Visual comparison of 10-week old untreated Npc1-/- mouse (left) and age-matched 
AAV9-hNPC1 treated Npc1-/- mouse (right). 
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4.5 Normalisation of neurological, locomotor and 
coordination symptoms in Npc1-/- mice following low 
dose AAV9-hNPC1 treatment 
To evaluate the therapeutic efficacy of low dose AAV9-hNPC1 treatment on basic 
locomotor and coordinative function, a series of repeated performance tests were 
carried out. One of the studies conducted was an open field test, where mice were 
placed in an open field environment and monitored for their ability to conduct 
rearing events, which requires a combination of coordination, hind-limb strength and 
natural exploratory behaviour. Up to 7 weeks of age, no statistically significant 
difference was observed in the number of average rearing events between wild-type, 
untreated Npc1-/- and AAV9-hNPC1 treated Npc1-/- mice (Figure 28). However, by 8 
weeks of age the untreated Npc1-/- mice showed a significant decrease in the number 
of average rearing events when compared to age-matched wild-type control mice (p 
= 0.004) and AAV9-hNPC1 treated Npc1-/- mice (p = 0.002). There was no 
significant difference between wild-type and Npc1-/- mice treated with AAV9-
hNPC1. This was also seen at 9 weeks of age, at which point the untreated Npc1-/- 
mice had reached their humane endpoint and were sacrificed. The complete 
normalisation in the number of rearing events was consistent throughout the lifespan 
of the Npc1-/- mice treated with AAV9-hNPC1, with no significant difference 
measured when compared to the age-matched control wild-type mice. 
 
4.5 Normalisation of neurological, locomotor and coordination symptoms in Npc1-/- mice 
following low dose AAV9-hNPC1 treatment 
145 
 
Figure 28: Permanent normalisation of rearing count in Npc1-/- mice following 
low dose AAV9-hNPC1 treatment. 
Sustained normalisation of locomotor and co-ordination symptoms of AAV9-hNPC1 
treated Npc1-/- mice in an open filed setting, where number of rearing events were 
monitored during a 5-minute period. Data represented as mean ± S.D., compared by 
two-way ANOVA followed by Tukey’s HSD test. * p < 0.05. W, weeks of age; GT, 
gene therapy treated Npc1-/-; UT, untreated Npc1-/-; n, sample size. 
Npc1-/- mice exhibit a noticeable tremor from 7 to 8 weeks of age (Lloyd-Evans et 
al., 2008, Smith et al., 2009), a trait often exhibited by NP-C patients. The efficacy of 
low dose gene therapy treatment on the tremor of Npc1-/- mice was evaluated against 
competing therapies using an automated tremor sensor, where mice were placed and 
monitored for a 256 second period. The resulting amplitude of tremors from 
frequencies 1 - 64hz were recorded in wild-type, untreated Npc1-/- and Npc1-/- mice 
treated with AAV9-hNPC1, miglustat or HP-β-CD (Figure 29). As measurements at 
frequencies below 30hz are affected by general mouse behaviour and grooming, only 
high frequency tremor data from 32 to 55hz was analysed. The mice cohorts were 
recorded at 9 (Figure 29A) and 16 weeks of age (Figure 29B), at which time points 
untreated Npc1-/- mice and low dose AAV9-hNPC1 treated Npc1-/- mice were 
reaching the end-stage of their average lifespan respectively. At 9 weeks, end-stage 
untreated Npc1-/- mice demonstrated the characteristic high frequency tremor 
compared to age-matched wild-type mice. However, Npc1-/- mice treated with 
miglustat, HP-β-CD or AAV9-hNPC1 all demonstrated no high frequency tremor, 
4.5 Normalisation of neurological, locomotor and coordination symptoms in Npc1-/- mice 
following low dose AAV9-hNPC1 treatment 
146 
comparable to age-matched wild-type mice. Comparison of high frequency mean 
amplitudes confirmed no significant difference of the treated cohorts with wild-type 
mice (Figure 29C). All Npc1-/- mice that received treatment had significantly lower 
mean amplitudes of tremor compared to untreated Npc1-/- mice (p < 0.0001). This 
normalisation in tremor was sustained at 16 weeks of age in Npc1-/- treated mice 
cohorts, with no significant difference to age-matched wild-type mice. 
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Figure 29: Permanent normalisation of high frequency tremor in Npc1-/- mice 
following low dose AAV9-hNPC1 treatment. 
High frequency tremor analysis comparing untreated Npc1-/-, AAV9-hNPC1 treated 
Npc1-/- and wild-type mice. Measurements were taken at 9 and 16 weeks of age: wild-
type (week 9 and 16, n = 7), untreated Npc1-/- (week 9, n= 3), Npc1-/- with 1,200mg/kg 
miglustat via oral administration (week 9, n = 7; week 16, n = 2); Npc1-/- with 
4,000mg/kg HP-β-CD via intraperitoneal administration (week 9, n = 3; week 16, n = 
11) and AAV9-hNPC1 treated Npc1-/- mice (week 9, n = 7; week 16, n = 5). 
(A) High frequency tremor data recorded at 9 weeks of age. Data represented as mean 
± SEM. 
(B) High frequency tremor data recorded at 16 weeks of age, compared to untreated 
Npc1-/- data from 9 weeks of age. Data represented as mean ± SEM. 
(C) Comparison of averaged high frequency amplitudes. Data represented as mean ± 
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Ataxia is a prevalent neurological symptom presented in NP-C patients and is 
recapitulated in Npc1-/- mice, which develop abnormal gait from 7 weeks of age 
(Maue et al., 2012). Automated gait analysis (Noldus CatWalk XT) was used 
qualitatively and quantitatively to assess gait in wild-type control mice, untreated 
Npc1-/- mice and AAV9-hNPC1 treated mice (Figure 30). In wild-type control mice 
hind paw prints were in close proximity to the front paw prints, with a typical 
alternate step sequence of right front, left hind, left front and right hind (Figure 
30A). 9-week old untreated end-stage Npc1-/- mice demonstrated clear irregular gait 
compared to age-matched wild-type and older end-stage Npc1-/- mice treated with 
low dose AAV9-hNPC1. No obvious differences were observed between 9-week old 
wild-type mice and 16-week old AAV9-hNPC1 treated Npc1-/- mice. To quantify 
this, the data from the CatWalk was analysed using the CatWalk XT 10.6 software. 
 
The quantified data from the three mice cohorts was subsequently compared at 9 and 
16 weeks of age (Figure 30B). At 9 weeks of age, significant AAV9-hNPC1 induced 
improvements were observed in treated Npc1-/- mice, compared to age-matched 
untreated Npc1-/- mice in a range of analysed parameters, including: stride length 
(distance between two consecutive paw placements of the same paw; p < 0.0001), 
swing speed (time between two consecutive paw placements; p = 0.02), regularity 
index (degree of interlimb coordination; p < 0.0001), step sequence (duration of time 
with a normal alternative step sequence; p < 0.0001), body speed (p < 0.0001), 
support single (duration of glass plate contact with single paw; p < 0.0001), support 
lateral (duration of glass plate contact with two side paws; p < 0.0001) and support 
girdle (duration of glass plate contact with two front or hind paws; p < 0.001). In 6 
out 8 of these parameters no statistically significant difference was observed between 
the low dose AAV9-hNPC1 treated Npc1-/- mice and age-matched wild-type mice. 
At 16 weeks of age normalisation of the gene therapy treated Npc1-/- mice to wild-
type levels was maintained in 5 out the 8 monitored parameters. When compared to 
9-week old end-stage untreated Npc1-/- data, 16-week old AAV9-hNPC1 treated 
Npc1-/- mice demonstrated significant improvements in all parameters. 
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Figure 30: Permanent normalisation or significant improvement in the gait of 
Npc1-/- mice following low dose AAV9-hNPC1 administration. 
(A) Graphical representation of paw prints captured during an average run using the 
Noldus CatWalk automated gait analyser. Runs represent 9-week old wild-type, 
9-week old end-stage Npc1-/- and 16-week old AAV9-hNPC1 treated Npc1-/- 
mice. Individual paws are identified via unique colours, with a normal alternating 
step seuqnece of: right front (RF, blue), left hind (LH, green), left front (LF, 
yellow) and right hind (RH, purple). 
(B) Automated gait analysis (Noldus CatWalk XT 10.6) quantification of 5 valid run 
average from wild-type (n=6), untreated Npc1-/- (n=3) and AAV9-hNPC1 treated 
Npc1-/- mice (week 9, n = 8; week 16 n = 4). Wild-type and AAV-hNPC1 treated 
Npc1-/- mice measurements were taken at 9 and 16 weeks of age and compared to 
9-week old end-stage Npc1-/- data. Data represented as mean ± S.D., compared by 
two ANOVA followed by Tukey’s HSD test. ns - non significant, * p < 0.05, ** p 
< 0.01,*** p < 0.001, **** p < 0.0001. 
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4.6 Summary 
The results in this chapter demonstrate that a single low dose of AAV9-hNPC1 
administered via intracerebroventricular injection into neonatal Npc1-/- mice resulted 
in a significant increase in lifespan and weight gain, and either permanent 
normalisation or significant improvement of locomotor and coordination systems. 
This initial preclinical study with low dose gene therapy treatment resulted in a 55% 
increase in the lifespan of Npc1-/- mice, which is equivalent to the survival extension 
exhibit by miglustat, currently the only European Medicines Agency approved 
treatment for Niemann-Pick Type C. However low dose administration of AAV9-
hNPC1 also resulted in significant improvements to the weights of Npc1-/- mice, 
compared to the extreme lack of weight gain observed in Npc1-/- mice treated with 
miglustat. The reduced weight of these mice is reflected by miglustat’s appetite 
suppressing effect (Priestman et al., 2008) and disturbances to the gastrointestinal 
tract that correlate with the gastrointestinal side effects seen in 80% of treated 
patients, which can in severe cases lead to miglustat discontinuation (Belmatoug et 
al., 2011) . The improvements observed to Npc1-/- body weight following low dose 
gene therapy treatment were comparable to HP-β-CD treatment, however weekly 
administration of HP-β-CD did result in a significant increase in lifespan, compared 
to low dose ICV AAV9-hNPC1 treatment. Npc1-/- mice developed neurological 
symptoms from 7 weeks of age, reflective of symptoms present in Niemann-Pick 
Type C patients. Low dose gene therapy treated mice presented normalisation of 
these symptoms to wild-type levels, as demonstrated by rearing, tremor and gait 
studies. Even at the point where the gene therapy treated Npc1-/- mice had reached 
their humane-endpoint, due to 1g of weight loss during a 24-hour period, the 
normalisation or improvement of these parameters was maintained. The combination 
of these results indicates improvements to both life expectancy and the quality of life 
of Npc1-/- mice in this initial study, following single low dose AAV9-hNPC1 
treatment. 
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 Analysis of neurodegeneration 
and neuropathology following low 
dose AAV9-hNPC1 treatment 
5.1 Introduction 
The data presented in the previous chapter summarised the therapeutic efficacy of 
low dose AAV9-hNPC1 treatment on lifespan, neurological symptoms and quality of 
life of Npc1-/- mice. Although there were significant improvements and in some cases 
even normalisation of certain disease manifestations, treated Npc1-/- mice still 
exhibited disease progression. As a result, the efficacy of this treatment on the 
underlying neurodegeneration and neuropathology needed to be evaluated. Previous 
examination of transgene expression following low dose AAV9-hNPC1 (Section 
3.11) and AAV9-eGFP (Section 3.12) administration resulted in transduction 
throughout crucial areas of the brain in terms of NP-C pathology, however large 
populations of neurons remained untransduced. Additionally, due to the rationale of 
using a strong neuronal promoter, glial cells would have remained untransduced 
(Section 3.13). Taking these two factors into account, neurodegeneration and 
neuroinflammation would continue to a certain extent, in these low dose gene 
therapy treated Npc1-/- mice. 
5.2 Chapter Aims 
The aim of this chapter is to further evaluate treatment efficacy by presenting the 
results of a series of neuropathology studies, which were carried out on the brains of 
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Npc1-/- mice treated with low dose AAV9-hNPC1. Due to the limited amount of 
vector and time available for this initial low dose study, all Npc1-/- mice administered 
with AAV9-hNPC1 were aged out until their respective humane end-points, to allow 
higher power statistical analysis of survival, weight and motor-function. As a result, 
the brains of these end-stage P120 AAV9-hNPC1 treated Npc1-/- mice were 
compared with the significantly younger end-stage P65 untreated Npc1-/- mice. While 
the addition of age-matched treated mice for comparison would be desirable and may 
show higher therapeutic efficacy at that time point, the following results demonstrate 
that even at their humane end-point the gene therapy treated Npc1-/- mice exhibited 
significant neurological improvements. The extent of neuronal loss, atrophy, 
astrogliosis, microglial activation and lysosomal staining are analysed and quantified 
throughout regions of the brain previously shown to be severely affected in the  
Npc1-/- brain (Pressey et al., 2012). The effect of low dose gene therapy treatment on 
biochemistry, specifically cholesterol and glycosphingolipid accumulation in the 
brain is also addressed. While this study has focused on the neurological implications 
of Niemann-Pick Type C disease, the visceral pathology remains important. To 
assess disease progression in the viscera, where hNPC1 expression following low 
dose AAV9-hNPC1 treatment via ICV injection is expected to be extremely limited, 
concentrations of glycosphingolipids in the liver are compared in treated, untreated 
and wild-type mice. 
5.3 Low dose AAV9-hNPC1 treatment ameliorates 
neurodegeneration in Npc1-/- mice 
To examine the ability of low dose gene therapy to prevent neurodegeneration in the 
Npc1-/- mice, brains from end-stage untreated Npc1-/- mice (P65), age-matched wild-
type control mice (P65) and end-stage Npc1-/- mice treated with AAV9-hNPC1 
(P120) were harvested, fixed and sectioned. Nissl staining is widely used to study the 
cytoarchitectonics of the brain, as well as the morphology and pathology of neurons. 
The dye ‘cresyl violet’ binds to DNA and RNA, each highly concentrated in the 
nuclei and ribosomes of the rough endoplasmic reticulum respectively (Scott and 
5.3 Low dose AAV9-hNPC1 treatment ameliorates neurodegeneration in Npc1-/- mice 153 
Willett, 1966). Although nucleic acids in all cells are stained, the relatively high 
concentration of ribosomes and rough endoplasmic reticulum in the cytoplasm of 
neurons (Knowles et al., 1996) allows the differentiation between neural and glial 
cell populations (Figure 10).  
 
In the first, instance Nissl staining of the sections allowed for an assessment of brain 
architecture and revealed improvement in the 120-day old end-stage Npc1-/- mice that 
had received low dose gene therapy, when compared to the untreated Npc1-/- mice 
that died significantly earlier at 65 days (Figure 31A). This was most obvious in the 
cerebral cortex, thalamus and substantia nigra, which showed significant pathology 
in the end-stage untreated Npc1-/- brain. The end-stage untreated Npc1-/- mice showed 
significant deterioration in brain tissue and cytoarchitecture at 65 days of age with 
loss of cellular density and degeneration. However in comparison, Npc1-/- gene 
therapy treated mice at 120 days of age demonstrated a significant improvement in 
both preservation of brain tissue and cytoarchitecture, comparable to the brain 
sections from wild-type mice. 
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Figure 31: Amelioration of neurodegeneration in AAV9-hNPC1 treated Npc1-/- 
mice. 
End-stage AAV9-hNPC1 treated Npc1-/- mice (P120, n = 3) were compared to end-
stage untreated Npc1-/- mice (P65, n = 3) and wild-type mice (P65, n = 3). Data 
represented as mean ± S.D., compared by two-way ANOVA followed by Tukey’s 
HSD test. ns – non significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 
0.0001. 
(A) Representative images of NP-C disease characterised brain regions from Nissl 
stained sections, illustrating deterioration of brain architecture in end-stage 
untreated Npc1-/- mice compared to end-stage AAV9-hNPC1 treated Npc1-/- and 
wild-type (WT) control mice. Scale bar: 100µm. 
(B) Optical fractionator estimates of neuron number from the somatosensory 
barrelfield cortex (S1BF), ventral posterior medial and lateral nuclei (VPM/VPL) 
and the substantia nigra pars reticulate (SNR) demonstrating amelioration of 
neuronal loss in end-stage AAV9-hNPC1 treated Npc1-/- mice compared to end-
stage untreated Npc1-/- mice. 
(C) Cortical atrophy in end-stage untreated Npc1-/- and end-stage AAV9-hNPC1 
treated Npc1-/- mice, measured via cortical thickness of the S1BF region. 
(D) Cavalieri estimates of VPM/VPL and SNR regional volumes. 
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To quantify the effect of low dose AAV9-hNPC1 treatment on neuronal loss in 
Npc1-/- mice, stereological counts of neurons from Nissl stained sections were carried 
out (Figure 31B). Brain regions analysed included the somatosensory barrelfield 
cortex (S1BF) region of the cortex, the ventral posterolateral and ventral 
posteromedial nuclei (VPM/VPL) regions of the thalamus and the substantia nigra 
pars reticulate. In all three regions, untreated end-stage Npc1-/- mice exhibited a 
significant decrease in the estimated number of neurones, compared to age-matched 
wild-type mice at approximately 65 days of age. However in comparison, there was a 
significant increase in the number of neurons in all quantified regions in end-stage 
AAV9-hNPC1 treated Npc1-/- mice at approximately 120 days of age. These 
improvements translated to a mean average increase of 30% in the S1BF, 73% in the 
thalamus and 79% in the substantia nigra, when compared to the untreated Npc1-/- 
mice that died at approximately 65 days of age. Although treated Npc1-/- mice 
showed amelioration in neurodegeneration, the neuronal counts were not completely 
normalised and remained significantly lower than the counts from wild-type control 
mice in all three regions examined. These results were not unexpected, as studies in 
previous chapters showed low dose administration did not result in complete 
transduction of cell populations in these regions. 
 
This was further reflected by the significant increase of brain region atrophy, 
observed in end-stage AAV9-hNPC1 treated Npc1-/- mice, despite amelioration of 
neurodegeneration. Measurements of cortical thickness in the S1BF region of the 
cortex revealed that end-stage Npc1-/- mice (P120) treated with AAV9-hNPC1 had 
significantly reduced cortical thickness, when compared to control wild-type mice 
(P65) (Figure 31C). Furthermore, there was no significant difference when 
compared to end-stage untreated Npc1-/- mice (P65). Using the Cavalieri sterological 
probe for regional volume measurements, end stage AAV9-hNPC1 treated Npc1-/- 
showed significant atrophy of the VPL/VPM region, when compared to wild-type 
control mice (Figure 31D). Again, no significant difference was observed when 
compared to end-stage untreated Npc1-/- mice. Volumetric measurements in the 
substantia nigra revealed sustained tissue volume in the Npc1-/- mice treated with 
AAV9-hNPC1, with no significant difference to control wild-type mice. End-stage 
untreated Npc1-/- mice had significant atrophy in this area compared to age-matched 
control wild-type mice. 
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Figure 32: Amelioration of Purkinje cells loss in the cerebellum of Npc1-/- mice 
following low dose AAV9-hNPC1 treatment. 
Cerebellar sections immunostained for Purkinje cell marker calbindin from wild-type 
(P65, n = 3), untreated end-stage Npc1-/- (P65, n = 3) and AAV9-hNPC1 treated end-
stage Npc1-/- mice (P120, n = 3). Data represented as mean ± S.D., compared by two-
way ANOVA followed by Tukey’s HSD test. ns - non significant; ** p < 0.01; *** p 
< 0.001; **** p < 0.0001. 
(A) Representative images of whole cerebellar sections stained for Purkinje cell 
marker calbindin. Scale bar: 1000µm. 
(B) Representative images from the II cerebellar lobule of sections stained for 
Purkinje cell marker calbindin. Scale bar: 40µm. 
(C) Quantification of immunoreactivity for calbindin positive staining revealing 
normalisation or amelioration of Purkinje cell loss within the VIII, IV/V and II 
cerebellar lobules of end-stage Npc1-/- mice treated with AAV9-hNPC1 compared 
to end-stage untreated Npc1-/- mice. 
 
The loss of Purkinje cells in the cerebellum is a hallmark characteristic of 
neurodegeneration in patients with Niemann-Pick Type C (Vanier, 2010) and is also 
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observed from 7 weeks of age in Npc1-/- mice (Sarna et al., 2003). However, the 
analysis of Purkinje cells via Nissl staining is challenging, due to their relatively low 
levels of staining compared to the compact and numerous granule cells (Whitney et 
al., 2008). Evaluation of Purkinje cell loss was therefore carried out via 
immunostaining using the Purkinje cell-specific marker calbindin-D28k (Bastianelli, 
2003). A light microscopy examination of brain sections from 9-week old end-stage 
untreated Npc1-/- mice showed a substantial loss of positive calbindin staining in the 
cerebellum, representing Purkinje cell degeneration, compared to age-matched 
control wild-type mice (Figure 32A-B). However, calbindin positive Purkinje cells 
were clearly visible in higher numbers in cerebellar sections from 17-week old  
Npc1-/- mice treated with low dose AAV9-hNPC1, when compared to 9-week-old 
untreated Npc1-/- mice.  
 
To quantify this observation, image thresholding analysis was conducted in discrete 
regions of the cerebellar sections from wild-type, untreated Npc1-/- and gene therapy 
treated Npc1-/- mice (Figure 32C). Measurements of percentage immunoreactivity 
per unit area within the VIII, IV/V and II cerebellar lobules showed a significant loss 
of calbindin positive Purkinje cells in sections from 9-week old end-stage untreated 
Npc1-/- mice, compared to age-matched control wild-type mice (p < 0.0001). 
However, measurements taken from the VIII (p < 0.0001), II (p = 0.0011) and IV/V 
(p = 0.0005) regions of 17-week old end-stage AAV9-hNPC1 treated Npc1-/- mice 
showed a significantly higher rate of calbindin positive Purkinje cell staining, when 
compared to 9-week old end-stage untreated Npc1-/- mice. Furthermore, there was no 
significant difference in measurements taken in the VIII and IV/V lobules between 
control wild-type and end-stage treated Npc1-/- mice, suggesting extensive survival of 
Purkinje cells in response to low dose gene therapy.  
 
The combination of stereological and immunohistochemical analysis of brain 
sections from the low dose AAV9-hNPC1 treated Npc1-/- mice revealed significant 
amelioration of neurodegenration or complete neuroprotection in brain regions most 
severely affected by NP-C, even when the treated mice had reached their humane 
endpoint. Importantly, while neuron numbers were not rescued to wild-type levels in 
certain brain regions, these improvements can be correlated to the normalisation of 
neurological symptoms presented in the previous chapter. 
5.4 Limited amelioration of inflammatory response in  
Npc1-/- mice following low dose AAV9-hNPC1 administration 
158 
5.4 Limited amelioration of inflammatory response in  
Npc1-/- mice following low dose AAV9-hNPC1 
administration 
We next investigated whether low dose AAV-mediated gene therapy could 
ameliorate the microglia-mediated inflammatory response and astrogliosis previously 
observed in the Npc1-/- mouse model (Pressey et al., 2012). Immunohistochemistry 
with antibodies against CD68 (Figure 33) to label microglia and GFAP (Figure 34) 
to label fibrillary astrocytes were used to assess levels of neuroinflammation in wild-
type (P65, n = 3), untreated end-stage Npc1-/- (P65, n = 3) and AAV9-hNPC1 treated 
end-stage Npc1-/- mice (P120, n = 3). Analysis of brain sections from these groups 
revealed extensive microglial activation in untreated end-stage Npc1-/- mice, which 
exhibited widespread CD68 positive staining of activated and engorged microglia 
throughout all regions of the brain examined, compared to low level resting 
microglial staining in age-matched wild-type mice (Figure 33A). 120-day old 
AAV9-hNPC1 treated Npc1-/- mice displayed microglial activation comparable to 
65-day old end-stage untreated Npc1-/- mice. However, quantification of CD68 
positive immunoreactivity in brain regions known to be acutely affected in the  
Npc1-/- mouse revealed significantly reduced levels of immunoreactivity in the 
substantia nigra (SNR, p = 0.0005) and II lobule of the cerebellum (p = 0.003), 
following low dose AAV9-hNPC1 treatment (Figure 33B).  Other analysed areas 
exhibited no significant differences in levels of microglial activation in the older end-
stage AAV-hNPC1 treated Npc1-/- mice (P120) compared to the younger end-stage 
untreated Npc1-/- mice (P65), with the exception of the brain stem (Gi) and cortex 
(S1BF) where an increase in CD68 positive staining was measured. 
 
5.4 Limited amelioration of inflammatory response in  




Figure 33: Limited amelioration of microglial activation in end-stage Npc1-/- mice 
following low dose AAV9-hNPC1 treatment. 
Quantification of microglial marker CD68 in end-stage AAV9-hNPC1 treated Npc1-/- 
mice (P120, n = 3) compared to end-stage untreated Npc1-/- (P65, n = 3) and wild-type 
control mice (P65, n = 3). 
(A) Representative images from NP-C disease characterised brain regions of wild-
type, untreated Npc1-/- and AAV9-hNPC1 treated Npc1-/- sections, stained for 
microglial marker CD68. Scale bars: 100µm. Insets show positively stained 
individual cells at higher magnification. 
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(B) Quantification of microglial activation via immunoreactivity quantification of 
CD68 positive staining. Data represented as mean ± S.D., compared by two-way 
ANOVA followed by Tukey’s HSD test. ns – non significant, * p < 0.05; ** p < 
0.01; *** p < 0.001; **** p < 0.0001. S1BF – somatosensory barrelfield cortex; 
VPM/VPL – ventral posterior medial and lateral nuclei of the thalamus; SNR – 
substantia nigra pars reticulate; II – II lobule of the cerebellum; IV/V – IV/V 
lobules of the cerebellum; Gi – gigantocellular reticular nucleus.  
The efficacy of low dose AAV9-hNPC1 on the extent of astrogliosis in Npc1-/- mice 
was evaluated via immunostaining of the glial fibrillary acid protein. Analysis of 
brain sections from 9-week old end-stage untreated Npc1-/- mice stained for GFAP 
revealed widespread astrogliosis throughout all examined areas (Figure 34A). 17-
week old end-stage AAV9-hNPC1 treated Npc1-/- mice exhibited a similar GFAP 
staining profile, apart from the cerebellum where astrogliosis appeared to be reduced 
compared to untreated Npc1-/- mice. Quantification of GFAP positive 
immunoreactivity supported this finding, with significantly lower levels of GFAP 
positive staining reported in the II (p = 0.0007) and IV/V lobules (p < 0.0001) of the 
cerebellum (Figure 34B). No differences were observed within the thalamus 
(VPM/VPL) and substantia nigra (SNR), however the somatosensory cortex (S1BF, 
p = 0.002) and brain stem (Gi, p = 0.01) exhibited higher levels of GFAP positive 
staining compared to 9-week old untreated Npc1-/- mice. 
 
The significant reduction in both CD68 and GFAP positive staining within areas of 
the cerebellum from end-stage AAV9-hNPC1 treated Npc1-/- mice support the 
previously suggested survival of Purkinje cells and normalisation of neurological 
symptoms, as a result of low dose AAV9-hNPC1 treatment. In other brain regions of 
gene therapy treated Npc1-/- mice, microglial activation and astrogliosis were either 
identical or higher, compared to untreated Npc1-/- mice. However as previously 
mentioned, the gene therapy treated Npc1-/- mice were analysed and compared at a 
significantly older time point and were also at their humane endpoint. 
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Figure 34: Limited amelioration of astrogliosis in end-stage Npc1-/- treated with 
low dose AAV9-hNPC1. 
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Quantification of astroglial marker GFAP in end-stage AAV9-hNPC1 treated Npc1-/- 
mice (P120, n = 3) compared to end-stage untreated Npc1-/- (P65, n = 3) and wild-type 
control mice (P65, n = 3). 
(A) Representative images from NP-C disease characterised brain regions of wild-
type, untreated Npc1-/- and AAV9-hNPC1 treated Npc1-/- sections, stained for 
astroglial marker GFAP. Scale bars: 100µm. Insets show positively stained 
individual cells at higher magnification. 
(B) Quantification of astrogliosis via immunoreactivity quantification of GFAP 
positive staining. Data represented as mean ± S.D., compared by two-way 
ANOVA followed by Tukey’s HSD test. ns – non significant, * p < 0.05; ** p < 
0.01; *** p < 0.001; **** p < 0.0001. S1BF – somatosensory barrelfield cortex; 
VPM/VPL – ventral posterior medial and lateral nuclei of the thalamus; SNR – 
substantia nigra pars reticulate; II – II lobule of the cerebellum; IV/V – IV/V 
lobules of the cerebellum; Gi – gigantocellular reticular nucleus. 
5.5 Gene therapy ameliorates increase of lysosomal staining 
in Npc1-/- mice 
To test the corrective effect of gene therapy on the late endosomal/lysosomal 
compartment, immunohistochemistry using an antibody against the lysosomal-
associated membrane glycoprotein 1 (LAMP1) was carried out (Figure 35).  LAMP1 
was used as a marker for the expanded lysosomal compartment resulting from lipid 
storage, previously observed in Npc1-/- mice (Demais et al., 2016). Sections from 9-
week old end-stage untreated Npc1-/- brains (n = 3) were compared to age-matched 
wild-type (n = 3) and 17-week old end-stage AAV9-hNPC1 treated Npc1-/- brains (n 
= 3). A distinctive low level punctate staining was observed in wild-type mice, 
compared to untreated Npc1-/- mice, where cells displayed a significantly increased 
LAMP1 positive staining (Figure 35A). Cells with a LAMP1 staining profile similar 
to untreated Npc1-/- mice were also observed in 17-week old end-stage  
AAV9-hNPC1 treated Npc1-/- mice. However, quantification of LAMP1 
immunoreactivity showed a significant reduction of average LAMP1 positive 
staining, to within wild-type levels in the somatosensory cortex (S1BF, p < 0.0001) 
and II lobule of the cerebellum (II, p = 0.05) in low dose gene therapy treated Npc1-/- 
mice (Figure 35B). Other highly affected disease brain regions of the longer 
surviving gene therapy treated Npc1-/- mice exhibited average LAMP1 reactivity 
comparable to 9-week old end-stage untreated Npc1-/- mice. 
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Figure 35: Regional reduction of increased LAMP1 staining in end-stage Npc1-/- 
mice following low dose AAV9-hNPC1 treatment. 
Quantification of LAMP1 lysosomal marker in end-stage AAV9-hNPC1 treated mice 
(P120, n=3) compared to end-stage untreated Npc1-/- (P65, n=3) and WT mice (P65, 
n=3). Data represented as mean ± S.D., compared by two-way ANOVA followed by 
Tukey’s HSD test. ns, non significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p 
< 0.0001.  
(A) Representative images from brain areas severely affected by NP-C 
neuropathology of brain sections stained for lysosomal marker LAMP1. Scale 
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bars: 100µm. Insets show positively stained individual cells at higher 
magnification. 
(B) Quantification of LAMP1 positive immunoreactivity in LAMP1 stained brain 
sections. Data represented as mean ± S.D., compared by two-way ANOVA 
followed by Tukey’s HSD test. ns – non significant, * p < 0.05; ** p < 0.01; *** p 
< 0.001; **** p < 0.0001. S1BF – somatosensory barrelfield cortex; VPM/VPL – 
ventral posterior medial and lateral nuclei of the thalamus; SNR – substantia nigra 
pars reticulate; II – II lobule of the cerebellum; IV/V – IV/V lobules of the 
cerebellum; Gi – gigantocellular reticular nucleus. 
5.6 Low dose gene therapy results in redistribution of lipids 
in Npc1-/- mice 
The Npc1-/- mouse model recapitulates many of the prominent features of human 
Niemann-Pick Type C disease, including progressive neurodegeneration, 
neuroinflammation and resulting neurological symptoms. Npc1-/- mice also exhibit 
the severe accumulation of a range of lipids within late endosomal/lysosomal 
compartments (Walkley and Suzuki, 2004), as observed in NP-C patients (Vanier, 
1983, Vanier, 1999). One of these lipid species is the abnormal accumulation of 
unesterified cholesterol within late endosomal/lysosomal compartments. The filipin 
test remains a standard tool for NP-C disease diagnosis in patients (Vanier et al., 
2016), where the fluorescent filipin stain is used to localise and quantitate 
unesterified cholesterol (Kruth et al., 1986). 
 
To evaluate the effect of low dose gene therapy on unesterified cholesterol 
distribution and accumulation, filipin staining was performed on 120-day old end-
stage AAV9-hNPC1 treated Npc1-/- brain sections, which were subsequently 
compared to 65-day old end-stage untreated Npc1-/- and wild-type brain sections 
(Figure 36). As expected, untreated Npc1-/- mice exhibited high levels of filipin 
staining, with widespread accumulation clearly visible in individual cells within the 
cortex and thalamus, with many exhibiting clear neuronal morphology (white 
arrows). Positive filipin staining in age-matched wild-type control mice was either 
weak or absent. End-stage AAV9-hNPC1 treated Npc1-/- mice exhibited positive 
filipin staining within the cortex and thalamus, however compared to end-stage 
untreated Npc1-/- mice the staining was less extensive and appeared more diffuse. In 
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the thalamus in particular, the number of clear filipin positive cells was decreased in 
Npc1-/- mice treated with AAV9-hNPC1, compared to untreated Npc1-/- mice. A 
decrease in well-defined filipin positive cells was also observed, potentially 
indicating a deceleration or alteration in the distribution of lipid accumulation in 
neuronal cell populations.  
 
 
Figure 36: Redistribution of positive unesterified cholesterol filipin staining in 
the cortex and thalamus of Npc1-/- mice following low dose AAV9-hNPC1 
treatment. 
Representative images demonstrating the redistribution of unesterified cholesterol 
accumulation, via filipin staining, in the somatosensory barrelfield cortex and ventral 
posterior medial and lateral nuclei of the thalamus of AAV9-hNPC1 treated Npc1-/- 
mice (P120), compared to untreated end-stage Npc1-/- (P65) and wild-type mice (P65). 
Arrows and inset images indicate filipin staining in cells with a neuronal morphology. 
Scale bar: 100µm. 
The extent of individual lipid species accumulation differs in individual organs of 
Npc1-/- mice and NP-C patients (Fan et al., 2013). Although unesterified cholesterol 
accumulation is observed in the brain, the predominant species to accumulate are 
sphingolipids, including sphingosine and gangliosides, such as GM2 and GM3. In 
comparison the liver predominantly accumulates cholesterol, GM2 and to a lesser 
extent GM3 gangliosides. To evaluate the effect of low dose gene therapy on the 
accumulation of glycosphingolipids (GSL) in Npc1-/- mice, glycosphingolipids 
quantification was performed on whole brain and liver tissue lysates in collaboration 
with M. Huebecker (Department of Pharmacology, University of Oxford) (Figure 
37). GSL concentrations in the brains from end-stage AAV9-hNPC1 treated Npc1-/- 
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mice (P120, n = 8) were compared to end-stage untreated Npc1-/- (P65, n = 3) and 
wild-type control mice (P65, n = 6) (Figure 37A). Untreated Npc1-/- mice brains 
exhibited significantly higher concentrations of total glycosphingolipids tested, 
compared to normal wild-type levels (p < 0.0001, 2 - fold increase in mean average). 
Consistent with previous reports GM2 and GM3 gangliosides concentrations were 
observed at high levels in untreated Npc1-/- brains (Fan et al., 2013). Other notable 
increases in GSL species included the glycolipid lactosylceramide and gangliosides 
GA2, GA1 and GM1a. Brains from the significantly older end-stage Npc1-/- mice 
treated with low dose AAV9-hNPC1 (P120) demonstrated comparable levels of total 
GSL concentration as the younger end-stage untreated Npc1-/- brains (P65). 
However, a significant decrease in GM2 (p = 0.0001), a key ganglioside accumulated 
in the brain in NP-C disease, was observed in end-stage gene therapy treated mice 
(Gondre-Lewis et al., 2003).  
 
 
Figure 37: Glycosphingolipid quantification of brain and liver tissue lysates from 
Npc1-/- mice following low dose AAV9-hNPC1 treatment. 
Quantification of total and individual GSL species extracted from brains (A) and 
livers (B) of wild-type (P65, n = 6), end-stage untreated Npc1-/- (P65, n = 3) and end-
stage AAV9-hNPC1 treated Npc1-/- mice (P120, n = 8). Data represented as mean ± 
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S.D., compared by two-way ANOVA followed by Tukey’s HSD test. ns - non 
significant; *** p < 0.001; **** p < 0.0001. GSL – glycosphingolipid; LacCer – 
lactosylceramide; GA2 – gangliotriglycosylceramide; Gb3 – globotriaosylceramide; 
GM3 – II3-a-N-acetylneuraminyllactosylceramide; GM2 - II3a-N-acetylneuraminyl-
gangliotriglycosylceramide; GA1 – gangliotetraglycosylceramide; GM1a - II3a-N-
acetylneuraminylgangliotetraglycosylceramide; GD3 - II3-a-N-acetylneuraminyla-2,8-
N-acetylneuraminyllactosylceramide; GD1a - II3, IV3-a,a-Di-N-acetylneuraminyl-
gangliotetraglycosylceramide; GD1b - II3-a-N-acetylneuraminyla-2,8-N-
acetylneuraminylgangliotetraglycosylceramide; GT1b - II3-a-N-acetylneuraminyla-
2,8-N-acetylneuraminyl-IV3-a-N-acetylneuraminylgangliotetraglycosylceramide; 
GQ1b - II3-a-N-acetylneuraminyla-2,8-N-acetylneuraminyl-IV3-a-N-acetylneuraminyla 
-2,8-N-acetylneuraminylgangliotetraglycosylceramide; GM3Gc - II3-a-N-
glycolylneuraminyllactosylceramide; GM2Gc - II3-a-N-glycolylneuraminyl-
gangliotriglycosylceramide; GM1aGc - II3-a-N-glycolylneuraminyl-
gangliotetraglycosylceramide; GD1alpha - II3,IV3-a,a-Di-N-acetylneuraminyl-
gangliotetraglycosylceramide. 
Although this study and low dose administration was targeted to the brain, it was 
important to also analyse potential ongoing visceral pathology. As a result, liver 
glycosphingolipid concentrations from the different animal cohorts were measured 
(Figure 37B). 9-week old end-stage untreated Npc1-/- mice again exhibited 
significantly increased total GSL levels, compared to age-matched wild-type control 
mice (p < 0.0001). Similarly, gene therapy treated Npc1-/- also exhibited significantly 
higher levels of total liver GSL compared to wild-type control (p < 0.0001). 
However, unlike in the brain, total liver GSL levels were significantly higher in these 
end-stage gene therapy treated mice, with a 1.9 - fold increase compared to the 
younger end-stage untreated Npc1-/- mice (p = 0.0002). Analysis of individual GSL 
species revealed an increase in all individual GSL levels, however the accumulation 
of GM2Gc and GM3Gc gangliosides in particular were higher in the Npc1-/- mice 
with ICV AAV9-hNPC1 treatment. These liver GSL results suggest that untreated 
organs continue to accumulate lipids, past the levels observed in untreated Npc1-/- 
mice, for a significantly longer period of time, due to the extension in lifespan that 
brain-directed gene therapy offers. In comparison the GSL levels in the brains of 
end-stage ICV treated Npc1-/- mice were similar to end-stage untreated Npc1-/- 
despite their significantly longer lifespan. 
5.7 Summary 
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This chapter details the results of a series of neuropathology and biochemical studies 
evaluating the effect of low dose AAV9-hNPC1 gene therapy on Npc1-/- mice. 
Significant reductions in the amount of neuronal loss were observed throughout all 
analysed areas of the brain, including complete neuroprotection of the Purkinje cells 
in certain areas of the cerebellum to normal levels. While the number of neurons 
were not completely normalised in all areas (Section 5.3), this partial amelioration 
did lead to the normalisation or improvement of neurological symptoms and quality 
of Npc1-/- mice life (Chapter 4). Despite the amelioration of neuronal loss in all 
areas of the brain, the atrophy of these regions remained untreated in gene therapy 
treated Npc1-/- mice. Analysis of neuroinflammatory and lysosomal markers also 
revealed regional amelioration of microglial activation, astrogliosis and quantity of 
lysosomal staining, particularly in the cerebellum of Npc1-/- mice treated with low 
dose AAV9-hNPC1. In the remaining areas no difference was observed between 
treated and untreated Npc1-/- mice. The results of biochemical analysis of 
unesterified cholesterol and glycosphingolipid accumulation followed a similar trend 
of partial amelioration. Although positive unesterified cholesterol accumulation was 
observed in the brains of gene therapy treated Npc1-/- mice, the staining appeared 
more diffuse and cells with clear neuronal morphology were limited or absent. The 
effect of low dose AAV9-hNPC1 treatment on brain lipid accumulation was further 
demonstrated by GSL quantification, where a significant reduction in gangliosde 
GM2 was observed in the brain of gene therapy treated Npc1-/- mice. Total brain 
GSL levels of the older P120 AAV9-hNPC1 treated Npc1-/- mice were also 
comparable to the levels observed in the P65 untreated Npc1-/- mice, despite the large 
increase in lifespan, suggesting a deceleration of GSL accumulation. In comparison 
the liver of gene therapy treated Npc1-/- mice, which should remain untransduced 
following low dose ICV AAV9-hNPC1 administration, exhibited a 1.9 - fold 
increase in total GSL levels relative to untreated Npc1-/- mice. The addition of age-
matched comparison of AAV9-hNPC1 treated and untreated Npc1-/-, may further 
clarify the effect of low dose ICV gene therapy and will be carried out in the future. 
 
The next step in this study was to conduct a second preclinical study in the Npc1-/- 
mouse model, where an increase in AAV9-hNPC1 dose was evaluated for increased 
therapeutic efficacy. 
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 Ongoing high dose AAV9-
hNPC1 study 
6.1 High dose AAV9-hNPC1 survival study 
The preclinical low dose study covered in the previous two chapters, confirmed the 
safety and demonstrated promising therapeutic efficacy of neonatal ICV AAV9-
hNPC1 administration in the Npc1-/- mouse model. Very low dose treatment resulted 
in a 55% increase in the lifespan of treated Npc1-/- mice, with the correction of 
multiple locomotor function indices, however only partial amelioration of 
neurodegeneration, neuroinflammation and lipid storage was observed. The partial 
transduction of brain areas resulting from low dose AAV9-hNPC1 administration 
was hypothesised as being the primary possible cause for incomplete neuronal rescue 
and continued activation of neuroinflammatory cells. The dose evaluation study 
carried out previously with low dose AAV9-eGFP (4.6 x 109 vp) clearly 
demonstrated transduction of cell populations in brain regions critical to NP-C 
pathology, however transduction was not ubiquitous (Figure 21). In comparison, 
high dose AAV9-eGFP (5 x 1011 vp) administration resulted in a visible increase in 
the spread of transduction throughout the same regions, albeit ubiquitous neuronal 
transduction was still not observed. To follow on from the initial preclinical low dose 
study presented in the previous chapters, a second study was carried out in the Npc1-
/- mouse model, where the dose was increased by 54-fold, from 4.6 x 109 GC to 2.5 x 
1011 GC. High titer AAV9-hNPC1 was sourced from Vector BioLabs (Malvern, 
Pennsylvania) at a titer of 2.5 x 1013 GC/ml. This increased dose reflects those used 
in other preclinical gene therapy studies utilising ICV administration, such as the 
injection of AAV2/1 into neonatal GM1-gangliosidosis mice (Broekman et al., 
2007). The primary aim of this high dose proof of concept study was to evaluate any 
toxicity and the potential enhancing therapeutic effect in Npc1-/- mice, compared to 
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low dose AAV9-hNPC1, miglustat and HP-β-CD treatment. In total, 7 Npc1-/- mice 
were treated P0/1 with 2.5 x 1011 GC of AAV9-hNPC1 via bilateral ICV 
administration, which were subsequently monitored and compared to the animal 
cohorts from the low dose study (Table 10). Identical to the previous preclinical 
study, any mouse exhibiting a 1g-weight loss within a 24-hour period was deemed to 
have reached their humane endpoint and was sacrificed. 
 










Single dose of 2.5 x 1011 GC 
at P0/1 
ICV 
Wild-type 6 (3/3) - - 




Single dose of 4.6 x 109 GC 
at P0/1 
ICV 
Npc1-/- + miglustat 8 (4/4) 1,200mg/kg/day from P21 Oral 
Npc1-/- + HP-β-CD 11 (6/5) 4,000mg/kg/week from P21 IP 
Table 10: List of animal cohorts compared throughout this study. 
High dose (HD) AAV9-hNPC1 treated Npc1-/- mice compared to cohorts from low 
dose preclinical study (Table 9), including untreated, low dose (LD) AAV9-hNPC1, 
miglustat and HP-β-CD treated Npc1-/- mice and wild-type mice. 
6.2 No toxicity associated with high dose AAV9-hNPC1 
administration 
Although no vector related toxicity was observed following low dose administration, 
potential toxicity associated with a further increase in both vector dose and 
downstream hNPC1 overexpression was evaluated. Wild-type mice administered 
P0/1 ICV with 2.5 x 1011 GC of AAV9-hNPC1 (n=3) were sacrificed at 30 days of 
age for evaluation of neuroinflammatory markers, with comparison of age-matched 
negative control uninjected wild-type mice (n=3) and P11 positive control Gba1-/- 
mice, which have previously been shown to demonstrate an acute form 
6.2 No toxicity associated with high dose AAV9-hNPC1 administration 171 
ofneuroinflammation (Enquist et al., 2007). Following the observations of 
particularly extensive eGFP expression in the cortex of AAV9-eGFP injected wild-
type mice (Figure 21), the toxicity analysis was focused on the S1BF region of the 
somatosensory cortex. Evaluation of brain sections was carried out by 
immunohistochemical analysis with antibodies against the astrocytic marker glial 
fibrillary acid protein (GFAP) and the microglial marker CD68, to screen for 
astrogliosis and microglial activation respectively (Figure 38). 
 
 
Figure 38: No neurological toxicity resulting from high dose AAV9-hNPC1 
administration 
Analysis of brain sections subjected to anti-CD68 and anti-GFAP 
immunohistochemistry and resulting quantification of P30 wild-type mice 
administered neonatally with 2.5 x 1011 GC of AAV9-hNPC1 (n=3), age-matched 
uninjected control mice (n=3) and positive control Gba1-/- mice (n=3).  
(A) Representative images from the somatosensory barrelfield cortex region of CD68 
and GFAP stained sections. Scale bars: 50µm.  
(B/C) Quantification of positive anti-GFAP (B) and anti-CD68 (C) immunoreactivity 
from regions with high levels of AAV9-hNPC1 induced hNPC1 overexpression. Data 
presented as mean ± S.D., compared by two-way ANOVA and Tukey’s HSD test. ns, 
non significant, **** p < 0.0001. 
As with low dose AAV9-hNPC1 administration, no change in resting astrocyte and 
microglial cell morphology was observed in brains administered with high dose 
AAV9-hNPC1 compared to brain sections from uninjected control mice, while 
severe astrogliosis and microglial activation was observed in Gba1-/- brain sections 
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(Figure 38A). Thresholding analysis of GFAP (Figure 38B) and CD68 (Figure 
38C) immunoreactivity in the cortical S1BF region demonstrated no statistical 
significance between uninjected control mice and high dose AAV9-hNPC1 
administered mice. In comparison to these groups, a significant increase in both 
GFAP (p < 0.0001) and CD68 (p < 0.0001) staining was measured in Gba1-/- brain 
sections. These results further confirmed that no neurotoxicity resulted from 
extensive and widespread overexpression of NPC1 to supraphysiological levels in 
the brain of AAV9-hNPC1 administered mice.  
6.3 Enhanced survival and weight of Npc1-/- mice following 
high dose AAV9-hNPC1 treatment 
Npc1-/- mice administered ICV with a single dose of 2.5 x 1011 GC AAV9-hNPC1 
(n=7) exhibited no obvious indications of severe adverse affects in the weeks 
following vector administration procedure. At the time of thesis submission, 3 of the 
7 Npc1-/- mice treated with high dose AAV9-hNPC1 were sacrificed as they had 
reached their humane endpoint, with an average survival of 151 days. However at the 
point of thesis submission, the remaining 4 Npc1-/- mice treated with high dose 
AAV9-hNPC1 demonstrated continued survival. Assuming a minimal average 
survival of 151 days, treatment of Npc1-/- mice with high dose AAV9-hNPC1 
resulted in a significant extension in lifespan compared to untreated Npc1-/- mice (p < 
0.0001), miglustat treated Npc1-/- mice (p < 0.0001) and low dose AAV9-hNPC1 
treated Npc1-/- mice (p = 0.0001) (Figure 39). Although this survival study remains 
ongoing, assuming an average survival of 151 days, there is no significant difference 
between AAV9-hNPC1 and systemic HP-β-CD treatment. Future completion of this 
survival study will reveal if ICV treatment with high dose AAV9-hNPC1 further 
improve or surpass the 168-day average survival age of  
Npc1-/- treated with HP-β-CD. Although this survival study is still currently ongoing, 
the results at this stage have demonstrated that enhanced survival correlated with 
increased AAV9-hNPC1 dose. 
 




Figure 39: High dose AAV9-hNPC1 treatment further enhances survival of  
Npc1-/- mice. 
Kaplan-Meier survival curve depicts continued survival of 4 out of 7 Npc1-/- mice 
treated with a single ICV administration of 2.5 x 1011 GC of AAV9-hNPC1 (n=7) at 
approximately 151 days of age (± 21 days, HD AAV9-hNPC1). Data is compared to 
cohorts from the previous low dose study: wild-type (n=6), untreated Npc1-/- mice 
(n=8, 75 days), Npc1-/- mice with daily oral administration of 1,200mg/kg of miglustat 
(n=8, 108 days), Npc1-/- mice treated with weekly intraperitoneal administration of 
4,000mg/kg of HP-β-CD (n=11, 168 days) and Npc1-/- mice treated neonatally with a 
single ICV administration of low 4 x 109 GC of AAV9-hNPC1 (n=8, 116.5 days, LD 
AAV9-hNPC1). 
The weight of high dose AAV9-hNPC1 treated Npc1-/- mice was monitored weekly 
and compared to the weight data from the low dose study animal cohorts (Figure 
40). Npc1-/- mice treated with a single high dose AAV9-hNPC1 demonstrated 
sustained weights throughout their lives compared to untreated Npc1-/- mice, where 
dramatic weight loss was observed after 7 weeks of age. Weight of high dose AAV9-
hNPC1 treated Npc1-/- mice was maintained at level comparable to both low dose 
AAV9-hNPC1 and HP-β-CD treated Npc1-/- mice until 17 weeks of age. After 17 
weeks of age, the weight of high dose treated Npc1-/- mice remained stable with no 
significant weight loss observed, compared to the decline of low dose AAV9-hNPC1 
and HP-β-CD treated Npc1-/- mice. However the weights were not normalised, as the 
high dose AAV9-hNPC1 treated Npc1-/- mice exhibited significantly lower weight 
compared to wild-type mice throughout their lifespan. 




Figure 40: Sustained weight improvement in Npc1-/- mice following high dose 
AAV9-hNPC1 treatment. 
Weekly weight monitoring of Npc1-/- mice treated neonatally with a single ICV 
administration of high dose of AAV9-hNPC1 (HD AAV9-hNPC1, 2.5 x 1011 GC, 
n=7) until 19 weeks of age. Compared to weight data from low dose study including, 
wild-type (n=6), untreated Npc1-/- mice (n=8), Npc1-/- mice with daily oral 
administration of 1,200mg/kg of miglustat (n=8), Npc1-/- mice treated with weekly 
intraperitoneal administration of 4,000mg/kg of HP-β-CD (n=11), Npc1-/- mice treated 
neonatally with a single ICV administration of low dose (LD, 4 x 109 GC) of AAV9-
hNPC1 (n=8). Data represented as weekly weight mean ± SEM. 
6.4 Early indications of locomotor normalisation following 
administration of high dose AAV9-hNPC1 
At the time of thesis submission this high dose survival study remained ongoing, 
with 4 out of 7 AAV9-hNPC1 treated Npc1-/- mice still alive with an average lifespan 
of 151 days (±21 days). Therefore, the data available for detailed analysis and 
presentation in this section was limited to the monitoring of rearing activity to assess 
improvements in locomotor function. 
 



















Npc1-/- + HP- -CD
Npc1-/- + HD AAV9-hNPC1




Figure 41: Correction of rearing activity in high and low dose AAV9-hNPC1 
treated Npc1-/- mice. 
Sustained normalisation of locomotor and co-ordination symptoms of high dose 
AAV9-hNPC1 treated Npc1-/- mice (n=6) in an open filed setting, where number of 
rearing events were monitored during a 5-minute period. As study remained ongoing, 
data presented until 15 weeks of age and compared with low dose study. Data 
represented as mean ± S.D., compared by two-way ANOVA followed by Tukey’s 
HSD test. * p < 0.05. W, weeks of age; LD, low dose gene therapy treated Npc1-/-; UT, 
untreated Npc1-/- ; n, sample size. 
The treatment of Npc1-/- mice with low dose AAV9-hNPC1 resulted in the 
permanent correction of key locomotor function readouts associated with NP-C 
disease progression (Chapter 4). These parameters were also monitored weekly in 
the Npc1-/- mice treated with high dose AAV9-hNPC1, to confirm whether sustained 
correction was being achieved. The number of rearing events from Npc1-/- mice 
treated with high dose AAV9-hNPC1 was analysed in an open field environment and 
was subsequently compared to rearing data from the low dose study cohorts (Figure 
41). The act of rearing demonstrates a combination of coordination, hind-limb 
strength and natural exploratory behaviour, with a significant reduction in the 
number of rearing events correlating to disease progression in Npc1-/- mice (Figure 
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28). Npc1-/- mice treated with high dose AAV9-hNPC1 exhibited significantly higher 
numbers of rearing events, compared to untreated Npc1-/- mice after 7 weeks of age. 
Comparable to low dose treatment, high dose AAV9-hNPC1 treatment of Npc1-/- 
mice demonstrated correction of rearing activity, with no significant differences 
compared to age-matched wild-type mice in the data available at the point of thesis 
submission. Continued monitoring of this cohort will reveal if high dose treatment 
results in the permanent correction of rearing deficiencies to wild-type parameters, 
past the survival point achieved with low dose AAV9-hNPC1 treatment. 
6.5 Completion of high dose ICV AAV9-hNPC1 study 
At the point of thesis submission, only 3 of the 7 Npc1-/- mice in the cohort treated 
P0/1 with a high dose of 2.5 x 1011 GC of AAV9-hNPC1 (n=7) had reached their 
humane endpoints. As the primary focus of this high dose study was survival 
analysis, no treated mice were prematurely sacrificed for analysis, as this would have 
reduced the statistical power of this survival study. Although the data presented 
throughout this section was therefore limited, high dose AAV9-hNPC1 treatment 
was demonstrated to result in a further significant enhancement of lifespan compared 
to untreated, miglustat and low dose AAV9-hNPC1 treated Npc1-/- mice. There was 
also no significant difference between high dose gene therapy and HP-β-CD 
treatment in terms of survival in Npc1-/- mice. Early weight and rearing data, also 
indicated either equivalent or further improvement compared to low dose AAV9-
hNPC1 treated Npc1-/- mice data. The 4 remaining treated Npc1-/- mice in this 
survival study will be continued to be monitored until their humane endpoints are 
reached, at which point detailed analysis of various locomotor parameters throughout 
their lifespan will be added to survival and weight data. As with the low dose study, 
the brains will be analysed for amelioration of neurodegeneration and 
neuroinflammation and storage material accumulation via lysosomal marker and 
glycosphingolipid analysis. 
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The results of analyses from this proof of concept survival studies will be critical in 
evaluating whether this neurological focused approach of targeting extensive 
neuronal rescue is sufficient for long-term therapeutic benefit of Npc1-/- mice. 
Although this increase in AAV9-hNPC1 dose has already exhibited an enhancement 
to the lifespan and weight of Npc1-/- mice, the resulting final average survival and 
affect on neuroinflammation and neurovisceral lipid storage will indicate if the 
broadened transduction of other non-neuronal cells in the brain or vital visceral 
tissues needs to be investigated.  
 
Comparison of data sets from both the low and high dose administration studies in 
Npc1-/- mice will also allow the evaluation of dose response in terms of neurological 
disease amelioration. As the ultimate aim of this work is clinical translation, the 
identification of this dose to therapeutic benefit correlation may also be beneficial in 
assessing potential doses required in larger animal models or human patients. 
  
7.1 Overview 178 
 Discussion 
7.1 Overview 
Loss of function mutations to the NPC1 gene give rise to the rare lysosomal storage 
disorder Niemann-Pick Type C disease. This is characterised by severe 
neurodegeneration that results in progressive neurological disease manifestations and 
ultimately premature death. NP-C disease models and patients exhibit an 
accumulation of a range of lipid species, and while NPC1 dysfunction has been 
linked to various potential cell pathology pathways, the exact mechanism of how 
NPC1 dysfunction results in cellular pathology still remains unclear. There is 
currently no curative treatment for NP-C disease, although several small molecule 
treatments have demonstrated therapeutic efficacy by slowing disease progression 
(Section 1.3.7). However, these potential treatment options are associated with 
notable disadvantages, such as adverse side effects or the need for repeated invasive 
administration for the duration of the patient’s life. 
 
Following recent clinical successes in the field of gene therapy (Maguire et al., 2008, 
Stroes et al., 2008, Nathwani et al., 2011) and promising preclinical results for 
lysosomal storage disorders (Section 1.7), the potential use of viral vector mediated 
gene therapy has expanded to diseases previously considered as more challenging 
targets. Disorders caused by loss of function mutations to non-soluble lysosomal 
membrane-bound proteins, including NP-C disease, have been classified as 
challenging gene therapy targets due to the absence of cross-correction potential. 
Cell rescue is therefore dependent on successful gene delivery and downstream 
NPC1 expression in individual cells. However, advances in viral vector gene 
delivery systems have led to the identification and production of a variety of viral 
vectors, such as rAAV9 vectors, which are capable of efficient and extensive 
transduction in vivo.  
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To this end, this project has investigated the use of a viral gene delivery system for 
the treatment of Niemann-Pick Type C disease. The primary aim of this study was 
the development of a viral vector expressing the human NPC1 cDNA and the 
subsequent preclinical evaluation of this vector in a mouse model of NP-C disease. 
Results and information gained from these proof of concept studies, would allow 
further optimisation and testing of this approach thereby aiding the ultimate long-
term goal of clinical translation. 
 
The work and results presented in this study have outlined the successful 
development of a functional AAV vector system that is capable of efficient NPC1 
cDNA delivery and downstream expression. A series of preclinical survival studies 
in a mouse model of NP-C have demonstrated increased survival and significant 
therapeutic efficacy utilising this gene delivery system, in a disease that has until 
recently thought to be an unsuitable target for effective gene therapy. This work 
therefore provides important findings and implications for the future development of 
gene therapy for not only Niemann-Pick Type C disease, but also other challenging 
lysosomal storage disorders involving membrane-bound proteins and monogenic 
neurological disorders. 
 
Each chapter of this thesis has presented a summary discussion to provide insight 
into the scientific rationale and approach for subsequent chapters and experiments. 
This final chapter will further supplement these discussions by evaluating the overall 
presented findings and the wider context and implications of this work. The aims 
outlined in the Introduction chapter (Section 1.9) will be addressed along with the 
limitations of the methods and approaches used throughout this study. Finally, 
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7.2 AAV construct for optimised expression of larger 
transgenes 
The initial challenge addressed in this study was the issue of balancing sufficient 
viral vector packaging capacity with transduction efficiency. While AAV based viral 
vectors are currently regarded as the optimal approach for gene delivery to the brain, 
the incorporation of larger transgenes into functional rAAV vectors remains a major 
obstacle. At 3.8kb the human NPC1 cDNA pushes the upper limit of efficient AAV 
construct packaging, with oversized genomes resulting in a significant reduction of 
downstream transgene expression (Dong et al., 1996, Lai et al., 2010, Wu et al., 
2010, Choi et al., 2014). This limitation has also been a common problem in the 
development of efficient rAAV vectors for other more common genetic diseases, 
such as haemophilia A, cystic fibrosis and Duchenne muscular dystrophy. A series of 
different strategies to increase AAV packaging capacity beyond 4.7kb without 
creating an oversized genome have been established, including transgene 
overlapping, trans-splicing or a hybrid combination of both techniques, whereby dual 
rAAV vectors are administered simultaneously and the constructs recombine in the 
cell post-transduction (Trapani et al., 2014, Chamberlain et al., 2016, Hirsch et al., 
2016). However, the resulting transgene expression efficiency of these strategies can 
vary greatly and the complex constructs can require significant optimisation.  
 
Before committing to a potentially complex AAV-based approach, a gene delivery 
vector comparison study was carried out at the beginning of this project. This 
comparison was used to evaluate whether alternative gene delivery systems without 
the packaging capacity constraints of AAV vectors could be of potential use for 
efficient transduction throughout the brain (Section 3.3). Following ICV 
administration, lentiviral and canine adenoviral based vectors demonstrated limited 
localised transduction of neural cells, with transgene expression predominantly 
around the site of injection and in the ependymal cells lining the luminal surface of 
the ventricle walls. This limited transduction profile may have been sufficient for 
lysosomal storage disorders involving soluble acid hydrolases that can take 
advantage of cross-correction, with transduced ependymal cells excreting therapeutic 
protein into the CSF for widespread distribution. This has been demonstrated by the 
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neurological correction of MPS VII mice following intracranial canine adenovirus 
administration (Ariza et al., 2014). However, we expected that effective NP-C gene 
therapy would require the transduction of significantly higher numbers of neural 
cells in several brain areas, due to the lack of potential cross-correction. Similar to 
other studies (Kim et al., 2014, McLean et al., 2014), the extensive transgene 
expression throughout all monitored brain regions following neonatal ICV 
administration with an AAV9 vector (Section 3.3) led to the decision to utilise an 
AAV9 vector for NPC1 delivery, despite potential downstream complications 
associated with an oversized vector genome. 
 
Although the NPC1 cDNA was considered relatively large for incorporation into a 
standard rAAV construct, the decision was made to utilise a basic AAV gene 
delivery system as opposed to exploring more complex approaches. Initial rAAV-
hNPC1 constructs based on commonly utilised rAAV template vectors conceived at 
the start of this study resulted in a final oversized construct of 5.0kb and over. 
Previous studies analysing the effect of oversized rAAV vector genomes on 
packaging efficiency and downstream transgene expression have identified a critical 
packaging capacity threshold at approximately 5.0kb, after which transgene 
expression is significantly reduced (Wu et al., 2010, Choi et al., 2014). This project 
therefore focused on the modification and optimisation of a standard rAAV template 
construct to reduce the completed NPC1 construct size under this threshold, as 
opposed to a likely less efficient and more complex dual vector approach. 
 
Modification of the template rAAV construct for large transgene expression was 
carried out by the removal of all sequences and spacers that were not essential for 
transgene expression. As a result of these changes, the final rAAV-hNPC1 construct 
remained oversized by 200bp at 4.9kb, however it was under the critical 5.0kb 
threshold. In vitro testing of the construct plasmid confirmed the significant 
overexpression of the complete NPC1 protein compared to endogenous NPC1 levels 
(Section 3.7). The completed construct was subsequently used to successfully 
produce AAV9-hNPC1 viral vectors, which were analysed for vector genome 
integrity and quantification (Figure 18). Despite the oversized nature of the final 
AAV9-hNPC1 vector, complete packaging of the viral genome was observed, which 
crucially indicated the absence of genome truncation variants that would have 
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significantly lowered functional NPC1 expression levels. The titer of this first batch 
of vector was significantly lower than the average viral titer obtained during a 
standard rAAV vector preparation, however this was partially expected due to the 
oversized nature of the rAAV-hNPC1 construct. At 4.6 x 1011 GC, this 22-fold 
reduction in titer compared to standard preparations was sub-optimal, however this 
initial preparation was utilised to confirm successful transduction and NPC1 
overexpression, following P0 ICV administration in vivo (Section 3.11). As expected 
transduction was far from ubiquitous, however despite this low dose significant viral 
spread was still achieved, as cell populations demonstrated overexpression of NPC1 
throughout all observed brain regions, including sites relatively distant from the site 
of injection such as the cerebellum and brain stem. Importantly, the production of the 
full length NPC1 protein was also confirmed, which further supports that despite the 
marginally oversized vector genome, no truncated variants of either the genome or 
downstream NPC1 protein were being produced. It is important to note that the 
method of rAAV vector purification utilised in this study may have potentially 
enhanced dose efficiency, as iodixanol centrifugation results in the separation of 
empty viral capsids from packaged viral capsids (Lock et al., 2010), thereby 
increasing the number of active viral particles available for transgene cassette 
expression in a given dose. 
 
In combination, these results demonstrate that although the final minimal rAAV 
construct may still not be suitable for the incorporation and expression of extremely 
large transgenes, such as the dystrophin gene for Duchene muscular dystrophy, this 
construct can be effectively utilised for efficient gene delivery to the brain, with 
expression of transgenes potentially up to 4kb. Further modifications may allow the 
expression of even larger transgenes, such as through the use of minimal promoters 
(Ostedgaard et al., 2005), extreme minimal polyadenylation signal sequences 
(McFarland et al., 2006) or the use of AAV pseudotypes demonstrated to have 
enhanced packaging capacity, such as AAV2/5 (Allocca et al., 2008, Wu et al., 
2010). The observed reduction in viral titer in the first batch represented an 
additional challenge, however optimisation and up-scaling of the vector preparation 
protocol can be carried out to improve production efficiency and the AAV9-hNPC1 
can be produced to a more standard titer of >1 x 1013 GC. 
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At the start of this project we hypothesised that in addition to achieving efficient 
expression of NPC1 in as many cells as possible, several other important criteria 
would have to be met for a NPC1 gene delivery vector to achieve significant 
therapeutic efficacy in both NP-C animal models and future NP-C patients (Section 
1.8). While NP-C is a neurovisceral disease, in the majority of patients the visceral 
pathology is limited to non-fatal and often temporary hepatosplenomegaly, with only 
rare and extreme cases leading to fatal liver failure (Vanier, 2010). However, in 
comparison almost all NP-C patients will ultimately develop a progressive and fatal 
neurological disease. As a result, the treatment of the neurological aspects of NP-C 
was prioritised in this study. The efficient transduction of as many cells throughout 
the CNS was therefore targeted, leading to the ultimate use of an ICV AAV9 vector 
delivery system, as detailed in the previous section. 
 
In a series of complementary studies, neurodegeneration has been to shown to occur 
in a cell autonomous fashion in NP-C disease, with loss of NPC1 function in neurons 
thought to be primarily responsible for the progressive neurodegeneration and 
neurological disease manifestations (Lopez and Scott, 2013). The delivery and robust 
expression of NPC1 in large populations of neurons was therefore identified as 
crucial for achieving significant therapeutic efficacy in the neurological aspects of 
NP-C disease. This was achieved through the choice of the well characterised, 
neuronal-selective and constitutively active human synapsin I promoter for NPC1 
expression, with even low dose AAV9-hNPC1 administration resulting in NPC1 
overexpression throughout brain regions critical to NP-C neuropathology (Section 
3.11). At approximately 480bp, the human synapsin I promoter also had the 
additional benefit of a relatively small size, compared to other promoters commonly 
used for neuronal expression, such as the chicken-beta actin promoter at 1.6-1.8kb 
(Shevtsova et al., 2005, Gray et al., 2011a), thereby further increasing vital 
packaging space. While the human synapsin I promoter is ideal for significant and 
long-term transgene expression in neurons, no activity has been observed in other 
cells of the CNS (DeGennaro et al., 1983). This exclusively neuronal expression was 
confirmed in this study via a series of AAV9-hNPC1 vector tropism experiments, 
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with significant NPC1 overexpression exhibited in transduced neuronal cells, 
however no NPC1 overexpression was observed in either astrocytes or microglia 
(Section 3.13). It is important to note that a previous study has demonstrated that the 
loss of NPC1 function solely in astrocytes does not result in neuronal toxicity or is 
sufficient in causing neurodegeneration and neurological disease recapitulation (Yu 
et al., 2011). Similarly, disease progression was not significantly altered by 
expression of functional NPC1 within astrocytes in otherwise NPC1-deficient mice 
(Lopez et al., 2011). In comparison, the conditional loss of neuronal NPC1 function 
was sufficient in recapitulating neurological disease (Elrick et al., 2010, Yu et al., 
2011) and neuron specific NPC1 expression within NPC1-dificient mice resulted in 
the prevention of neurological disease progression (Lopez et al., 2011). Microglial 
activation also appears to be secondary to neuronal loss, as an Npc1 chimeric mouse 
model demonstrated that microglial activation was only observed within the 
proximity of dead or dying NPC1-deficient neurons, whereas nearby wild-type 
neurons remained unaffected (Ko et al., 2005). So while a rAAV vector that can 
achieve ubiquitous expression of NPC1 in all neural cell types may be ideal, in the 
first instance in this proof of concept study we have targeted the neurons. As a result 
of the strong and efficient activity of the human synapsin I promoter in neurons, P0 
ICV administration of AAV9-hNPC1 in wild-type mice resulted in the 
overexpression of the NPC1 protein to supraphysiological levels (Section 3.11). As 
intercellular secretion and uptake of the overexpressed NPC1 protein is not possible, 
there is likely little benefit in the overexpression of NPC1 above wild-type levels, as 
targeted by gene therapy approaches for disorders with soluble lysosomal proteins. 
Importantly, a series of neuropathology studies demonstrated that AAV9-hNPC1 
vector administration and the resulting downstream human NPC1 overexpression did 
not result in any indications of toxicity throughout the brain, in the form of either 
astrogliosis or a microglial-mediated inflammatory responses (Section 3.14). These 
findings are supported by an early study using prion-promoter-driven Npc1 cDNA 
expression to rescue neurodegeneration in a different NP-C mouse model, with no 
long-term toxicity associated with over 10-fold levels of endogenous Npc1 
expression (Loftus et al., 2002). While a complete GLP-compliant toxicological 
survey will be required to confirm the safety of this treatment in a clinical context, 
these are important early considerations from a preclinical safety and toxicology 
point of view. 
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Timing and route of administration were also carefully considered to achieve optimal 
spread and delivery throughout as much of the brain as possible. Intravenous 
administration for CNS delivery has become a realistic target, as certain rAAV 
serotypes have been demonstrated to cross the blood-brain barrier extremely well in 
neonatal mice (Foust et al., 2009, Zhang et al., 2011). However, in older adult mice 
the efficiency of rAAV movement across the blood-brain barrier reduces 
significantly (Duque et al., 2009, Gray et al., 2011b), resulting in an ultimate 
reduction of neurological therapeutic efficacy. As the approach taken in this study 
was to maximise CNS transduction, we concluded that direct administration into the 
CNS, while more invasive, would greatly improve vector bioavailability in the brain. 
A less invasive intrathecal route of administration into the CSF was also considered, 
however as only a single round of administration will be possible, the benefit of 
potentially increased efficiency resulting from ICV administration directly into 
lateral ventricle may outweigh the disadvantage of it being a more invasive 
procedure. Neonatal administration was chosen as the time point for vector 
administration in this proof of concept project, in an attempt to maximise the 
transduction efficiency and viral spread of the AAV9-hNPC1 vector. As a result, 
evaluation of the therapeutic efficacy of AAV9-hNPC1 was carried in optimal 
conditions. 
 
The initial in vivo test of AAV9-hNPC1 in wild-type mice supported these decisions, 
as even at a significantly lower dose, efficient neuronal NPC1 expression in a large 
number of cells within brain areas particularly affected by NP-C induced 
neuropathology, including the cortex, thalamus and cerebellum, was being achieved 
(Figure 20). High magnification imaging of these transduced cells also revealed a 
distinct punctate distribution of the overexpressed NPC1 protein, which was 
confirmed as successful localisation of the NPC1 protein to within LAMP1 positive 
structures, including late endosomes and lysosomes, via scanning confocal 
microscopy of immunofluorescence staining (Figure 24). It was important to show 
that hNPC1 protein was able to traffic correctly to endosomal and lysosomal 
compartments given that the human NPC1 and murine Npc1 cDNA and protein 
sequence are not completely conserved. As these sequences share a relatively high 
homology, at 84% and 86% respectively, we decided to utilise the human NPC1 
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cDNA for evaluation in an NP-C mouse model to facilitate potential future clinical 
translation. While incorporation of the murine Npc1 variant may have been more 
effective in mouse models, many of the preclinical experiments carried out in this 
project would have had to have been repeated with the human variant. 
 
In combination, these points and considerations support why the AAV9-hNPC1 
vector designed and produced in this project was not only a suitable candidate for the 
preclinical evaluation in a Npc1-/- mouse model, but also in a configuration that could 
be realistically translated for future clinical use. 
7.4 Therapeutic efficacy of AAV9-hNPC1 
A series of preclinical studies have been carried out in the Npc1-/- mouse model in 
this study, with low and high dose AAV9-hNPC1 treatment evaluated for their 
therapeutic efficacy on survival, weight and amelioration of neurological NP-C 
disease manifestations. The reasons to initially carry out a low dose study followed 
by a subsequent high dose study were threefold. (1) In the initial wild-type in vivo 
vector testing, the levels of NPC1 overexpression observed in widespread cell 
populations appeared promising, with AAV9-hNPC1 induced expression in all brain 
regions severely affected by NP-C associated neurodegeneration, despite the very 
low dose; (2) given that the exact function of the NPC1 protein remains currently 
unclear we wanted to be cautious with the dose in the first round of preclinical 
testing; (3) taking the limited timeframe into consideration, rather than solely 
focusing on vector production optimisation, we reasoned that valuable preclinical 
results could be gained from the readily available low titre AAV9-hNPC1 batch, 
with a subsequent high dose study when higher titer vector was available. In the first 
round of preclinical testing, AAV9-hNPC1 was therefore administered at a relatively 
low dose of 4 x 109 GC (4 x 1012 GC/kg), compared to other studies using rAAV 
vectors in neonates via the same route of injection, where up to approximately 3 x 
1014 GC/kg has been utilised (Broekman et al., 2007). 
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Encouragingly, low dose AAV9-hNPC1 ICV treatment of Npc1-/- mice resulted in an 
average 55% increase in lifespan and significant weight improvements, compared to 
untreated Npc1-/- mice (Chapter 4). The improvements to lifespan and weight were 
accompanied with permanent normalisation or improvement in various indices of 
neurological disease manifestations, including rearing, tremor and gait. These 
promising results confirm that even at a very low dose, the AAV9-hNPC1 vector 
designed in this project was capable of significant and long-term therapeutic efficacy 
in a disease that was until recently considered a difficult target for effective gene 
therapy treatment. Further analysis of brain sections from these end-stage low dose 
AAV9-hNPC1 treated Npc1-/- mice (Chapter 5) revealed significant or permanent 
neuronal rescue in all quantified brain regions, including the cortex, thalamus, 
substantia nigra and complete normalisation to wild-type levels in several regions of 
the cerebellum. The partial preservation of neurons had been expected, as previous 
low dose AAV9-hNPC1 vector evaluation in wild-type mice demonstrated that 
transduction of neurons was not ubiquitous. This therefore implies that at least in this 
animal model of NP-C, universal or extensive neuronal rescue through AAV9-
hNPC1 transduction may not be necessary to achieve significant therapeutic benefits. 
These clear therapeutic effects on critical clinical endpoints in this model are 
encouraging since motor co-ordination and ataxia are hallmark symptoms in NP-C 
patients. However, despite AAV9-hNPC1 treatment and significant neuronal rescue, 
the regional atrophy and inflammatory responses observed in the brains of untreated 
Npc1-/- mice remained present in these low dose Npc1-/- treated mice. The reason for 
these findings is unclear, although several theories are proposed: (1) following non-
ubiquitous transduction, the untransduced cells underwent continued 
neurodegeneration resulting in neuroinflammation, which may also account for the 
regional atrophy; (2) alternatively, as NPC1 expression was restricted to neurons, 
other neural cells may have continued to accumulate storage material leading 
ultimately to cellular pathology and an inflammatory response. However, it is 
important to note that significant amelioration of neuroinflammation was observed in 
several brain regions, indicating that gene therapy was having an affect on the extent 
of neuroinflammation within treated brains. This was particularly apparent in the 
cerebellum, as significant neuronal rescue within the simple and paramedian lobules 
of the cerebellum correlated with a reduction in both astroglial and microglial 
induced neuroinflammation. Additionally, as this was a survival study, the brain 
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sections of the low dose gene therapy treated Npc1-/- mice were analysed at their end-
stage, at a significantly older time point. This may have allowed longer pathology 
progression in cells and areas left untransduced following low dose AAV9-hNPC1 
administration. Comparison of younger gene therapy treated Npc1-/- mice with age-
matched untreated Npc1-/- mice may in future clarify the efficacy of AAV9-hNPC1 
treatment on glial cell activation, however due to time constraints this was not 
investigated during the course of this project. 
 
As NP-C disease is a lysosomal storage disorder, the effect of gene therapy treatment 
on the accumulation of various lipid species has also been investigated in this project 
(Section 5.6). Analysis of cholesterol accumulation in the brain revealed that 
significant amounts of unesterified cholesterol were present within cells, above the 
levels observed in wild-type brains. However, there was a clear difference in the 
profile of positively stained filipin cells between low dose AAV9-hNPC1 treated and 
untreated Npc1-/- mice. The positive and clear staining of cells exhibiting neuronal 
morphology observed in the untreated Npc1-/- mice could not be detected in the gene 
therapy treated Npc1-/- mice, which were characterised by a more diffuse staining 
profile. The number of filipin positive cells also appeared to be reduced as a result of 
low dose gene therapy treatment, which was particularly evident within the thalamus. 
A possible explanation for this change in filipin staining may be a redistribution of 
unesterified cholesterol accumulation within the brains of gene therapy treated  
Npc1-/- mice. Due to the exclusive expression of NPC1 protein in neurons, lipid 
accumulation may have been ameliorated in rescued neurons, however other 
untransduced neural cells such as astrocytes and microglia will continuously 
accumulate lipids. This theory is supported by the reduction of filipin positive cells 
with neuronal morphology in gene therapy treated Npc1-/- mice, indicating 
amelioration of neuronal cholesterol accumulation. Additionally, the diffuse filipin 
staining observed in low dose AAV9-hNPC1 treated Npc1-/- brains may represent 
glial cells and their processes, however further evaluation of the filipin stain in 
combination with neural cell markers will be necessary to support this hypothesis.  
 
Quantification of glycosphingolipids within the brain revealed no significant 
difference between the high total GSL concentrations observed in untreated and 
older low dose gene therapy treated Npc1-/- mice. However, compared to untreated 
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Npc1-/- mice, low dose AAV9-hNPC1 administration resulted in the significant 
reduction of GM2, one of the key glycosphingolipids species known to accumulate 
within the brain of Npc1-/- mice and NP-C patients (Fan et al., 2013) and its 
accumulation has been linked to neuronal degeneration and dysfunction in both NP-
C and other storage disorders (Siegel and Walkley, 1994, Walkley, 1995). Taking the 
significantly longer lifespan of AAV9-hNPC1 administered Npc1-/- mice into 
account, we hypothesised that if lipid accumulation was left unaffected by gene 
therapy, the GSL concentrations in the brain of these significantly older mice would 
have accumulated beyond the levels demonstrated by the younger untreated Npc1-/- 
mice. However, as the total brain GSL concentrations in brains of low dose gene 
therapy treated Npc1-/- mice were comparable to untreated Npc1-/- mice, there may 
have been a deceleration of GSL accumulation. This theory was supported by the 
observation of highly elevated GSL levels within the livers of ICV AAV9-hNPC1 
treated Npc1-/- mice, which were significantly higher than liver GSL levels in 
untreated Npc1-/- mice. This would be expected from a gene therapy approach 
targeted to the brain and not the viscera. Combined with the longer lifespan, the 
visceral tissue may have continuously accumulated lipids beyond the average levels 
observed in untreated younger Npc1-/- mice. A future comparison of age-match gene 
therapy treated and untreated Npc1-/- mice may answer these points more 
definitively, where comparable GSL levels in the liver and a reduction in brain GSL 
accumulation would confirm a deceleration of CNS GSL accumulation. This highly 
significant build-up of glycosphingolipids species within the liver confirmed that the 
focus of neuronal rescue combined with low dose ICV administration had not 
addressed the visceral pathology of NP-C.  
 
Although visceral symptoms are common in NP-C patients, severe and fatal visceral 
pathology has been limited to a minority of patients, with neurological disease 
manifestations thought to ultimately be responsible for severe disease progression 
and death. However, following the observation of extreme GSL levels in the liver of 
low dose AAV9-hNPC1 treated Npc1-/- mice, the importance and potential impact of 
visceral pathology and visceral lipid accumulation in this model has to be taken into 
consideration. While the Npc1-/- mouse model utilised in this study does not replicate 
the fact that missense mutations are found in the majority of patients (Carstea et al., 
1997, Bauer et al., 2002, Park et al., 2003), it does generally recapitulate the 
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behavioural, neuropathological and biochemical defects seen in human patients. 
Although similar lipid storage profiles have been observed in the viscera of Npc1-/- 
mice, compared to human patients, the accumulation in the liver of Npc1-/- mice is 
more severe than in the spleen, which is the opposite to human disease (Vanier, 
2015). This inherent enhanced lipid accumulation in the liver of Npc1-/- mice may 
have been further amplified in ICV AAV9-hNPC1 administered Npc1-/- mice, where 
the viscera was left untreated and pathology was allowed to continuously progress 
during the longer lifespan, as supported by the finding of extreme liver GSL 
concentrations in treated Npc1-/- mice. As a result of this high lipid accumulation rate 
in the liver, pathology associated with the liver or other visceral tissues may have 
become more critical over time in the older gene therapy treated Npc1-/- mice. 
Additionally, severe visceral storage may also be capable of affecting CNS 
pathology via the movement of toxic, water-soluble metabolites across the blood-
brain barrier, subsequently contributing to neurodegeneration and inflammation 
(Jones and Weissenborn, 1997). While a significant extension in Npc1-/- mouse 
lifespan has been achieved by the neurologically focused AAV9-hNPC1 treatment, 
the reason for these mice reaching their humane endpoint via significant weight loss 
remains unclear. At their humane endpoints, AAV9-hNPC1 treated Npc1-/- mice did 
not exhibit the standard Npc1-/- phenotype, as all indices of neurological disease were 
either normalised or significantly improved. We initially hypothesised that while 
extremely promising, the modest number of neurons transduced following low dose 
AAV9-hNPC1 treatment may have been sufficient in rescuing the neurological 
phenotype, with continued degeneration of large populations of untransduced 
neurons ultimately contributing to disease progression and weight loss. As a result of 
the 54-fold increase in viral particles administered, high dose AAV9-hNPC1 
administration is expected to result in significantly higher numbers of transduced 
neurons and subsequent therapeutic efficacy. However, while a significant 
improvement over low dose treatment has been observed in the lifespan and weight 
of gene therapy treated Npc1-/- mice, 3 of the 7 high dose AAV9-hNPC1 treated 
Npc1-/- mice were ultimately sacrificed due to significant weight loss. Future analysis 
of these brains will reveal the extent of neuronal rescue, however similar to low dose 
treatment, at their humane endpoint these high dose treated Npc1-/- mice did not 
exhibit the classical Npc1-/- neurological phenotype. Although the ratio of transduced 
neurons following high dose administration may still not be sufficient, these findings 
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indicate that there may be additional factors, such as visceral pathology, contributing 
towards the ultimate death of high dose AAV9-hNPC1 treated Npc1-/- mice. As with 
low dose treatment, the ICV administration of high dose AAV9-hNPC1 into the CSF 
should result in basal visceral transduction, resulting in continued visceral lipid 
accumulation. However, if this were to be the primary cause of deterioration in gene 
therapy treated cohorts, the average survival should not be affected by the increase in 
AAV9-hNPC1 dose within the CNS, as visceral tissues should remain unaffected at 
both doses. It is important to note that in the high dose study, the 54-fold increase in 
vector administration may cause additional leakage of the vector into the blood 
stream, such as through the eventual drainage of CSF into the venous system 
(Haurigot et al., 2013). Additionally, although the human synapsin I promoter is 
exclusively neuronal in the CNS, synapsin I protein expression has been observed in 
visceral tissue (Bustos et al., 2001). Synapsin I promoter activity has recently been 
demonstrated within the livers of mice following intravenous administration of an 
AAV9-synapsin vector (Jackson et al., 2016). An increase in ICV AAV9-hNPC1 
dose may therefore result in NPC1 production and subsequent clearance of lipids 
within transduced liver cells. This factor may contribute to the extended survival 
observed following high dose AAV9-hNPC1 treatment compared to low dose, 
however future tissue transduction evaluation and further visceral analysis will be 
needed to confirm potential liver transduction.  
 
The conclusion of the high-dose gene therapy survival study, subsequent tissue 
analysis and comparison with the data from the low dose cohort will give a clearer 
indication of the complete neurological and visceral therapeutic efficacy of neonatal 
ICV AAV9-hNPC1 treatment of Npc1-/- mice. However, the experiments presented 
in this project demonstrate critical proof of concept results, where administration of 
AAV9-hNPC1 to Npc1-/- mice resulted in a significant therapeutic benefit. This 
includes either normalisation or significant improvements in a number of key 
readouts including lifespan, quality of life and indices of behaviour, neuropathology 
and biochemistry, as determined in a well-characterised mouse model of NP-C.  
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7.5 Limitations 
This project focused on the development of a functional AAV9-hNPC1 gene 
delivery vector, optimised for efficient transgene expression in neurons and was used 
in a series of preclinical survival studies. While significant improvements in lifespan, 
weight, locomotor function and neurodegeneration were observed, there are 
important limitations regarding the approach and utilised methods that need to be 
highlighted.  
 
Firstly, the clinical translation of results from P0/1 neonatal administration approach 
for the evaluation of NPC1 gene delivery vector must be considered, as neonatal pre-
symptomatic administration will not reflect the likely standard scenario of clinical 
application. Although there are exceptions, as in certain rare cases NP-C can be 
diagnosed either in utero or post-natally through the presence of severe 
hepatosplenomegaly or ascites (Spiegel et al., 2009), though in the majority of 
circumstances patients are diagnosed after the onset of symptoms. Fast and efficient 
diagnosis remains a key issue for NP-C patients, however recent advances in the 
identification of NP-C biomarkers and their screening may significant improve this 
diagnostic delay (Welford et al., 2014, Giese et al., 2015, Reunert et al., 2016). These 
advances in diagnostics may also enable the development of comprehensive neonatal 
screening, which would allow initiation of therapy, such as gene therapy, in 
neonates. Alternatively, this neonatal gene therapy approach may be viable in cases 
where the diagnosis of an NP-C patient leads to the subsequent diagnosis of a pre- or 
very early- symptomatic sibling.  
 
As the major aim of this project was demonstrating proof of concept of therapeutic 
efficacy resulting from ICV AAV9-hNPC1 treatment, vector administration was 
carried out as early as possible to achieve optimal transduction spread. Previous 
studies have demonstrated that ICV administration of rAAV9 into neonatal mice 
resulted in extensive and widespread transgene expression throughout the entire CNS 
(Kim et al., 2014, McLean et al., 2014). However, as the brain is not fully developed 
at this early stage of administration, the transduction profiles observed in this study 
may differ when translated to an adult brain. A number of studies have investigated 
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the transduction efficiency of ICV rAAV9 vector administration in adult rodents and 
larger animal models, where widespread transgene expression throughout the brain 
could still be observed (Samaranch et al., 2012, Haurigot et al., 2013, Donsante et al., 
2016).  
 
Another important point to address is the translatability of results from the relatively 
small brain size of a mouse or more specifically neonatal mouse, compared to the 
much larger human brain. A common criticism with the small size of the neonatal 
mouse brain is that the general plasticity of the brain at that time point allows the 
administration of relatively high rAAV doses in relation to overall brain size. While 
correct, it is also important to note that total CSF volume increases with larger brain 
size, from 0.035ml in mice to approximately 140ml in humans, allowing the relative 
dose to be scaled up with delivery of significantly larger volumes over longer time 
periods possible within the CSF of larger brains (Gray et al., 2013). For example, in 
this study neonatal mice were administered with a low dose of 4.6 x 109 GC and high 
dose 2.5 x 1011 GC, compared to the significantly higher dose of 5.5 x 1012 vector 
genomes of AAV vector administered ICV in adult non-human primates (Gray et al., 
2013), representing a 1,100-fold and 22-fold increase respectively. It will be 
important to re-evaluate ICV administration of AAV9-hNPC1 in the slightly larger 
and fully developed adult Npc1-/- mouse brain, to compare with the proof of concept 
efficacy results produced following the neonatal ICV administration in Npc1-/- mice. 
Ideally this vector could also be tested in a larger model of NP-C disease, such as the 
well-characterised feline NP-C model. However, the information gained in terms of 
additional clinical translational value of AAV9 efficacy between a murine and feline 
NP-C model compared to human NP-C patients may be limited, mainly as a result of 
the unpredictable nature rAAV transduction profiles between species. As with all 
gene therapy studies, it is currently impossible to predict how efficient and 
widespread rAAV9 transduction will be in the large brains of human patients when 
administered into the CSF. However, the use of rAAV9 vectors has already 
translated through to the clinical trials using this approach for spinal muscular 
atrophy type 1 (ClinicalTrials.gov Identifier: NCT02725580) and CLN6 Batten 
disease (ClinicalTrials.gov Identifier: NCT02725580). 
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One of the major limitations of the preclinical studies carried out in the Npc1-/- 
mouse model during this project was the lack of data for age-matched gene therapy 
treated AAV9-hNPC1 Npc1-/- mice, to allow clear comparisons with 9-week old end-
stage untreated Npc1-/- mice. Design, modification and production of the AAV9-
hNPC1 construct and vector required significant amounts of time, leading to a 
limited timeframe for preclinical vector evaluation. As the primary aim of this study 
was to establish proof of concept results that ICV administration of AAV9-hNPC1 in 
neonatal Npc1-/- mice could demonstrate significant therapeutic benefit and extension 
of lifespan, we decided to conduct a survival study, where all animals were kept until 
their respective humane endpoints. The main reason for prioritising the ageing out of 
all mice cohorts was to allow higher power statistical analysis of survival, weight and 
motor-function, rather than reducing potential significance by sacrificing a minimum 
of 3 treated Npc1-/- mice at 9 weeks of age for neuropathology and biochemistry 
analysis. As a result these analyses were carried out on end-stage AAV9-hNPC1 
treated Npc1-/- mice, which are compared with significantly younger untreated  
Npc1-/- mice. The future addition of age-matched AAV9-hNPC1 treated Npc1-/- 
samples may clarify some of the points raised in this chapter, such as the possible 
deceleration of brain lipid accumulation, or may even demonstrate greater significant 
therapeutic effects at that time point. On the other hand, the analysis of end-stage 
Npc1-/- tissue allowed the recognition of significant, long-term neuronal rescue in all 
analysed brain regions, accompanied with regional reductions in neuropathological 
and lysosomal markers. 
 
Finally, as this project aimed for a neurologically focused gene therapy approach for 
NP-C disease, the majority of analysis was naturally targeted towards the CNS and 
neurological disease manifestations associated with neurodegeneration. However as 
previously discussed in this chapter, ongoing visceral pathology may play a role if 
left untreated by the AAV9-hNPC1 vector evaluated in this study. In future, more in 
depth analysis of visceral tissue pathology following ICV AAV9-hNPC1 treatment, 
with a particular focus on the liver, may clarify the extent of the affect of progressive 
visceral pathology on gene therapy treated Npc1-/- mice and also potentially further 
demonstrate the importance of visceral pathology in NP-C disease. 
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7.6 AAV9-hNPC1 and competing NP-C therapies 
To place the therapeutic efficacy of this gene therapy study in the context of other 
competing therapies in the NP-C arena, AAV9-hNPC1 treatment has been directly 
compared to miglustat and HP-β-CD treatment in Npc1-/- mice in terms of survival, 
weight and tremor analysis. ICV administration of AAV9-hNPC1 in neonatal Npc1-/- 
mice resulted in a significant extension of lifespan at both low and high doses. Low 
dose treatment extended the survival of Npc1-/- mice (116.5 days ± 12.22) to that 
exhibited by miglustat treated mice (108 ± 8.071), which represents the only 
currently licenced drug for NP-C disease within the EU. Interestingly, gene therapy 
did not exhibit the adverse side effects seen in the miglustat treated mice. This was 
most evident through the inability of miglustat treated mice to gain weight, due to the 
known appetite suppressive properties associated with this drug (Priestman et al., 
2008). Furthermore, miglustat also inhibits gastrointestinal disacchardisases leading 
to the disruption of gastrointestinal function, which is present in 80% of patients 
receiving miglustat within the first 6 months of treatment and 60% of patients long-
term (Remenova et al., 2015), and is the most common cause of discontinuation of 
use (Belmatoug et al., 2011, Lyseng-Williamson, 2014). Both treatment options 
resulted in the normalisation of NP-C induced tremor in Npc1-/- mice throughout 
their lifespan. These results demonstrate that even at a low dose, ICV treatment of 
Npc1-/- mice with AAV9-hNPC1 is comparable to the therapeutic efficacy of 
miglustat, without the associated adverse effects. 
 
Although the high dose survival study remained ongoing at the time of thesis 
submission, a further extension in lifespan from low dose gene therapy treatment 
(116.5 days ± 12.22) was recorded in Npc1-/- mice treated with a 54-fold higher dose 
of AAV9-hNPC1 (151 days ± 21). Assuming 151 days as the minimal survival, the 
extended survival exhibited by Npc1-/- mice following high dose AAV9-hNPC1 
treatment was comparable to the survival achieved by systemic HP-β-CD treatment 
(168 ± 29.31), with no significant difference between the two options. Future 
completion of the high dose survival study will clarify if high dose AAV9-hNPC1 
further improves on the 151-day lifespan or potentially surpasses the 168-day 
average survival age demonstrated in Npc1-/- treated with viscerally with HP-β-CD. 
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These treatments also exhibited comparable improvements in the weights of Npc1-/- 
mice until 17 weeks of age, after which continued stabilisation in the weight of high 
dose gene therapy treated Npc1-/- mice was contrasted by the decline in weight of  
HP-β-CD treated Npc1-/- mice. As with low dose AAV9-hNPC1 and miglustat 
treatment, HP-β-CD treated Npc1-/- mice demonstrated the normalisation of tremor at 
both 9 and 16 weeks of age, indicating therapeutic efficacy on the neurological 
disease manifestations of NP-C. As HP-β-CD has been shown to inefficiently cross 
the blood-brain barrier (Pontikis et al., 2013), high dose systemic administration of 
HP-β-CD is required to have a significant neurological effect (Vite et al., 2015). 
However, pulmonary toxicity has been observed in Npc1-/- cats treated intravenously 
with high doses of HP-β-CD (Vite et al., 2015). Alternatively, HP-β-CD can be 
injected directly into the CSF allowing the safer administration of lower doses to 
achieve similar neurological improvements. However, this approach requires 
administration of HP-β-CD every two weeks via invasive intrathecal administration, 
which is currently being evaluated in an ongoing clinical trial in NP-C patients 
(Phase II/III ClinicalTrials.gov Identifier: NCT02534844). There are also concerns 
relating to ototoxicity and subsequent hearing loss that have been observed in mice 
(Crumling et al., 2012) and cats (Ward et al., 2010) following HP-β-CD treatment. 
Therefore, while HP-β-CD is promising, there are concerns around the viability of 
long-term administration and potential toxicity that a gene therapy approach could 
avoid, as the ICV single injection of high dose AAV9-hNPC1 resulted in a 
comparable extension of lifespan. 
 
The results of this project are encouraging, as we have demonstrated significant 
therapeutic efficacy of ICV AAV9-hNPC1 administration in a disease, which has 
until recently been considered as a relatively challenging target, due to the lack of 
cross-correction potential and large transgene size. The rise in gene therapy 
preclinical and clinical successes combined with the progression of viral vector 
technology has led to the expansion of viable gene therapy targets, with increased 
attention given to these more challenging disorders. Along with this project, two 
recently published studies have investigated the potential use of AAV9 vectors for 
the treatment of NP-C disease, both supporting our findings of significant 
neuropathological improvements in Npc1-/- mice following gene therapy treatment. 
However, there are significant differences in terms of construct variations, route of 
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administration and general approach between the different studies. One of the recent 
studies demonstrated that high dose intravenous administration of AAV9 vectors 
carrying the hNPC1 cDNA to neonatal (P1-3, 1 x 1011 GC) and pre-symptomatic 
weanling mice (P20-25, 1 x 1012 GC) significantly extended the lifespan, with 
reduced neuropathology and liver cholesterol accumulation in the Npc1-/- mouse at 9 
weeks of age (Chandler et al., 2016). The approach of intravenous administration 
allows the transduction of visceral tissues in combination with neural transduction, as 
rAAV9 vectors are capable of crossing the blood-brain barrier, however efficiency is 
significantly reduced from neonatal to adult period (Duque et al., 2009, Foust et al., 
2009, Gray et al., 2011b). The authors additionally compared the use of the neuron-
specific promoter CamKII with a more ubiquitous shortened EF1a promoter in terms 
of survival and weight, following gene therapy treatment. High dose injection of the 
neuron specific AAV9 vector resulted in a mean survival of 97 days (± 18.5) 
following neonatal intravenous administration and 103 days (± 29.7) when injected 
into weanling Npc1-/- mice. Although the humane endpoints between studies will 
vary, as this work has been carried out in the same NP-C animal model used in this 
study using a comparable technique, these results can tentatively be compared with 
the results from this study (Figure 42). These survival results are comparable to the 
survival of miglustat treated Npc1-/- mice and are significantly lower than Npc1-/- 
mice treated ICV with both high and low dose AAV9-hNPC1 vector. Treatment with 
the CamKII vector resulted in the correction of cholesterol accumulation in 
transduced neurons and the significant increase of Purkinje neurons within several 
lobules of the cerebellum compared to untreated treated Npc1-/- mice, however in 
contrast to this study this analysis was only carried out at 9 weeks of age. In 
combination with a lack of behavioural analysis, it is difficult to assess the long-term 
efficacy of this approach on the disease progression of Npc1-/- mice. Interestingly, 
the intravenous administration of an AAV9 vector with the human NPC1 cDNA 
controlled by a ubiquitous shortened EF1a promoter resulted in a significant 
improvement in survival of Npc1-/- mice (166 days ± 89.2) relative to the neuron 
specific promoter. These results are comparable to the survival observed in Npc1-/- 
mice treated systemically with HP-β-CD and high dose AAV9-hNPC1, with no 
significant difference between all groups. As subsequent neuropathology analysis 
was limited to the observation of reduced filipin staining within the pons and liver of 
9-week old treated brains, the full impact of this treatment on both neurological and 
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visceral pathology remains unclear. Additionally, the transduction profile of the 
shortened EF1a AAV9 vector within the brains or visceral tissue was not addressed, 
allowing minimal comparison. Given the dominance of neurodegeneration in fatal 
NP-C symptoms and the need for high levels of transduction, we have prioritised the 
brain for maximum treatment using an ICV administration directly into the CSF. We 
have subsequently demonstrated that administration of AAV9-hNPC1 into neonatal 
Npc1-/- mice resulted in the significant long-term protection of neurons within brain 
areas most several affected by NP-C neurodegeneration, such as the cortex, 
thalamus, substantia nigra and cerebellum, however this has been at the expense of 
the viscera. The efficiency of transduction within the brain of intravenously 
administered weanling mice would be expected to be significantly reduced compared 
to direct ICV administrations into the CSF of neonatal mice, however both 
approaches have demonstrated comparable levels of survival. This observation may 
indicate that additional transduction of non-neuronal cells, such as glial cells in the 
brain or hepatocytes in the viscera may benefit towards the long-term survival of 
Npc1-/- mice.  
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Figure 42: Summary of average survival data of Npc1-/- mice in recent NP-C gene 
therapy studies. 
IP, intraperitoneal; IV, intravenous; ICV, intracerebroventricular; ICA, intracardiac; 
LD, low dose; HD, high dose; NEO, neonatal; WEAN, weanling. Data represented as 
mean ± S.D. 
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Another recent study demonstrated that high dose (2.5 x 1011 vector genomes) 
intracardiac administration of AAV9 vectors carrying a modified murine Npc1 
cDNA variant under the control of the viral CMV promoter into Npc1-/- mice resulted 
in increased survival, delayed Purkinje cell loss and improved locomotor activity 
(Xie et al., 2017). The moderate improvement in lifespan achieved with this 
approach (94 days ± 4) is significantly less than that from low dose ICV AAV9-
hNPC1 treatment in this study (Figure 42). Similar to Chandler et al. (2016), 
neuropathology and locomotor function were only analysed at 9 weeks of age and 
not conducted on end-stage Npc1-/- mice. The end-stage phenotype or humane 
endpoint is not described, however the authors hypothesise that the limited 
improvement following intracranial AAV9 delivery may possibly be attributed to 
insufficient neuronal transduction within the brain of treated Npc1-/- mice. 
Alternatively, Npc1 expression may have been affected by silencing of the 
transcriptional activity of the CMV promoter through methylation, which has 
previously been described following in vivo gene delivery with a viral vector (Brooks 
et al., 2004). Taken together, these studies demonstrate that lysosomal storage 
disorders, such as Niemann-Pick Type C that can’t take advantage of cross-
correction may not be as refractory to gene therapy as previously thought. Direct 
injection into the CNS may represent the optimal route of administration for the 
treatment of the neuropathology and associated disease manifestations, however a 
certain level of visceral expression in combination with efficient CNS transduction 
may be required for long-term survival. ICV administration also allows more 
efficient transduction of the CNS using lower doses, thereby increasing safety, which 
from a clinical, economic and vector manufacturing point of view, the scale-up to 
human parameters would be practically and financially more feasible. An interesting 
compromise between the two approaches could be a low dose dual ICV and 
intravenous administration as previously demonstrated in a mouse model of multiple 
sulfatase deficiency, where dual administration of an AAV9 vector enhanced 
systemic therapy compared to single administration routes alone (Spampanato et al., 
2011).  
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7.7 Future Work 
Several recommendations for future work have already been suggested throughout 
this chapter, however certain key experiments to further improve and clarify some of 
the results and observations presented in this thesis are addressed here. 
 
In the short-term, conclusion of the high dose AAV9-hNPC1 study in Npc1-/- mice 
remains the top priority, as complete survival and weight data will allow a more 
effective comparison with low dose AAV9-hNPC1 treatment and other recently 
published gene therapy approaches for NP-C disease. Detailed neuropathology 
analysis of end-stage high dose treated Npc1-/- brains will confirm if further 
improvements in the number of permanently rescued neurons has been achieved and 
whether this translates to reduced neuroinflammation. Similarly, analysis of visceral 
tissue in comparison with tissue from end-stage untreated Npc1-/- mice will be crucial 
in clarifying the extent of continued and long-term visceral disease progression. The 
additional analysis of tissue samples from 9 week-old gene therapy treated Npc1-/- 
mice to allow age-matched comparison with untreated Npc1-/- mice would also be of 
great benefit. Age-matched comparison data in combination with the end-stage data 
presented in this project would reveal if the extent to which neurological and visceral 
NP-C disease progresses, following brain directed gene therapy.  
 
While the approach utilised during this project was focused on the treatment of the 
neurological aspects of NP-C disease, our findings in combination with the results 
published in other NP-C gene therapy studies indicate that while neuronal 
transduction is crucial in the amelioration of major disease manifestations, this 
transduction may be needed in combination with NPC1 expression in certain visceral 
tissues to achieve long-term survival. Additional effort should therefore be invested 
into the analysis of visceral diseases progression and whether this plays a crucial role 
in disease progression, which is amplified in these significantly older gene therapy 
treated Npc1-/- mice, ultimately leading to their deterioration. Although the visceral 
pathology is non-fatal in the majority of NP-C patients, the potential impact of 
continued and long-term visceral lipid accumulation may become amplified over 
time. As previously discussed, a valuable future study may therefore be the 
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evaluation of combination approaches, where the CNS focused ICV AAV9-hNPC1 
administration is combined with a systemic directed therapy. This could either be 
achieved through combinational therapy with small molecule drugs such as miglustat 
and HP-β-CD, where lower systemic doses could be administered, leading to the 
potential reduction in the impact of the adverse side effects associated with the two 
drugs. Alternatively, this could also be accomplished through a dual AAV approach, 
with simultaneous ICV and intravenous AAV9-hNPC1 administration. While, the 
synapsin I promoter has been demonstrated to express within the liver (Jackson et al., 
2016), the activity of this promoter in other visceral tissues will need to be assessed. 
Otherwise a series of more ubiquitous promoters could be evaluated for enhanced 
systemic transgene expression. 
 
The translation of these studies and results from neonatal to adult administration will 
be crucial, as pre-symptomatic neonatal administration will only be viable in rare 
cases. Ideally preclinical studies would be carried out with adult ICV AAV9-hNPC1 
administration in two stages. First, administration into pre-symptomatic adult Npc1-/- 
mice between 4 and 5 weeks of age as a further proof of concept experiment, 
followed by a second study where symptomatic Npc1-/- mice are administered ICV 
with AAV9-hNPC1 between 6 and 7 weeks of age, which represents the most likely 
clinical use scenario. 
 
Finally, while the improvements in neuropathology and neurological disease 
manifestations presented here are encouraging, there is certainly further scope for 
significant optimisation and improvement of the vector for enhanced CNS 
transduction efficiency. Due to the lack of any potential for cross-correction in this 
disease, transduction efficiency will be of paramount importance for ultimate 
therapeutic efficacy in both NP-C animal models and human patients. The creation 
of novel AAV capsid variants has resulted in the identification of variants with 
increased transduction efficiency compared to normal AAV serotypes. One such 
variant is AAV-PHP.B, which demonstrated a 40-fold greater efficiency in the CNS 
compared to an equivalent AAV9 vector following adult administration (Deverman 
et al., 2016). This particular variant also had the added advantage of increased 
efficiency in human neurons compared to AAV9 in vitro, however ultimate clinical 
translation with this capsid variant will be an additional challenge, as unlike rAAV9 
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vectors, AAV-PHP.B has not previously been administered into humans and so may 
require to be tested in non-human primates. 
7.8 Conclusion 
Taken together, the work presented in this thesis signals that AAV-mediated gene 
therapy has significant therapeutic potential for treating Niemann-Pick Type C 
disease and warrants further investigation. We have verified that the human NPC1 
cDNA can viably be incorporated into a functional rAAV construct to produce 
functional and fully packaged AAV9-hNPC1 vectors, which were validated in vivo 
to confirm overexpression of NPC1 in transduced neurons. A series of crucial proof 
of concept experiments and preclinical survival studies in a well-characterised 
murine model of NP-C demonstrated that a single ICV administration of an efficient 
and neuronal-selective AAV9-hNPC1 vector directly into the CSF of neonatal mice 
can increase the lifespan of Npc1-/- mice by 120%. Improvements in weight were 
accompanied with the long-term normalisation of locomotor and coordination 
activity, significant and long-term neuronal protection in monitored brain regions 
and a likely deceleration of lipid accumulation within AAV9-hNPC1 treated brains. 
The therapeutic efficacy of this gene therapy study on Npc1-/- mice was also placed 
in the context of other competing therapies in the NP-C arena, with AAV9-hNPC1 
treatment demonstrating a significant improvement in average lifespan compared to 
the only currently licenced drug for NP-C patients, without the associated adverse 
side effects.  
 
Although more work needs to be done to determine the importance of non-neuronal 
transduction for longer-term survival and whether these results will translate through 
to adult mice or larger animal models, it is hoped that this work represents an 
important step towards the development of an effective gene therapy treatment for 
NP-C disease. The translation of preclinical gene therapy studies to successful 
clinical trials for neurodegenerative conditions very similar to NP-C, and the current 
interest in commercialisation of gene therapy means that this is an opportune 
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moment and climate in which to continue the pursuit towards development of gene 
therapy for NP-C. 
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Supplementary Figure S1: Human NPC1 and murine Npc1 cDNA homology 
Alignment of human NPC1 (CCDS11878.1) and murine Npc1 (CCDS29064.1) cDNA 
coding sequences sourced from the CCDS Database 
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Supplementary Figure S2: Human and murine NPC1 protein homology 
Alignment of human NPC1 (NP_000262.2) and murine NPC1 (NP_032746.2) amino 
acid sequences. 
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Supplementary Figure S3: Human NPC1 cDNA 
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